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Abstract 
 
Cell therapy products offer the potential for treatment and possibly cure of a number of 
indications, such as cancer, diabetes and heart disease. However, a number of economic, 
regulatory, logistical and technical challenges need to be addressed so as to achieve 
successful commercialisation of cell therapy products. With more cell therapy products 
reaching commercial stage, there is an increased interest in developing and evaluating 
novel manufacturing strategies to enhance cost-effectiveness while accommodating the 
unique features of cell therapy products. This thesis aims to develop and apply advanced 
decisional tools so as to provide an integrated approach that offers valuable insights to 
some of the dominant challenges faced by cell therapy developers.  
The decisional tools developed in this thesis comprise the following models tailored to 
cell therapy products: a technology-specific detailed factorial method for fixed capital 
investment (FCI) estimation, a process economics model for computing cost of goods 
(COG), brute force optimization, a multi-attribute decision making model, a robustness 
analysis model and a risk-adjusted net present value model. A key novel contribution is 
the detailed factorial methodology for estimating FCI and footprint for bespoke cell 
therapy facilities that accounts for technology-specific factors for key manufacturing 
platforms as well as the implications of single-use technologies and open versus closed 
operations. This is used to derive benchmark values for short-cut Lang factors for typical 
cell therapy facilities according to the technologies and commercialisation scenario 
selected. 
A set of industrially-relevant case studies is presented for topical cell therapies, namely 
mesenchymal stem cell (MSC) therapies and chimeric antigen receptor (CAR) T-cell 
therapies. The case studies explored different aspects of the manufacturing strategy of 
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cell therapy products such as optimal technology selection, process robustness, 
performance targets for successful commercialisation, fixed capital investment 
requirement, the cost benefits of allogeneic cell therapy products with respect to 
autologous cell therapy products and the effect of decentralised multi-site manufacture of 
autologous products. In particular, the MSC case study provides a more holistic approach 
to evaluating different technologies that considers both financial and operational features. 
The CAR T-cell case study provides the first in-depth economic analysis and set of 
insights at both the technology level and an enterprise’s facility configuration level. The 
work in the thesis illustrates how the decisional tools developed can facilitate the design 
of cost-effective manufacturing strategies for cell therapy products. 
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Impact Statement  
 
Decisional tools have been successfully employed in providing some useful insights to 
the critical questions facing biopharmaceutical companies when bringing new products 
to market. This thesis extended the creation and use of decisional tools to tackle some of 
the challenges faced by cell therapy companies, by addressing topics related to technology 
selection, reimbursement constrains and facility configuration. The insights gained from 
the tools can help cell therapy developers make the right decisions in multiple aspects of 
the manufacturing strategy early on within process development. Doing so will allow 
companies to save time and money though allocating their development efforts and 
capital investment to the most profitable solutions. Moreover, identifying the optimal 
manufacturing strategy will also decrease the manufacturing cost of goods, which will 
increase the commercial feasibility of novel cell therapy products and help relieve the 
economic strain that has been put onto our healthcare system. 
The potential of the work described in this thesis has been recognised by several industry 
experts that were involved in sponsoring the research.  Matthieu Egloff (ex-Pall Life 
Sciences; currently Co-founder and Marketing Architect at OUAT Life Science, Brussels, 
Belgium) stated that “The commercial scale manufacture of cell therapy products at 
affordable costs is clearly linked to our ability to identify, develop and implement smart 
engineering and process solutions early on within the process development. Tania's 
works clearly illustrates how computer-aided methods can be used to identify the possible 
bottlenecks within the manufacturing strategy of cell therapy products as well as ways to 
tackle these challenges such as to achieve appropriate strategies for sustainable 
manufacture of cell therapy products”. This was reinforced by a statement by Fabien 
Moncaubeig (ex-Pall Life Sciences; currently Co-founder and Consultant at BIP-partners, 
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Cugnaux, France) “It is a real challenge for start-ups or academics developing cell 
therapy products to balance their economical and time constraints with their medical and 
clinical expectations. Having cost models, case studies and predictive tools publicly 
available is a real asset to make critical decisions regarding the process development 
and long term manufacturing strategies as early as possible. This will help avoiding the 
recent challenges faced by the latest approved therapies where reimbursement has been 
denied by authorities (e.g. Alofisel, Takeda)”. Moreover, the potential of decisional tools 
in enabling better decision-making in cell therapy manufacture was also recognised by 
Clive Glover (Global Marketing Manager, Pall Corporation, NY, USA) though the 
following statement “As cell and gene therapies become commercialized, understanding 
the most efficient ways to manufacture these products will be extremely important. 
Tania’s thesis provides important insights into how both allogeneic as well as autologous 
therapies can be effectively manufactured while keeping efficiency and cost in mind as 
well as revealing areas that require additional technology development. This type of 
research can help cell therapy developers save time and money as it allows them to 
evaluate different aspects of the manufacturing strategy early on within the process 
development through the use of computer-based methods.” 
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Chapter 1: Scope and Background 
 
1.1 Introduction 
Traditional healthcare has relied on the use of pharmaceuticals, biopharmaceuticals and 
medical devices for patient care (Mason et al. 2011). Such treatments are considered 
efficient, however, they have failed to efficaciously treat a number of indications 
including chronic diseases (Mason et al. 2011). The national annual costs of chronic and 
long term diseases  including dementia, cancer and diabetes amount to £18.7 million, and 
it is expected to rise significantly in the next years (Department of health 2010).  As 
chronic diseases have a higher incidence among the older population, the demographic 
shift seen in the recent years puts an unprecedented economic strain on our healthcare 
system (Department of health 2010; Naughton et al. 2006; Connolly et al. 2011; Prasad 
et al. 2012; Dunnell 2007). 
Cell therapies have been proposed as a novel approach for treatment and possibly cure of 
number of chronic indications; however, these powerful therapeutics present significant 
challenges inherent of the complexity of these products. These challenges include high 
cost of goods (COG), high process variability and complex logistics (Heathman et al. 
2015; Lapinskas 2010; Lopez et al. 2010; Christodoulou et al. 2013; Ratcliffe et al. 2011; 
Levine et al. 2017; Mount et al. 2015a; Sharpe & Mount 2015b). Decisional tools have 
been utilized to provide valuable insights to some of the dominant challenges faced by 
cell therapy manufactures (Jenkins et al. 2016; Simaria et al. 2014a; Hassan et al. 2016; 
Hassan et al. 2015). This introductory chapter provides an insight on the therapeutic 
potential of cell therapies, their manufacturing process as well as the challenges 
associated with these products, with focus on mesenchymal (MSC) and chimeric antigen 
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receptor T-cell (CAR T-cell) based products. This chapter also describes the potential of 
decisional tools to solve some of the challenges associated with cell therapy manufacture.  
The first section of this chapter (Section 1.2) provides an introduction to cell therapy 
products, their mode of action, the types of cells used in cell therapy applications and the 
differences between patient specific (Autologous) and universal donor (Allogeneic) cell 
therapy manufacture. Section 1.2 also highlights the market opportunity for cell therapy 
products as well as the current products in the market, the key trends in cell based clinical 
trials and the development pathway for cell therapy products . Section 1.3 focuses on 
MSC and CAR T-cell based cell therapy products and provides an overview of their 
characteristics, market potential and clinical trial landscape. This section is 
complemented by Sections 1.4 and Section1.5, where the manufacturing process and 
current technologies for the manufacture of these cell therapy products are described. 
Section 1.6 discusses some of the key challenges faced by cell therapy manufacturers 
considering clinical performance issues, manufacturing process and supply chain 
bottlenecks and costs and reimbursement challenges. Section 1.7 describes the unique 
features of  cell therapy facilities. This section also discusses the trade-offs of future 
trends for cell therapy facilities including the implementation of automation and  the 
adoption of a decentralised approach to cell therapy manufacture. The previous use of 
decisional tools to address challenges related to cell therapy manufacture is discussed in 
Section 1.9. The final section (Section 1.10) describes the aims and organisation of this 
thesis. 
1.2 Cell therapy overview 
Cell therapies belong to the field of regenerative medicine (Wei et al. 2013a), and are 
defined as the administration of cells to improve the health condition of the recipient 
(Anon 2012). The first use of this type of treatment was in the form of bone marrow 
transplants, with the first successful allogeneic bone marrow transplant taking place in 
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the early 70s (Appelbaum 2007). Years later, these therapies now provide possible 
solutions to multiple currently unmet clinical needs (Heathman et al. 2015; Ratcliffe et 
al. 2011). 
There are three key mechanisms in which cell therapy products can act: (1) replacement 
of damaged cells or tissues (e.g. the use of stromal cells for organ repair) (Alliance for 
Regenerative Medicine 2013; Bussolati 2011). (2) stimulation of self-healing by the body 
(e.g. modify the patients inflammatory response to maximise and accelerate regeneration) 
(Ennis et al. 2013; Alliance for Regenerative Medicine 2013), and (3) delivery of 
molecular or genetic agents (e.g. the delivery of RNA sequences which inhibits the 
formation of the huntingtin) (Olson et al. 2012; Alliance for Regenerative Medicine 
2013). 
1.2.1 Characteristics of cells used in cell therapy 
Different types of cells have been used for cell therapy applications, including 
hematopoietic stem cells (HSCs/HPCs), fibroblasts, MSCs, placenta cells, chondrocytes, 
liver cells, endothelial cells, induced pluripotent cells and lymphocytes (Martin et al. 
2009; Li et al. 2014a; Heathman et al. 2015). The source of these cells maybe autologous, 
allogeneic and xenogeneic. This thesis will focus on the two former cell sources. The key 
differences between them are summarised on Table 1.1. 
1.2.1.1 Autologous or patient-specific  
In allogeneic cell therapy, the patient and the donor are the same person, which reduces 
the chances of immune response by the body (Mason & Dunnill 2009; Forbes & 
Rosenthal 2014; Jansen of Lorkeers et al. 2014; Smith 2012a; Malik 2012). Additional 
advantages of the use of this type of cell source is the relatively less extensive cell line 
development process as possible abnormalities in the cell bank will only affect one patient 
(Mason & Dunnill 2009). Disadvantages of autologous cell therapy manufacture include 
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the requirement for a of scale-out manufacturing approach which  does not benefit from 
economies of scale and hence, increases the COG (Malik 2012; Mason & Dunnill 2009). 
Since the starting material for each lot is attained from a different donor, there is also a 
higher chance for process variability (Mason & Dunnill 2009; Brandenberger et al. 2011). 
Furthermore, process scheduling maybe relatively more challenging due possible delays 
in patient sample arrival.  
Table 1.1 Comparison between autologous and allogeneic cell therapy manufacture 
 
1.2.1.2 Allogenic or universal  
In allogeneic cell therapy manufacture the cells from a single donor are used to produce 
a master cell bank (MCB) and create an “of-the-shelf” product for multiple patients 
(Malik 2012; Brandenberger et al. 2011; Whittle 2017). The main concern surrounding 
the use of this type of therapies is the possibility of immunogenic response by the 
recipients body (Whittle 2017; Mason & Dunnill 2009; Smith 2012a). This issue can be 
addressed using immune suppression (Smith 2012a). Additional drawbacks of allogeneic 
Parameter Autologous Allogeneic 
Manufacture - High lot-to-lot 
variability 
- Donor is the patient 
- Lower batch failure 
costs 
- Low lot-to-lot 
variability 
- Single donor for 
multiple patients 
- Higher batch failure 
costs 
Process planning - Complex logistics 
- Unsuitable for 
emergency situations 
- Complex process 
scheduling 
- Simpler logistics 
- “Off-the-shelf” product 
suitable for emergency 
situations 
- Fixed process schedule 
Regulation and Product & 
Process characterisation 
- Simpler cell bank 
characterisation 
- Reduces the risk of 
graft-versus-host 
disease 
- Complex cell bank 
characterisation  
- May require extensive 
immunotherapy to avoid 
graft-versus-host 
disease 
COG & Reimbursement - Minimal economies of 
scale and higher COG 
- Requires QC testing for 
each patient 
- COG decreases with the 
scale of production 
- Does not require  QC 
testing for each patient 
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cell processing is that one MCB is unlikely to last for the whole business life cycle of the 
product (Bravery n.d.). Therefore, comparability studies are required whenever a new cell 
bank is introduced. This process can cost up to $1M USD including agency fees and 
comparability testing and last up to 1 year (Bravery n.d.). 
 Furthermore, more extensive cell bank testing maybe required in allogeneic processing 
(Mason & Dunnill 2009). The costs associated with the additional testing required are 
however spread over a higher number of doses (Malik 2012). In allogeneic cell therapies 
the commercial scale manufacture approach adopted is scale-up, which benefits from 
economies of scale (Malik 2012; Mason & Dunnill 2009; Whittle 2017). The main 
challenge in scaling-up is maintaining the product characteristics and low manufacturing 
costs (Brandenberger et al. 2011). 
For some indications, both allogeneic and autologous treatments may be applied (de 
Windt et al. 2013; Hosing et al. 2003; Majhail et al. 2015; de la Portilla et al. 2016; Jansen 
of Lorkeers et al. 2014); in which case the type of indication will dictate which approach 
will be more appropriate. For example, if the doctors are under time constraints due to 
the fact that the patient requires an emergency treatment (e.g. stroke),  then perhaps a 
allogeneic treatment would be more advantageous (Malik 2012; Mason & Dunnill 2009). 
Another example where allogeneic therapies may be preferred to autologous therapies are 
cases where insufficient starting material is available for collection from the patient due 
to old age or disease  (Malik 2012; Jansen of Lorkeers et al. 2014; Zhang et al. 2015). 
Despite the technical challenges associated with the commercial scale manufacture of 
autologous cell therapy products these have been prevalent in the cell therapy market and 
clinical trials (Brandenberger et al. 2011; Li et al. 2014a; Culme-Seymour et al. 2012). 
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1.2.2 Development pathway for cell therapies 
The development process of cell therapy products resembles the development process of 
traditional biopharmaceuticals products and includes product discovery & basic research 
followed by pre-clinical trials and clinical trials (Deans 2014; Paul et al. 2010). The total 
development  process can last between 10-15 years. The costs associated with developing 
a novel cell therapy product are higher than for biopharmaceutical products and range 
between $100’s millions to $1 billion (Deans 2014; Hassan et al. 2016; Nie 2015), with 
only about 30% of the successful products recovering the initial investment made during 
the process development (Deans 2014).  
Persisting through the time consuming and unpredictable product development process 
may pose some challenges as companies may struggle to raise enough capital (Dodson & 
Levine 2015a). Examples of the time taken to bring  a product to market include Osiris 
therapeutics, which released the products Osteocel® (2005) and Prochymal® (2012) 13 
and 20 years respectively after the company was founded in 1992  (Dodson & Levine 
2015a). Strategies to raise adequate funds to withstand the process development all the 
way through market approval include partnerships and funding from venture capitalists 
(Deans 2014; Dodson & Levine 2015a). Additional methods to raise capital include the 
development of a second line of products with lower regulatory requirements (Dodson & 
Levine 2015a). Figure 1.1 shows a schematic representation of the typical process 
development pathway for biologics. 
Parallel activities that take place during the development pathway of cell therapy products 
include clinical trials, assay development and product characterisation. The degree of 
clinical testing required may vary according to the target indication. For example, an 
MSC-based therapies for cardiovascular indications require more rigorous clinical trials 
than therapies targeting rare diseases (Mount et al. 2015b). Moreover the MSC-based 
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therapy will have to  demonstrate  superior performance with respect to current treatments 
(Mount et al. 2015b). 
Furthermore, the type of cells used will have an effect on the follow-up times. For 
example, an allogeneic MSC-based clinical trial may only require a 12month follow-up 
time due to their short half-life (Mount et al. 2015a), while trials using genetically 
modified cells may require follow-up times from 5 years (EMEA) (European Medicines 
Agency 2009b) to 15 years (FDA) (Food and drugs agency 2015). On average, only 10% 
of biopharmaceuticals which enter the clinical trial pathway receive successful market 
approval and the majority of these products are monoclonal antibodies (Thomas et al. 
2015; Deans 2014; Hassan et al. 2016; Nie 2015). The rate of market approval varies with 
the indication being targeted (Figure 1.2).  
When the first cell therapy products were developed, it was a challenge for regulatory 
agencies to regulate these novel products, hence the regulatory procedures applied to cell 
therapy products were ones established for other types of therapeutics (Dodson & Levine 
2015b). However, the use of regulation protocols of traditional biologics and small 
molecules in cell therapy is inadequate as cell therapies have very  particular features 
(Mount et al. 2015b). 
The identity of traditional products (small-molecules and proteins) is defined by the 
composition of the molecules (Lipsitz et al. 2016). In cell therapy the identity of the cells 
is given by the cell phenotype. The cells phenotype is complex and defined by the surface 
markers present on the cells (Lipsitz et al. 2016). 
 
30 
 
 
Figure 1.1 Development pathway of cell therapy products. Duration, stages, outcome and investment. Adapted from Deans (2014) 
and  Thomas et al (2015). 
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Figure 1.3 Schematic representation of the Japanese accelerated regulatory pathway. 
Adapted from Bubela et al., 2015. 
Figure 1.2 Success rate of products going though clinical trials by indication. Source: 
Thomas et al (2015). 
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The regulatory framework  for cell therapy products in Europe and USA is now divided 
into minimally and significantly manipulated therapies. Efforts for novel regulation 
methods have also been made in multiple geographic locations such as Japan, Canada, 
Singapore  and USA (Hara et al. 2014; Sherman et al. 2013; Eichler et al. 2012). Figure 
1.3 shows the difference between the typical process development pathway of a novel 
biopharmaceutical product and the accelerated development pathway in Japan. 
1.2.3 Cell therapy market 
Traditional healthcare is composed of pharmaceuticals, biopharmaceuticals and medical 
devices (Mason et al. 2011). Although these are considered efficient treatments, there are 
still indications with no current efficacious treatment such as chronic diseases (Mason et 
al. 2011). The number of patients with chronic or long-term diseases in the UK is around 
15.4 million. This amounts for 70% of the NHS spending (£ 18.7 billion) and it is 
expected to increase to £26.4 billion by 2020 (Department of health 2010). Chronic 
diseases are associated with age and include cancer, dementia, Parkinson’s, diabetes 
cardiovascular disease (CVD) etc. (Department of health 2010; Naughton et al. 2006; 
Connolly et al. 2011; Prasad et al. 2012). This poses an issue due the change in 
demographics caused by the fact that the population now has longer life expectancies 
(Department of health 2010; Dunnell 2007; Office for National Statistics 2014). Cell 
therapies where proposed as treatment of a number of chronic indications (Alliance for 
Regenerative Medicine 2013). 
The cell therapy market was estimated at $12 billion USD in 2016 and is estimated to 
grow at a CARG rate of 31.1% to $61 billion USD by 2022 (Prnewswire 2016). The first 
product to be approved was Apigraft® (Organogenesis, OH, USA) in 1998. This product 
had been used to treat  500,000 patients by the end of 2011 and 140,000 patients in 2012 
(Alliance for Regenerative Medicine 2013).  Since then, a number of cell therapy products 
targeting multiple indications have been commercialised in different countries. These 
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products include ChondroCelect® (TiGenix Leuven, Belgium), Prochymal® (Osiris, 
MD, USA) and Cartistem® (Medipost, Weymouth, UK). The key information regarding 
these therapies is summarised on Table 1.2. 
The selling prices for the commercialised therapies seen in the market vary significantly, 
and may reach the 100’s of thousands of dollars per treatment (GlobeNewswire 2016a). 
These numbers are highly dependent on the indication being targeted. Some of these 
therapies may replace the need for transplants which can costs as much as $600,000 USD 
(Touchot & Flume 2015), or target indications such as spinal cord injury for which current 
treatments are priced between $500,000 USD to $3million USD/ patient (Williams 2015).  
Historically, a very high percentage of COG on selling price values were expected for 
autologous products due to a combination of high manufacturing COG and limitations in  
reimbursement stipulated by the healthcare providers (Smith 2012a). Smith (2012) 
indicates that the COG as % of sales were 40%-50% for Provenge® and Carticel®, which 
have selling process of $93,000 USD and $15,000 USD respectively (Fierce Biotech n.d.; 
http://www.access.wa.gov), implying that the COG/dose of these therapies were 
approximately $46,500 USD and $7,200 USD respectively. 
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 Table 1.2 Cell therapy products on the Market. Allo = Allogeneic, Auto = Autologous 
Product name Manufacturer Indication Type Dose size Cell type Selling price Country 
Allostem® Allosource  Bone repaira Alloa 6.63K cells/mla Adipose MSCa $540 -$3,500 
(1ml-10ml )a 
US 
Apligraft® Organogenesis  Chronic woundsb Allob 44cm2c Keratinocytes & 
Neonatal 
Fibroblastsb 
$21.22/cm2d US/Saudi Arabia 
BioDfactor® BioDlogics  Tissue repaire Allof 0.25ml – 
1.25mlf 
Placenta cellsf - US 
BioDfence® BioDlogics Tissue repaire Allof 3cm2 – 12cm2f Placenta cellsf - US 
CardioRel® Reliance Life 
Sciences  
Myocardial 
infractiong 
Autog - MSCsg - India 
Carticel® Genzyme  Cartilage repairh Autoh 0.6-3.3M 
cells/cm2h 
Chrondocytesh $13,300 -15,000i US/EU 
Cartistem® Medipost  Osteoarthritisj Allok 2.5M cells/cm2l UC Mesenchymal 
cellsl 
$20,000 - 
$40,000m 
South Korea 
Chrondocelect® TiGenix  Cartilage repairn Auton 0.4 ml/vial Cartilage cellsn $24,000m EU (withdrawn ) 
(100 B cells/ 
ml)n 
Cupistem® Anterogen Rectal fistulao Autop - Adiposeo - South Korea 
Dermagraft® Organogenisis  Chronic woundsq Allor 37.5cm2s Fetal Fibroblastsq $1,406s US/ Canada 
DeNovo NT® Zimmer  Cartilage repairt Allot 2.5cm2/packetu Juvenile 
chondrocytest 
$1,440/ packett North America 
Epicel® Genzyme  Burns treatmentv Autov 50cm2/gauzew Keratinocytesw $6,000 - $10,000 
per 1% of total 
body surface 
areax 
US/EU 
Grafix® Osiris Therapeutics Chronic woundsy Alloy - Placental cellsy - US 
Gintuit® Organogenesis Mucogingival 
conditionsz 
Alloz 177cm2 cellular 
sheet with 
4Mcellsz 
Keratinocytesz - US 
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Product name Manufacturer Indication Type Dose size Cell type Selling price Country 
Heartcelligram-AMI® Pharmicell  Post-acute 
myocardial 
infractionaa 
Autoaa - BM MSCaa $19,000ab South Korea 
Heartsheet® Terumo Corporation  Heart failureac Autoac 5 sheetsac Skeletal myoblastsac $120,000ad Japan 
LaViv® (azficel) Fibrocell  Wrinklesae Autoae 3  treatment 
session 
Fibroblastsae $3,000 - $3,500ae US 
0.1 ml/linear 
cmae 
MACI® Genzyme Cartilage repairaf Autoaf 0.5 – 1M 
cells/cm2 of 
cellular sheetaf 
Chondrocytesaf - EU (suspended) 
US 
Orcel® Ortec International  Burnsag Alloag - Keratinocytes, 
fibroblastsag 
$27.8/cm2ah US 
Osteoplus® Nuvasive  Bone repairai Alloai 50K cells/mlaj MSCsaj $460 - $5,400 (1-
15 ml)a 
US 
Prochymal® Osiris GvHDak Alloal 2M cells/kgak BM-MSCsal $20,000/dosead Canada & New 
Zealand 
Provenge® Dendreon  Prostate canceram Autoam 50M cells/ 
vialam 
CD54+ cellsam $31,000/ infusion 
(3 infusions)an 
US 
Recell® Avita Medical  Skin loss, scaring 
and 
depigmentation 
after burn injuryao 
Autoao 1 
pack/320cm2ao 
Skin cellsao £950 + VAT/ 
packao 
EU, UK, Canada, 
Australia 
ReliNethra® Reliance Life 
Sciences 
Sight lossap Autoap 4cm2/graftap Epithelia cellsap - India 
TEMCEL® Mesoblast  GvHDaq Alloaq 1.2 – 1.7B 
cellsaq 
MSCaq $7,079/ 72M 
cellsaq 
Japan 
Transcyte® Organogenisis Temporary would 
healingar 
Alloar - Fibroblastsar $11.75/cm2as US 
Trinity/Trinity evolution 
® 
Orthofix  Bone repairat Alloat >1K cells/mla MSCat $540-$5,455 for 
(1-15 ml)a 
US 
a Skovrlj et al., 2014 
b Food and drugs agency, 1998 
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Product name Manufacturer Indication Type Dose size Cell type Selling price Country 
c Organogenesis, 2008 
d Carroll, 2013 
eLesBiologics, n.d.  
fBioDlogics, 2014 
gReliance life sciences, n.d.  
hFood and drugs Agency, 2007 
iDepartment of Labor and Industries, 2002 
jAdis Insight, 2016b 
kScience daily, 2013 
lMedipost, n.d.  
mBersenev, 2016 
nEuropean Medicines Agency, 2009 
oAdis Insight, 2016a 
pmillipore sigma, 2017 
qFelder, Goyal, & Attinger, 2012 
rMansbridge, 2006 
sOrganogenesis, 2015 
tTompkins, Adkisson, & Bonner, 2013 
uZimmer & Inc, 2009 
vGenzyme Biosurgery, 2014 
wVericel, 2016 
xSchlatter & Sood, n.d.  
yGibbons, 2015 
zFood and drugs agency, n.d.-a 
aaBersenev, 2012 
ab(Bravery n.d.) 
acKonishi, Sakushima, Isobe, & Sato, n.d.  
adBersenev, 2016 
aeZhion, 2011 
afFood and drugs agency, n.d.-b 
agFood and drugs agency, 2001 
ahPourmoussa, Gardner, Johnson, & Wong, 2016 
aiNuvasive, 2017 
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Product name Manufacturer Indication Type Dose size Cell type Selling price Country 
ajAcesurgical, n.d.  
akOsiris, n.d.  
alWaltz, 2013 
amFood and drugs agency, n.d.  
anFierceBiotech, 2010 
aoThe National Institute for Health and Care Excellence, 2014 
apreliance life sciences, n.d.  
aqGlobeNewswire, 2016 
arBello, Falabella, & Eaglstein, 2001 
asStone, 2013 
atOrthofix, n.d. 
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1.2.4 Clinical trials landscape of cell therapies 
Different articles have been  published regarding the trends in cell therapy clinical trials 
(Martin et al. 2009; Li et al. 2014b; Heathman et al. 2015; Culme-Seymour et al. 2012). 
Among these articles is the article written by Li et al (2014a), where the author described 
a search using the term “stem cell” in the clinicalTrials.gov database and in the WHO’s 
international clinical trials registry, in order to identify the clinical trials for cell therapy 
registered before the 1st of January 2013. This article revealed a total of 4,749 clinical 
trials. The study also shown that cell based clinical trials  have increased over the years 
(Figure 1.4), and  that North America is the continent with the highest number of clinical 
trials (57%), follow by Europe (25%), Asia (16%).  
In the same year, a comprehensive report was produced by the Alliance for Regenerative 
Medicine, unveiling key trends in the cell therapy industry in the year 2014 including a 
snapshot into the cell therapy clinical trials landscape (Alliance for Regenerative 
medicine 2014). Martin et al (2009) has also presented key trends in clinical trials, in this 
report, the author describes the findings form a survey concluded in 2009, which included 
over 700 biotechnology companies, where 138 of these were  developing cell therapy 
products. The aim of the study was to assess the state of the private sector in cell therapy. 
Culme-Seymour et al (2012) reports key trends in cell therapy clinical trials over a decade 
(from 2000 till 2010), by typing the term “cell therapy” in search function of the  
clinicalTrials.gov database. This revealed a total of 2,724 cell therapy trials. A more 
recent status update on cell therapy clinical trials is the work published on Heathman et 
al (2015), where the authors collect data from all clinical trials registered in 
clinicalTrials.gov until the 1 January 2014 by typing the word “cell” in the search 
function. This revealed at total of 29,467 clinical trials, 1,342 of which were active cell 
therapy trials. 
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The key trends attained in these studies are summarised in Figures 1.4-1.6. Although the 
authors used different methods for  data collection, the trends show that the indications 
in which cell therapies have been most explored are cardiovascular disease, oncology and 
neurological and CNS indications. The studies also shown that the main cell types used 
are hematopoietic and mesenchymal stem cells. Furthermore, these studies revealed that 
most clinical studies are in phases I & II and that there are differences across studies in 
the donor type used. 
 
Figure 1.4 Clinical trials by year. Adapted from Li et al (2014). 
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Figure 1.5 Clinical trials by indication comparison. Endocrine, Metabolic & Genetic includes diabetes and renal diseases. Gastrointestinal 
includes Crohn’s disease and ulcerative colitis. Inflammation, Immunology & non-malignant hematologic includes: aplastic anaemia, systemic 
lupus, lupus Erythematosus, GVHD and non-malignant haematological diseases. Musculoskeletal excludes rheumatology indications, includes 
muscular dystrophy, ontogenesis imperfecta, bone and cartilage injuries and  degenerative disk disease. Neurological includes: spinal chord 
injury, brain injury, Parkinson's disease, multiple sclerosis, Alzheimer’s and ALS. Rheumatology includes: Rheumatoid arthritis and 
osteoarthritis. Sources: Alliance for regenerative medicine (2014), Heathman et al (2015), Li et al (2014) and Martin et al (2009). 
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Figure 1.6 a) Clinical trials by cell type comparison b) clinical trials by phase c) clinical 
trials by donor type. Sources: :Alliance for regenerative medicine (2014), Culme-Seymour 
et al (2012), Heathman et al (2014), Li et al (2014) and Martin et al (2009). 
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1.3 MSC-based and CAR T-cell therapy products  
1.3.1 MSC-based cell therapy products – characteristics, market and clinical trials 
MSCs also referred to as mesenchymal stromal cells were first identified by Friedenstein 
at colleagues (Mamidi et al. 2012). These are post-natal cells which are capable of self-
renewal and differentiation (Mendicino et al. 2014; Uccelli et al. 2008; Bianco 2014; 
Raynaud et al. 2012). MSCs can be retrieved from multiple sources such as: the bone 
marrow, adipose tissue, amniotic fluid, dental tissues, peripheral blood, placenta etc. 
(Raynaud et al. 2012; Pittenger et al. 1999; Williams & Hare 2011; Wagner et al. 2005; 
in `t Anker et al. 2003; Huang et al. 2009; Ab Kadir et al. 2012). Differences in in vitro 
performance across different sources have been reported. For example umbilical cord-
blood derived MSCs (UCB-MSCs) present superior proliferation rate (Jin et al. 2013; 
Wang et al. 2009). Moreover, neonatal MSCs (fetal, amniotic fluid, placental etc.) present 
higher potency than adult MSCs (Wang et al. 2009).  
The global market for MSCs is foreseen to reach $7.5B by 2022 with the United States 
having the largest market share (34.3%) and Asia being the continent with the highest 
projected CAGR (14.1%) (Global industry analysts 2016). MSCs have multiple 
characteristics, which make them suitable for the treatment of different indications. 
Benefits to the use of these cells include the fact that  they have a small half-life (Trounson 
& McDonald 2015), low immugenicity and low chances of tumour formation (Wei et al. 
2013a; Le Blanc 2003). 
Additional examples of the benefit of MSCs include their immunomodulatory capacity 
as MSCs aid the suppression of activated T-cell proliferation as well as the suppression 
of the release of cytokines by these T-cells. This makes MSCs suitable for the treatment 
of graft vs host disease (GvHD), rheumatoid arthritis and Alzheimer’s among other 
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indications (Glenn & Whartenby 2014; Reinders et al. 2013; Bernardo et al. 2013; 
Bartholomew et al. 2002; Sheng et al. 2008; Di Nicola et al. 2002; González et al. 2009).  
Another important feature of MSCs is its capacity of differentiating into different cell 
types such as cardiomyocytes, neurons and insulin producing cells.  Therefore, MSCs are 
suitable for the treatment of cardiovascular diseases, spinal cord injury, Parkinson’s  and 
diabetes (Noort et al. 2010; Ramkisoensing et al. 2011; Hare et al. 2009; Naghdi et al. 
2009; Wang et al. 2010; Kan et al. 2007). Moreover, MSCs have also a paracrine 
properties allowing them to secrete multiple molecules such as cytokines, chemokines 
and growth factors (Squillaro et al. 2016; Trounson & McDonald 2015). Furthermore, 
MSCs contain homing properties, which means that they are able to reach the location of 
the injury. The ability of MSCs to do so is however dependent on multiple parameters 
such as point of care delivery method, cell culture conditions, number of passages during 
in vitro cell culture, cell age etc. (Ullah et al. 2015; Squillaro et al. 2016; Trounson & 
McDonald 2015). Figure 1.7 summaries some of the target indications in MSC-based 
clinical trials. 
Multiple articles have been published on the trends of mesenchymal cell-based clinical 
trials (Chen 2016; Heathman et al. 2015; Wei et al. 2013b; Trounson & McDonald 2015; 
Ullah et al. 2015; Squillaro et al. 2016). These different sources have reported different 
numbers of registered mesenchymal stem cell-based clinical trials varying between 334 
and 578 (Chen 2016; Heathman et al. 2015; Wei et al. 2013b; Trounson & McDonald 
2015; Ullah et al. 2015; Squillaro et al. 2016).  
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Figure 1.7 MSC-based clinical trials by indication. Endocrine, Metabolic & Genetic includes diabetes and renal diseases. 
Gastrointestinal includes Crohn’s disease and ulcerative colitis. Inflammation, Immunology & non-malignant hematologic includes: 
aplastic anaemia, systemic lupus, lupus Erythematosus, GVHD and non-malignant haematological diseases. Musculoskeletal excludes 
rheumatology indications, includes muscular dystrophy, ontogenesis imperfecta, bone and cartilage injuries and degenerative disk 
disease. Neurological includes: spinal cord injury, brain injury, Parkinson's disease, multiple sclerosis, Alzheimer’s and ALS. 
Rheumatology includes: Rheumatoid arthritis and osteoarthritis. Sources: Chen et al (2016), Heathman et al (2015), Squillaro et al 
(2016), Trounson et al (2015), Ullah et al (2015) and Wei et al (2013). 
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Figure 1.8 a) MSC-based clinical trials by year b) MSC-based clinical trials by phase c) 
MSC-based clinical trials by cell source. Sources: Chen et al (2016), Heathman et al 
(2015), Squillaro et al (2016) and Trounson et al (2015). 
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MSC clinical trials have shown encouraging results. For example, a Phase I study using 
bone marrow MSCs in combination with peripheral blood  MSCs and pallet-rich plasma 
for the treatment of distal tibial fractures have shown that the use of MSCs results in a 
50% reduction in time for fracture union with no complications (Liebergall et al. 2013). 
Another example of the successful therapeutic application of MSCs is seen in Le Blanc 
et al (2008) where the authors describe the use of bone marrow MSCs in patients with 
acute GvHD following an allogeneic HSC transplant during a Phase I clinical trial. The 
results show that the mortality rate 1 year post infusion transplantation decreased from 
72% to 37% in patients that received the MSC-based treatment. This study also revealed 
that there were no side effects during or instantly after the transplantation.  
1.3.2 CAR T-cell therapy products – characteristics, market and clinical trials 
Adoptive cell transfer ( ACT) immunotherapies  have shown great potential during 
clinical trials for the treatment of oncology indications (Reuters 2015; Tumaini et al. 
2013; Valton et al. 2015; Hillerdal et al. 2014; Sumen et al. 2015; Cartellieri et al. 2014; 
Chmielewski et al. 2013; Rosenberg & Restifo 2015). Such results create hope for long 
term or total remission of cancer patients (Maus et al., 2014). 
Mature T-cells can be divided into two subgroups: memory T-cells and naïve T-cells. In 
case of infection, naïve T-cells are able to react to new antigens (Verhoeyen et al. 2003). 
Once these meet peptide-major histocompatibility complex (pMHC), which their T-cell 
receptor (TCR) shows affinity for, naïve T-cells start to divide and become effector cells. 
These cells then die after the infection has passed (Berard & Tough 2002). The fraction 
of differentiated effector cells which remain in the bloodstream are called memory T-cells 
(Berard & Tough 2002). T-cell-based ACT therapies can be separated into three main 
categories: Tumour infiltrating lymphocytes (TILs), T-cell receptors (TCRs) and 
chimeric antigen receptors T-cell (CAR T) (Rosenberg & Restifo 2015). The relative 
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percentage of clinical trials across the different categories can be estimated at 19%, 25% 
and 56% for TILs, TCRs and CAR T-cells respectively (PR Newswire 2016). 
TILs are attained from metastatic legions in tumours (Sharpe & Mount 2015a; Stroncek 
et al. 2015) via biopsy (Chmielewski et al. 2013; Dillman et al. 2004). These cells have 
shown success in treating melanoma (Ascierto et al. 2015; Marr et al. 2012; Chmielewski 
et al. 2013; Richard Morgan et al. 2006), with long lasting response rates of 50%-70% 
(Tran et al. 2008). However, attaining and expanding these cells for a variety of different 
tumours is challenging (Marr et al. 2012; Chmielewski et al. 2013; Hillerdal et al. 2014). 
In order to overcome this sourcing limitation, TCRs and CAR T-cell therapies can be 
used (Chmielewski et al. 2013; Sharpe & Mount 2015a). These cells are attained from the 
peripheral blood and genetically engineered to recognise specific tumour associated 
antigens (TAAs) (Chmielewski et al. 2013; Marr et al. 2012; Hillerdal et al. 2014; 
Stroncek et al. 2015). 
TCRs are an intracellular section of a T-cell receptor which recognizes specific pMHC in 
TAAs (Chmielewski et al. 2013). These have shown promising results in oncology 
clinical trials (Ascierto et al. 2015; R Morgan et al. 2006). However, a limited number of 
pMHCs have been identified to date, which restrains the range of indications in which 
TCRs can be applied as a therapy (Chmielewski et al. 2013). Moreover, the use of this 
technique carriers the potential for serious auto-immunity, due to the development of 
unexpected specificities (Chmielewski et al. 2013).  
A CAR is an extracellular fragment of an antibody recognition domain (Milone et al. 
2009; Chmielewski et al. 2013). CAR T-cells were first created in the Weizmann Institute 
of Science, Israel in the late 80’s (Brower 2015; Rosenberg & Restifo 2015). Using CAR 
T-cells has the advantage of having a non-pMHC dependent recognition (Rosenberg & 
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Restifo 2015; Chmielewski et al. 2013; Sumen et al. 2015; Maus et al. 2014; Kalos et al. 
2011; Poirot et al. 2015) , which enables a higher number of indications to be targeted. 
The global expenditure in cancer treatments reached $100B dollars in 2014 (Leonard 
2015), putting cancer at the top of the healthcare priorities (Liechtenstein et al. 2013). As 
such, the US Food and Drug Admiration (FDA) has endorsed the use CAR T-cell 
therapies which target indications with no current efficacious treatment, by awarding 
them the status of “breakthrough treatment“, which facilitates the market launch of such 
therapies (Brower 2015). An example of this is the CAR T-cell therapy targeted at 
lymphoblastic leukaemia and relapsed and refractory aggressive B Cell non-Hodgkin 
lymphoma developed by Juno therapeutics (Seattle, WA, US). This therapy has received 
the orphan drug status in 2014 (Brower 2015). Another example of the priority given to 
CAR T-cell therapy products by regulatory agencies is the “breakthrough status” received 
by Novartis (Basel, Switzerland) in 2014 for a CAR T-cell therapy product  targeting 
acute lymphoblastic leukaemia (Novartis 2015; Carroll 2014). 
The CAR T-cell therapy market is now estimated at $10B USD (Ledford 2014). This 
value  is foreseen to grow to $30B USD by 2030 (PR Newswire 2016). There are only  
two CAR T-cell products currently available in the market with selling prices ranging 
between $373,000 (Yescarta®, Gilead, Foster city, CA, USA) and $475,000 (Kymria®, 
Novartis, Basel, Switzerland) (Ramsey 2017; Sagonowsky 2017a). In America alone, the 
annual demand for these products is foreseen to be 10,000 patients that have not 
responded to traditional treatments (Reuters 2015; Porter et al. 2009). 
 The current COG per dose estimated for CAR T-cell therapies range between $45,000 
USD and $150,000 USD (Reuters 2015), and, once successful process optimization is 
achieved these costs are foreseen to drop to $25,000 USD - $35,000 USD (Walker & 
Johnson 2016b). Speculative selling prices for future products range from $150,000 USD 
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to values as high as $500,00 USD (Reuters 2015; Ledford 2014; Ward & Crow 2015; 
Voigt et al. 2016; Walker & Johnson 2016a). These selling prices would result in COG 
as % sales of 5%-23% and 9% -99.9% for optimized and non-optimized processes 
respectively. Moreover, if CAR T-cell therapies are to be curative treatments then selling 
prices as high as $500,000 USD may be acceptable, as costs of current treatment regimens 
for patients with multiple myeloma are around $318,000 USD to $1,190,120 USD for 
43.4 months (~4 years) of treatment (Niphadkar et al. 2016)). The commercial feasibility 
of current selling prices applied to CAR T-cell therapies was confirmed by a recent report 
by the National Institute for Health and Care Excellence (NICE) that has revealed that an 
acceptable reimbursement for these class of products would be around £356,100 per 
patient in remission (Crabb & Stevens 2016). 
The key indications being explored in CAR T-cell therapy clinical trials are 
haematological malignancies (Figure 1.9) (Sharpe & Mount 2015a; Kalos et al. 2011). 
Blood malignancies have a high incidence rate, with around 87,000 new cases of 
leukaemia and non-Hodgkin’s lymphoma being reported yearly in the US (Porter et al. 
2009), 4,000 of which are of acute lymphoblastic leukaemia (ALL) with 67% of these 
patients being children and adolescents (Pui & Evans 2006). CAR T-cell therapies may 
be used as an efficacious treatment for ALL as clinical trials have shown response rates 
as high as 80% (Sumen et al. 2015). 
Dose sizes explored during the clinical trials vary between 1×106 cells/ dose and 1×1011 
cells/ dose (clinicaltrials.gov n.d.; Rosenberg et al. 1994; Lamers et al. 2006; Porter et al. 
2009; Morgan et al. 2010b). The side effects reported in CAR T-cell clinical trials range 
from fever and diarrhoea (Parkhurst et al. 2011) to lethal cases of cardiactic toxicity, 
respiratory distress and neurologic toxicity (Morgan et al. 2010b; Morgan et al. 2013; 
Cameron et al. 2013; Linette et al. 2013). 
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A search on the ClinicalTrials.gov registry using the term “CAR T-cells” in January 2016, 
has revealed a total of 119 clinical trials. The results show that the number of clinical 
trials using CART-cells has increased over the years as shown in Figure 1.9 a. Moreover, 
the results also revealed that the key sponsors for clinical trials using CAR T-cells are 
Abramson cancer centre (University of Pennsylvania), the Bayor College of Medicine 
and the National Cancer Institute. Furthermore, the results show that the majority of 
clinical trials are autologous, on the initial stages of the clinical trial pathway and that 
there is an even distribution in the use of γ-retrovirus and lentivirus vector for gene 
editing. These trends are summarized in Figures 1.9-1.11.
Figure 1.9 a) CAR T-cell-based clinical trials by year b) CAR T-cell-based clinical trials 
by indication. Source: ClinicalTrials.gov. 
 
51 
 
 
Figure 1.10 CAR T-cell based clinical trials by sponsor. Source: ClinicalTrials.gov. 
 
52 
 
  
Figure 1.11 a) CAR T-cell-based clinical trials by donor source b) CART-cell-based 
clinical trials by gene delivery method. c) CAR T-cell based clinical trials by phase. 
Source:  ClinicalTrials.gov. 
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1.4 Manufacturing process 
 
The manufacturing process of allogeneic MSCs starts with the acquisition of the cells 
from donor tissue and it is followed by a cell culture step and a wash and concentration 
step. The manufacturing process of CAR T-cells is more complex and starts with attaining 
the donor’s peripheral blood mononuclear cells (PBMC). T-cells are then enriched, 
activated, genetically modified, cultured, washed and formulated. Figure 1.12 
summarises the key steps used in both processes. 
Figure 1.12 Schematic representation of manufacturing processes for MSC-based cell 
therapies and CAR T-cell therapies. 
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1.4.1 Pre-cell culture steps 
In MSC-based cell therapies, MSCs are first isolated from the initial cell source, (e.g. 
adipose tissue, bone marrow etc.). Techniques used for bone marrow isolation include 
enzymatic and mechanic methods (Lindroos et al. 2009). In CAR T-cell therapy the 
manufacturing process often starts with attaining the patients PBMCs (A Kaiser et al. 
2015; Poirot et al. 2015). This is typically done via leukapheresis (Singh et al. 2013a; 
Gašová et al. 2005; A Kaiser et al. 2015; Stroncek et al. 2015; B Levine 2015; Rees 2014). 
A relatively low risk procedure, during which typically 2 to 3 blood volumes from the 
patients is collected (Gašová et al. 2005; Bruce Levine 2015). 
In CAR T-cell manufacturing processes PBMCs may be enriched for T-cells (T-cell 
isolation) prior to activation (A Kaiser et al. 2015; Poirot et al. 2015; Kalos et al. 2011), 
or activated without enrichment (Poirot et al. 2015). T-cell enrichment can be carried out 
through different methods including size exclusion methods (e.g. Filtration) (Danova et 
al. 2011) and density gradient methods (e.g. Ficoll) (Danova et al. 2011; Lamers et al. 
2002; Zhou et al. 2003; Hillerdal et al. 2014). Additional techniques for T-cell enrichment 
include immune magnetic methods ( antibody-specific bead-based separation) (Ascierto 
et al. 2015; Stroncek et al. 2015; Danova et al. 2011). 
In both allogeneic CAR T-cell and allogeneic MSC-based processes, a cell bank may be 
built in order to produce and store an extensive uniform archive of readily available 
starting material. During this process, the isolated cells are cultured in order to achieve 
satisfactory numbers (Harel Adrian 2013). These cells are then characterized and 
cryopreserved (Harel Adrian 2013).  
During the manufacturing process of CAR T-cell therapy products, T-cell activation starts 
with the engagement of a TCR and an antigen  usually bound to a major histocompatibility 
complex (MHC) (Lever et al. 2014; Green et al. 2000). Once the T-cells are activated 
they start dividing, differentiating and destroying target cells (Lever et al. 2014). T-cell 
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activation often takes place in the presence of anti-CD3 and Anti-CD28 antibodies, 
(Trickett & Kwan 2003; Tumaini et al. 2013; Dropulic & June 2006; Zhou et al. 2003; 
Schoenborn et al. 2007; Kalos et al. 2011; Melchiori et al. 2014; Ascierto et al. 2015; 
Cartellieri et al. 2014; A Kaiser et al. 2015; B Levine 2015; Rees 2014; Walker & Johnson 
2016b). Anti-CD3 are able to stimulate T-cell proliferation through the TCR (Li & 
Kurlander 2010; Thompson et al. 1989). However, in the absence of a co-stimulatory 
molecule, the cells are short lived. Co-stimulatory molecules promote cell proliferation 
without early cell apoptosis (Li & Kurlander 2010). The most widely used co-stimulation 
factor is the CD28 receptor (Green et al. 2000; Li & Kurlander 2010; Thompson et al. 
1989). Anti-CD3 and CD28 stimulators can be used in three different configurations 
including antibody coated beads (Tumaini et al. 2013; A Kaiser et al. 2015; Zhou et al. 
2003; Melchiori et al. 2014; Cartellieri et al. 2014; B Levine 2015; Rees 2014; Li & 
Kurlander 2010), cell culture vessel coating (Schoenborn et al. 2007; Zhong et al. 2010) 
and nanomatrix (B Levine 2015).  
T-cell activation also requires interleukin 2 (il-2) (Lamers et al. 2002; Schoenborn et al. 
2007; Zhou et al. 2003; Ascierto et al. 2015). Interleukin 2 is essential in the 
differentiation of T-cells into effector cells after T-cell activation using antigens (Boyman 
& Sprent 2012). This compound was first approved by the FDA during the 90’s as a 
stimulator of effector cells for treatment for metastatic renal cancer (Dillman et al. 2004).   
Gene editing is a critical step of the CAR T-cell manufacturing process (Verhoeyen et al. 
2003). This step can be carried out using viral or non-viral methods (A Kaiser et al. 2015; 
Dai et al. 2016; Voigt et al. 2016). The challenges in achieving satisfactory T-cell genetic 
modification in the absence of viral vectors are higher (Zhao et al. 2006; Qasim & 
Thrasher 2014; Malek n.d.). These methods include DNA transfection (Jena et al. 2010; 
A Kaiser et al. 2015; Brentjens 2012; Qasim & Thrasher 2014; Malek n.d.) and 
transposons (Malek n.d.; Brentjens 2012; Dai et al. 2016; Qasim & Thrasher 2014; Voigt 
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et al. 2016; B Levine 2015), such as the sleeping beauty (Voigt et al. 2016; Qasim & 
Thrasher 2014; B Levine 2015). 
Typical viral vectors used for gene editing are the γ-retrovirus (Tumaini et al. 2013; 
Cartellieri et al. 2014; A Kaiser et al. 2015; Brentjens 2012; Morgan et al. 2010a; Ascierto 
et al. 2015; Malek n.d.; Walker & Johnson 2016b) and the lentivirus (Cartellieri et al. 
2014; A Kaiser et al. 2015; Brentjens 2012; Valton et al. 2015; Hillerdal et al. 2014; Kalos 
et al. 2011; Linette et al. 2013; Milone et al. 2009; Rees 2014). One of the key differences 
between the two is the fact that the γ-retrovirus cannot infect non-dividing cells (Cooray 
et al. 2012; L Naldini et al. 1996), as they require deconstruction of the nucleus of the 
target cell for integration of the cDNA into the chromosome (Liechtenstein et al. 2013). 
Lentiviral vectors on the other hand are capable of  transducing non-dividing cells 
(Liechtenstein et al. 2013; Dufait et al. 2012; Cribbs et al. 2013; Dai et al. 2016). 
Moreover, lentiviral vectors are potentially safer than γ-retroviral vectors (Liechtenstein 
et al. 2013; Kalos et al. 2011) as γ-retrovirus have a higher risk of insertional mutagenesis 
(Kalos et al. 2011; B Levine 2015). An example where the safety of γ-retrovirus was 
questioned is the clinical trial for X-linked severe combined imogenicity (SCID) using 
murine leukaemia virus (MlV), where several patients developed leukaemia (Dufait et al. 
2012; Qasim & Thrasher 2014). Furthermore, lentiviral vectors have also higher 
efficiency in transducing T-cells (Kalos et al. 2011; Zhou et al. 2003).  
The viral quantities added into the process are measured in multicity of infection (MOI). 
Different studies have employed different MOI values ranging from  between 0.2-18 
(Valton et al. 2015; Zhou et al. 2003; Milone et al. 2009; Barry et al. 2000). Barry et al. 
(2000) describes the transduction efficiency of up to 93% across T-cell lines with MOI 
values varying between 0.5 and 2 when using lentiviral vectors.  
One of the key disadvantages related to the use of lentiviral vectors relates to the difficulty 
of achieving stable packaging cell lines for viral production (Cooray et al. 2012; Qasim 
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& Thrasher 2014). Stable packaging cell lines are available with γ-retroviral vectors, 
facilitating large scale production of these vectors (Qasim & Thrasher 2014). Another key 
difference between the use of γ-retrovirus and lentivirus is that processes employing γ-
retrovirus for gene editing require the use of retronectin for co-localization of T-cells and 
the viral vector (Tumaini et al. 2013; Dodo et al. 2014; Rees 2014; Cooray et al. 2012; 
Ascierto et al. 2015). This reagent is typically added to the cell culture vessel at a 
concentration of 4-20 ug/cm2 (Takara n.d.; Lamers et al. 2002).  
A comparison between the use of lentiviral vector and the use of non-viral vector genetic 
modification methods such as transposons has revealed stable gene transfer using 
transposons with lower efficiency than with lentiviral vector (Field et al. 2013). Although 
lower transduction efficiencies have been reported with transposons, these have been used 
in clinical trials (Singh et al. 2013a). Moreover, transposons are seen as more cost-
effective method for gene editing than viral vectors (Field et al. 2013; Singh et al. 2013a; 
Dai et al. 2016). 
A second genetic modification step is used in allogeneic CAR T-cell processes. This step 
is used to genetically modify the transduced CAR T-cells in order to minimize the risk of 
GvHD and suppress the CD52 gene so that cells can survive even when drugs such as 
lemtuzumab (anti-CD52) have been used. GvHD is minimized by targeting the constant 
region of alpha chain of the T-cell receptor (TRAC). This second genetic modification 
step is currently carried out using transcription activator-like effector nuclease (TALEN) 
via electrophoration (Qasim et al. 2017). 
1.4.2 Cell culture 
MSCs require surface adherence for cell culture and have limited proliferation in vitro 
(Szczypka et al. 2014; Heathman et al. 2015). In large-scale manufacture of MSCs, 
multiple expansion stages are required, where the cells are collected from one reactor and 
diluted into multiple reactors. This process is called passage. During cell passage, the cell 
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culture media is removed from the cell containing cell culture vessel, the cells are then 
washed using PBS and detached from the surface of the cell culture vessel via enzymatic 
digestion (Hussain et al. 2013).  During enzymatic digestion,  trypsin is added to re-
suspend the cells at volume: area ratio of approximately 1ml:25cm2 and the cells are 
incubated at around 37°C for 2-10 minutes (Borowski et al. 2008). The enzymatic 
reaction is then quenched using cell culture  media and the resulting solution is distributed 
through a number of cell culture vessels prefilled with media (Borowski et al. 2008). 
MSCs grow to cell densities of 25,00-30,00 cells/cm2(Rowley et al. 2012; Szczypka et al. 
2014), with proliferation rates varying between  47 hours to over 80 hours depending on 
the cell source. The proliferation rate of MSCs decreases with increasing number of 
passages (Peng et al. 2008; Lu et al. 2006).  
 Given the limited in vivo proliferation of T-cells (Kalos et al. 2011; Sun et al. 2015), in 
vitro T-cell expansion is also required. This is done in suspension. CAR T-cell culture 
can last between 5 and 12 days and its  carried out in the presence of il-2 (Tumaini et al. 
2013; Valton et al. 2015; Linette et al. 2013; Porter et al. 2009; Kalos et al. 2011; 
Melchiori et al. 2014; Sumen et al. 2015; Granzin et al. 2015; B Levine 2015; Rees 2014; 
Dai et al. 2016; Walker & Johnson 2016b; Apel et al. 2013; Rosenberg & Restifo 2015). 
During the cell culture of CAR T-cells, the cells are often maintained at an optimal 
concentration of 2 × 106 - 1 × 107 (Ascierto et al. 2015; Hollyman et al. 2009b; GE 
healthcare n.d.; Cameron et al. 2013; Cartellieri et al. 2014; Singh et al. 2013b). This 
optimal concentration is considerably higher in perfusion cell culture as new cell culture 
media is constantly added to the bioreactor such as to replenish glucose and IL-2 levels 
and reduce lactate and ammonia levels in cell culture (Janas et al. 2015). Multiple sources 
have reported different proliferation rates for CAR T-cell therapies, these values are 
summarised in Table 1.3. 
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Table 1.3 Proliferation rate of CAR T-cells 
Source Fold increase No of 
days 
Activation method Expansion method Expansion mode Calculated Cell 
doubling time 
Bajgain et al (2014) 100 12 -  Gas permeable vessel Static 43 
Butler et al (2012) max ~3,000 28 CD3/CD28 dynabeads 
(Invitrogen) 
- - 164 
Butler et al (2012) Min ~200 28 CD3/CD28 dynabeads 
(Invitrogen) 
- - 239 
Carswell & Papoutsakis 
(2000) 
5 8 - Non- sparged STR STR 68 
Carswell & Papoutsakis 
(2000) 
3 8 - Sparged STR STR 96 
Carswell & Papoutsakis 
(2000( 
7 8 - T-flask Static 56 
Curran et al (2015) 
(Max) 
~70 21 CD3/CD28 dynabeads 
(Invitrogen) 
- - 168 
Curran et al (2015) 
(Min) 
~25 21 CD3/CD28 dynabeads 
(Invitrogen) 
- - 217 
Dang et al (2007) Max ~20 24 CD3/CD28 dynabeads 
(Invitrogen or Xcyte) 
Culture flasks Static 363 
Dang et al (2007) (Min) ~10 24 CD3/CD28 dynabeads 
(Invitrogen or Xcyte) 
Culture flasks Static 363 
Garland et al (1999) ~6.4 10 Allogeneic stimulator 
cells 
TTC bags Static 93 
Garland et al (1999) 
(Max) 
250 14 CD3/CD28 (Dynal 
biotech) 
- - 59 
Garland et al (1999) 
(Min) 
~4 10 Allogeneic stimulator 
cells 
Micro-well plates Static 120 
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Source Fold increase No of 
days 
Activation method Expansion method Expansion mode Calculated Cell 
doubling time 
Garland at al (1999) ~3.6 10 Allogeneic stimulator 
cells 
Culture flasks Static 120 
Garlie et al (1999) (Min) 4 14 CD3/CD28 (Dynal 
biotech) 
- - 212 
GE healthcare ( n.d.)  
(1L) 
~ 38 11 CD3/CD28 dynabeads 
(Invitrogen) 
VueLife bags & rocking 
motion bioreactor 
Static & perfusion 56 
GE healthcare (n.d.)  
(5L) 
~24 11 CD3/CD28 dynabeads 
(Invitrogen) 
VueLife bags & rocking 
motion bioreactor 
Static & perfusion 63 
Hoffmann et al (2004) 
(Min) 
2,200 26 CD3/CD28 (Dynal 
biotech) 
Micro-well plates Static 147 
Hoffmann et al (2004)  56,900 23 CD3/CD28 (Dynal 
biotech) 
Micro-well plates Static 80 
Hollyman et al (2009) 
(Max) 
668 17 CD3/CD28 dynabeads 
(Invitrogen or Xcyte) 
Orgien suspension bags 
& Rocking motion 
bioreactor 
 
Static & perfusion 
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Hollyman et al (2009) 
(Min) 
100 17 CD3/CD28 dynabeads 
(Invitrogen or Xcyte) 
Orgien suspension bags 
& Rocking motion 
bioreactor 
 
Static & perfusion 
104 
Jackson et al (2004) 
(Max) 
100 10 NY-ESO-11 – 13/ h NY-
ESO-1155 – 167 
Micro-well plates Static 36 
Jackson et al (2004) 
(Min) 
40 10 NY-ESO-11 – 13/ h NY-
ESO-1155 – 167 
Micro-well plates Static 45 
Janas et al (2015) 400 14 CD3/CD28 expander 
beads (Life technologies) 
Culture flasks & 
Rocking motion 
bioreactor 
Perfusion  39 
Janas et al (2015) 160 14 CD3/CD28 expander 
beads (Life technologies) 
Culture flasks & 
Rocking motion 
bioreactor 
Static 46 
Kalamasz et al (1997) 
(Control) 
~70 10 CD3/CD28 beads (Xcyte 
dynabeads) 
Micro-well plates  
Static 
39 
Kowolik et al (2005) 
(Max) 
40 14 - Micro-well plates Static 88 
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Source Fold increase No of 
days 
Activation method Expansion method Expansion mode Calculated Cell 
doubling time 
Kowolik et al (2005) 
(Min) 
1 14 - Micro-well plates Static - 
Lambert et al (2017) 
(Max) 
~16 19 CD3/CD28 PDMS beads Micro-well plates Static 228 
Lambert et al (2017) 
(Min) 
~6 19 CD3/CD28 PDMS beads Micro-well plates Static 288 
Levine et al (1998) 7.9 17 CD3/CD28 (Dynal 
biotech) 
Gas permeable bags 
(Nexcell therapeutics) 
Static 257 
Levine et al (1998) 9 17 CD3/CD28 (Dynal 
biotech) 
Culture flasks Static 204 
Mock et al (2016) 16.2 8 TransAct (soluble 
colloidal reagent with 
anti-CD3/CD28 
antibodies) 
Integrated USP/DSP 
platform 
Static 48 
Parker et al (2000) 
(Max) 
3,050,000 56 CD3 in solution Micro-well plate  
Static 
353 
Parker et al (2000) (Min) 119 25 CD3 in solution Micro-well plate  
Static 
214 
Rasmussen et al (2010) 
(Max) 
335 10 CD3/CD28 dynabeads 
(Invitrogen) 
Micro-well plates & 
culture flasks 
Static 29 
Rasmussen et al (2010) 
(Min) 
230 10 CD3/CD28 dynabeads 
(Invitrogen) 
Micro-well plates & 
culture flasks 
Static 31 
Smith et al (2015) (Max) 300 ~14 CD3/CD28 CTS 
dynabeads (Life 
technologies) 
Micro-well plates  
Static 
57 
Smith et al (2015) (Min) 120 ~14 CD3/CD28 CTS 
dynabeads (Life 
technologies) 
Micro-well plates  
Static 
68 
Startz et al (2016) (Max) 578 13 CD3/CD28 T-cell 
activator (Life 
technologies) 
Hollow fibre bioreactor Perfusion 34 
62 
 
Source Fold increase No of 
days 
Activation method Expansion method Expansion mode Calculated Cell 
doubling time 
Startz et al (2016) (Min) 73.5 12 CD3/CD28 T-cell 
activator (Life 
technologies) 
Hollow fibre bioreactor Perfusion 46 
Thompson et al (1989) ~35,000 38 CD3/CD28 (Dynal 
biotech) 
Micro-well plates & 
culture flasks 
Static 228 
Tran et al (2007) (Max) 1,700 14 Single chain CD3 Vue life Static 
suspension bag or culture 
flasks 
Rocking motion 
bioreactor 
Static & Perfusion 44 
Tran et al (2007) (Min) 247 14 Single chain CD3 Vue life Static 
suspension bag or culture 
flasks 
Rocking motion 
bioreactor 
Static & Perfusion 59 
Trickett & Kwan (2003) 
(Max) 
~1,800 14 CD3/CD28 dynabeads 
(Dynal biotech) 
Culture flasks Static 44 
Trickett & Kwan (2003) 
(Min) 
~10,000 14 CD3/CD28 dynabeads 
(Dynal biotech) 
Culture flasks Static 35 
* Doubling time were calculated under the assumption that the cells grow exponentially  
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1.4.3 Post-cell culture steps 
MSCs can  differentiate into multiple type of cells including adipose, chondrocytes and 
osteocytes (Lu et al. 2006; Peng et al. 2008; Hass et al. 2011). Cell differentiation is 
achieved through specific pathways using chemical stimulations in the cell culture 
(Brandenberger et al. 2011). These stimuli can be soluble (dissolved in the media) or 
insoluble (from the adhesion matrix) (Brandenberger et al. 2011). 
Washing and concentrating cells is required to remove unwanted process excipients such 
as residual serum and trypsin, as well as to reduce the volume of the product in order to 
achieve the desired final formulation cell concentration.  As the cells are the product, this 
process must have low shear such as to maintain cell viability (Raviv & Karnieli 2014).  
When designing a wash and concentration step for cell therapy products (including both 
CAR T-cell and MSC-based therapies), regulatory stipulations must be taken into 
account, for example the serum content of the final cell suspension must not exceed the 
1ppm (Pattasseril et al. 2013). Moreover, since the product cannot be sterilised and is 
often administrated intravenously, it is important to achieve an acceptably high impurity 
removal level of at least 85% and cell viabilities of at least 90% during the short 
downstream process (DSP) (Pattasseril et al. 2013).  
A final purification step is used in allogeneic CAR T-cell therapy and is carried out using 
magnetic selection (Qasim et al. 2017). This step is required to furthere reduce the risk of 
GvHD (Qasim et al. 2017).  
Cryopreservation is used to extend the shelf-life of the products. To do so, freezing media 
containing 10% dimethyl sulfoxide (DMSO) is typically used (Coopman & Medcalf 
2008; Borowski et al. 2008) and cells as frozen using a controlled rate freezer (Thirumala 
et al. 2009). 
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1.5 Technologies for cell therapy manufacture  
1.5.1 Pre-cell culture technologies  
In CAR T-cell therapy, technologies used to remove bulk red blood cells and platelet 
contaminants include: LOVO® (Frensenius Kabi, Bad Homburg vor der Höhe, 
Germany), COBE® 2991 (Terumo BCT, Lakewood, CO, USA) and the Cell Saver 5+® 
(Heamonetics, MA, USA) (Wang & Rivière 2016; Bruce Levine 2015).  LOVO® uses a 
spinning membrane filtration technology to purify cells (Wegener 2014). This technology 
can handle between 0.1L and 7.4L (Fresenius Kabi n.d.) at a flowrate of 1.7 L/h (200ml 
in 7min) (Fresenius Kabi n.d.) and achieve 92.3% recovery of white blood cells (Wegener 
et al. 2013). The COBE 2991® centrifuge, has been used in cell processing for over 30 
years (Rontis medical n.d.). This centrifuge has the ability to purify mononuclear cells 
with 89% recovery (Dragani et al. 1990) in a 0.55L chamber (Levine 2011a) and operates 
at a flowrate of 4L/h (Pattasseril et al. 2013).  The Cell saver 5+® is a autologous blood 
recovery system used in surgical procedures where blood loss occurs (Haemonetics n.d.). 
This technology is available in different bow sizes (70ml-225ml ) and can process 800ml 
per minute (Haemonetics n.d.). Moreover, the Cell saver 5+® can recover up to 94% of 
red blood cells (Serrick & Scholz 2005). 
For T-lymphocyte enrichment and monocyte reduction in CAR T-cell therapy processes 
technologies such as the Sepax® (Biosafe, GE healthcare,  Buckinghamshire UK) 
Elutra® (Terumo, Lakewood, CO, USA) can be used (Wang & Rivière 2016; Powell et 
al. 2009; Bruce Levine 2015; Levine 2011a). Sepax II®, employs centrifugation to wash 
volumes between 50 and 880ml, in approximately 40min, with approximately 94% CD4+ 
cell recovery (Biosafe n.d.; Food and drugs agency 2011). Elutra® is a counter flow 
separation system which can separate an entire apheresis sample in 1 to 2 hours (Levine 
2011b). This technology has a chamber volume of 40L and the flowrate is 150ml per 
minute (CaridianBCT 2008). For enrichment of specific T-cell populations such as CD4+, 
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CD8+ and CD25+, magnetic separation with instruments such as CliniMACS Plus® 
(Miltenyi Biotec) are often employed (Bruce Levine 2015; Wang & Rivière 2016; 
Willasch et al. 2010; Semple et al. 1993). This technology allows for purity and yield of  
95% and above to be achieved (Willasch et al. 2010; Semple et al. 1993). 
1.5.2 Cell culture technologies  
1.5.2.1 Planar cell culture vessels  
T-flasks & multilayer vessels 
T-flasks are available in different configurations, from 25cm2 to 1,720cm2 (Corning(R) 
n.d.). Both T-cells and MSC cells can be cultured using T-flaks (Stroncek et al. 2015; 
Ascierto et al. 2015; Granzin et al. 2015; Rowley et al. 2012). These flasks are often used 
in lab-scale manufacture and require open steps making the process  susceptible to 
microbial contamination (Ascierto et al. 2015). For larger scales  multilayer flaks  are 
available  (Lambrechts et al. 2016). These cell culture flasks are used in 26.1% of MSC-
based clinical trials (Lambrechts et al. 2016).  
Multilayer flasks are available in a 10-layer configuration and can be scaled-up to up to 
40 layers  in compliance with  good manufacturing practice (GMP) guidelines (Rowley 
et al. 2012). Moreover, these flasks can provide can provide up-to 25,280cm2 for cell 
growth (ThermoFisher scientific n.d.). Similarly to T-flasks, multilayer flasks  can also 
be used in MSC and CAR T-cell processes. Scaling-up using these multilayer flasks is 
achieved by increasing the number of layers and vessels (Rowley et al. 2012). 
Alternatives to ease scaling-up using multilayer vessels include the incorporation of 
robotics for cell culture vessel manipulation (Rowley et al. 2012). 
Multi-plate bioreactors  
Multi-plate bioreactors account for 1.4% of MSC-based cell therapy trials (Lambrechts 
et al. 2016), and offer a closed environment for cell expansion (Pereira Chilima et al. 
2016; Michiels & Egloff 2013). These bioreactors are typically used for the expansion of 
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adherent cells such as MSCs. Multi-plate bioreactors simulate a similar  
microenvironment as traditional open  processes while providing an integrated process 
control (Pereira Chilima et al. 2016; Michiels & Egloff 2013; Simaria et al. 2014b). 
Moreover, these bioreactors are also available in multiple configurations, which each 
plate providing 620cm2 for adherent cell growth, and, the number of plates per bioreactor 
varying between 10 and 200 (Szczypka et al. 2014; Castillo 2014; Michiels & Egloff 
2013).  
Gas permeable vessels (G-Rex ®) 
An example of a gas permeable vessel is the G-Rex ® series (WilsonWolf, Minnesota, 
US). These flasks can be used for T-cell expansion (A Kaiser et al. 2015; Sun et al. 2015; 
Somerville & Dudley 2012; Jin et al. 2012; Ascierto et al. 2015; Andrew Kaiser et al. 
2015). Gas permeable vessels are available in open and closed configurations, with sizes 
varying from 2cm2  to 500cm2  and cell growth capacity of 20B to 20B cells (Wilson 
Wolf n.d.). Key advantages using gas permeable vessels include the enhanced oxygen 
supply to the cells through the use of a gas permeable membrane and linear scale-up 
(Bajgain et al. 2014; Wilson Wolf n.d.). This enhanced oxygen supply allows cells to 
grow to a higher cell density (1x107 cells/ml) (Ascierto et al. 2015). Which results in 
lower costs with respect to T-flasks (Jin et al. 2012). Moreover, gas permeable vessels 
have also shown similar and even superior performance than rocking motion bioreactor 
(B Levine 2015). 
1.5.2.2 3-D cell culture vessels  
Static suspension bags  
T-cells can be cultured in suspension bags (Lamers et al. 2002; Somerville & Dudley 
2012). These gas permeable bags are available in multiple configurations with  volumes 
as high as 3L and hence are capable of supporting T-cell applications with high cell 
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numbers (Saint-Gobain 2016). Disadvantages of the use of static suspension bags include 
the fact that this technology is labour intensive (B Levine 2015; Somerville & Dudley 
2012) and scale-up using suspension bags may not be linear (Somerville & Dudley 2012). 
Typical cell concentrations achieved in suspension bags range between 2×106 and 6×106 
cells/ml (Ascierto et al. 2015). 
Hollow fibre bioreactor  
Hollow fibre bioreactors can be used for CAR T-cell culture and have been employed in 
11.6% of MSC-based clinical trials (Startz et al. 2016; Dillman et al. 2004; Ascierto et al. 
2015; Lambert et al. 2017). Hollow fibre technology has been applied in a number of 
applications such as tangential flow filtration (TFF) and perfusion cell cultures (Whitford 
& Cadwell 2009) and provide a functionally closed system for cell growth. Moreover, 
hollow fibre bioreactors can perform automated tasks such as  seeding, harvest and media 
exchange. Furthermore, these bioreactors provide up to 21,000cm2 for adherent cell 
growth (Startz et al. 2016). Hollow fibre bioreactors contain two circulation loops: 
interpapillary and extracapillary loops (Hanley et al. 2014). Media and reagents can be 
fed into the bioreactor through both loops and cells can only be fed via interpapillary loop 
(Hanley et al. 2014). A recycling loop is connected to the to the extracapillary loop where 
fresh or re-oxygenated media can circulate back to the cells (Whitford & Cadwell 2009; 
Hanley et al. 2014).  
Packed bed reactors  
Packed bed bioreactors where originally used in  manufacturing antibodies and proteins, 
since the extracellular product can be continuously harvested through media recycling 
(Rowley et al. 2012). These bioreactors are now employed in 8.7% of MSC-based clinical 
trials (Lambrechts et al. 2016). The size of packed bed bioreactors may vary between 
10ml to 40L  (Rowley et al. 2012). The carriers used in packed bed bioreactors may come 
in different configurations such as pours and non-pours glass beads, woven disks and 
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glass fibres (Meuwly et al. 2007; Park & Stephanopoulos 1993; Wang et al. 1992) and 
typically allow for a total surface are for cell growth of  8,000 cm2/L (Karnieli 2015). 
Furthermore, the use of this bioreactor is also believed to reduce cost of goods due to the 
high surface area to volume ratio (Raviv & Karnieli 2014). One of the challenges 
associated with the use of this technology is the maintenance of axial and radial 
homogeneous nutrient distribution (Rowley et al. 2012). This affects the homogeneity of 
the cell density profile across the bed (Rowley et al. 2012). A possible strategy to address 
this problem is the introduction of impellers to agitate the media for a more homogeneous 
profile  (Rowley et al. 2012). Furthermore, cell recovery from the carriers is also 
challenging   (Rowley et al. 2012; Raviv & Karnieli 2014). Pluristem (Haifa, Israel) has 
addressed this issue by employing controlled agitation and movement to aid enzymatic 
dissociation of cells from the carriers (Raviv & Karnieli 2014). 
Rocking motion bioreactor  
Rocking motion bioreactor has been used in other biopharma processes and can be 
operated in both batch and  perfusion mode (Sadeghi et al. 2011; Somerville & Dudley 
2012). These bioreactors employ rocking motion to enhance mixing (B Levine 2015). 
Rocking motion bioreactors can be employed for both suspension and adherent cells 
expansion (A Kaiser et al. 2015; Kalos et al. 2011; Sadeghi et al. 2011; Melchiori et al. 
2014; Somerville & Dudley 2012; Ascierto et al. 2015; Porter et al. 2009; Timmins et al. 
2012; Szczypka et al. 2014). The use of  rocking motion bioreactors in adherent cell 
culture is frequently coupled with microcarriers (Timmins et al. 2012; Szczypka et al. 
2014). Rocking motion bioreactors currently available in the market for cell therapy 
applications include the Xuri® (GE healthcare, Buckinghamshire, England) and the 
XRS® (Pall corporation, NY, US). Combined these can offer configurations ranging from 
2L to 50 L (GE Healthcare 2014; Pall Corporation n.d.). 
Stirred tank bioreactor  
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Stainless steel stirred tank bioreactors have been employed in the biopharmaceutical 
industry in volumes of up to 10,000’s of litres (Szczypka et al. 2014). In adherent cell 
therapy expansion, stirred tank bioreactors are single-use and are often used with 
microcarriers (Julaey et al. 2016; Mizukami et al. 2016; Lawson et al. 2017; Petry et al. 
2016; Jossen et al. 2014; Dufey et al. 2017; Rafiq 2013; Tsai & Ma 2016). These 
bioreactors, account for 52.2% of MSC-based clinical trials (Lambrechts et al. 2016). 
Stirred tank bioreactors with microcarriers have been proposed a solution for expansion 
of adherent stem cells for indications with very large annual demands due to their higher 
capacity (Simaria et al. 2014b). Besides the increased surface area for cell culture, an 
additional benefit of using stirred tank bioreactors  is that they give a greater control over 
the cell culture environment, including monitoring and control of process parameters 
(Petry et al. 2016). Stirred tank bioreactors available in the market include the CelliGen 
BLU® (Eppendorf, Hanburg, Germany)  CellReady® (Millipore, Billerica, MA USA), 
PadReactor® (Pall corporation, NY, US ) and BIOSTAT STR® (Sartorious Stedim, 
Aubagne, France). Together these bioreactors have volumes ranging from 1L to 2,000L 
(Brindley et al. 2014). One of the challenges to the use of this bioreactor is achieving 
optimal hydrodynamic shear which is controlled by the impellers in the bioreactor 
(Panchalingam et al. 2015). If this shear is too low then cell aggregates may formed; if is 
too high however, damage to the cells or unwanted differentiation may occur 
(Panchalingam et al. 2015). 
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Table 1.4  Examples of microcarriers available in the market 
Name Manufacturer Type Surface  Interaction type Surface 
area (cm2/g) 
Working 
concentration (g/l) 
Average  
cm2/L  
Cultispher-S Sigma-Aldrich   Porous Gelatinb Porcine Gelatinj 7,500j 1-3a, d, g, l 15,000 
Cytophore 1 Pharmacia  Macroporous Cross-linked cotton 
cellulosee 
 
Diethylaminoethyl e, j 11,000e 2 e, j 22,000 
Cytophore 2 Pharmacia Macroporous   11,000e 2e, j 22,000 
Cultispher-G Sigma-Aldrich Porous Gelatinb, e Gelatine, j 40,000e 1-8.5d, e, h 180,000 
Cytodex 3 GE Healthcare Microporous Dextran, Gelatinb, j Denatured collagene, j, k 2,700e,j 0.5-5c,e, g, k, l 6075 
Cytodex 1 GE Healthcare Porous Dextran, positively 
chargedb, j 
Diethylaminoethyle, j 4,400e, f, k 1.2-5e, f, h, k 13,860 
DE53 Whatman  Non-Porous Cellulosee Diethylaminoethyle 6,800e 4e 27,200 
DE52 Whatman Non-Porous Cellulosee Diethylaminoethyle 6,800e 4e 27,200 
QA52 Whatman Non-Porous Cellulosee Quaternary Ammoniume 6,800e 4e 27,200 
CM52 Whatman Non-Porous Cellulosee Carboxymethyle 6,800e 4e 27,200 
Typopearl Tosho Biosciences  Non-Porous Hydroxylated 
Methacrylatee 
Tresyl ligand derivatized 
with Protamine sulfatee 
42,00e 1e 4,200 
TSKge1 Tosho Biosciences Non-Porous Hydroxylated 
Methacrylatee 
Tresyl ligand derivatized 
with Protamine sulfatee 
9,000e 0.2e 1,800 
Hillex II Pall Solohil Non-Porous Dextran, surface coatedb, j Modified 
Polystyrene, 
modified with 
cationic trimethylammoniumj 
515i 10-50i, j 15,450 
aMelero-Martin et al. 2006 
bMartin, Eldardiri, Lawrence-Watt, & Sharpe, 2011 
cFernandes et al., 2009 
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dPercell Biolytica, n.d.  
eChen, Chen, Choo, Reuveny, & Oh, 2011 
fSchop, Janssen, Borgart, de Bruijn, & van Dijkhuizen-Radersma, 2008 
gSart, Schneider, & Agathos, 2010 
hNg, Berry, & Butler, 1996 
iPall Life sciences, 2015 
jIkonomou, Drugmand, Bastin, Schneider, & Agathos, 2002 
kFrauenschuh et al., 2007 
lFernandes et al., 2007 
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Microcarriers  
There are different microcarrier configurations currently in the market (Table 1.4). The 
selection of the right microcarrier is crucial as the use of different microcarriers will 
results in different growth rates and pluripotency profiles (Chen et al. 2011a) (Table 1.4). 
The different types of microcarriers available in the market can be made of polystyrene 
such as HyQsphere® by HyClone (GE healthcare, Buckinghamshire, England) and 
Hillex® by SoloHill Engineering (Pall corporation, NY, US). Others are made of cross-
linked dextran such as Cytodex® by GE Healthcare.  Cytodex® has a macroporous 
configuration whilst others are spherical and smooth or even rod-shaped (Rowley et al. 
2012).  One of the drawbacks of using microcarriers is the possible creation of fine 
particles during cell harvest, which must then be removed after expansion  (Rowley et al. 
2012). A possible solution to address issues with microcarrier removal is the use of 
biodegradable or thermosensitive microcarriers where the cells do not need to be detached 
from the carriers (Yang et al. 2010). 
1.5.3 Post-cell culture technologies  
1.5.3.1 Filtration techniques  
There are two types of filtration: dead-end filtration (NFF) and tangential flow filtration 
(TFF). These techniques are considered to be relatively fast, simple, scalable and cost-
effective (Pattasseril et al. 2013; Diogo et al. 2012). During a filtration run the separation 
is not only is done according to the particle size but also according to the adsorption of 
the particles to the membrane (Pattasseril et al. 2013; Diogo et al. 2012).  
TFF is widely used in the protein industry  and its able to treat 1,000s of litres. During a 
TFF run the transmembrane pressure (TMP) which is the driving flow for fluid motion, 
pushes the fluid parallel to the membrane in a flat sheet or cartilage (Kahn et al. 2001). 
TFF systems have been adapted to the manufacture of cell therapy products (CT-TFF) by 
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companies such as GE healthcare and Pall life sciences. Examples of changes made to 
the traditional TFF systems include the implementation of features such as non-invasive 
flow sensors and single-use pressure sensors (Pattasseril et al. 2013; Raviv & Karnieli 
2014). Both TFF and centrifugation can be used in sequence for harvesting volumes 
between 20L and 100L (Rowley et al. 2012). However, these require a high degree of 
optimisation and validation when microcarriers are used for cell culture (Rowley et al. 
2012).   
1.5.3.2 Fluidized bed centrifugation   
The only large scale single-use fluidised bed centrifuge currently available in the market 
is the kSep® (kSep systems, Morrisville, NC, USA). The kSep centrifuge is fully 
automated and has  the capacity of processing up to 1B cells per run (Raviv & Karnieli 
2014), with  yields of 80% and higher and  cell viabilities higher than 90% (Pattasseril et 
al. 2013). The major drawback of these technologies is that cells are discharged in 
extremely large densities which decreases the efficiency of the washing steps by reducing 
the yield by 10%-30% (Pattasseril et al. 2013). Moreover multiple washing steps maybe 
required which would result in a longer processing time and higher processing costs 
(Pattasseril et al. 2013). 
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Table 1.5 Example of downstream process technologies available in the market 
 
1.5.3.3 Additional methods for cell purification  
Additional methods for cell purification include cell culture-based separation, differential 
trypsinization, fluorescence activated cell sorting (FACS), immunomagnetic selection 
and affinity chromatography. In cell culture-based separation, cells are separated 
according to their ability to adhere to the plastic cell culture vessel. This method can be 
used for the separation of MSC cells from haematopoetic stem cells which do not often 
adhere to the surface of the cell culture vessel, and therefore can be removed during a 
buffer exchange step (Lennon & Caplan 2006). Differential trypsinization can be used to 
remove high cell numbers as different cells  detach from the adherent surface at different 
incubation times (Diogo et al. 2012). 
 FACS is widely used in cell isolation. This method employs size exclusion and light 
scattering of cells to achieve separation (Aubert et al. 2003).  Immunogenic selection was 
previously mentioned as a method for T-cell and CAR+ T-cell enrichment. This method 
uses magnetic interaction where monoclonal antibodies are bound to beads. These beads 
Name Vendor Capacity Principle Function (s) 
CT-TFF® Lonza 1.25-750L/ha Filtration Concentration 
Washa 
TFF® GE 
Healthcare  
25- 1250L/ha Filtration Concentration 
Washa 
Ksep® kSep Systems  114-720 L/ha Centrifugation Concentration 
harvest and 
washa 
Harvestainer® Thermo 
Scientific 
200L/bagb Size exclusion  Microcarrier-
supernatant 
separationb 
LOVO® Frensenius Kabi 1.4 L/hc Spinning 
membrane 
filtration 
Cell wash and 
concentrationc 
COBE® Terumo BCT 4L/ha Centrifuge  Cell wash and 
concentrationa 
Sepax®  Biosafe SA 0.88Ld Centrifugation  Cell wash and 
concentrationd 
aPattasseril et al. 2013 
bThermoscientific, 2017 
cFresenius Kabi, n.d.  
dBiosafe, n.d. 
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are then mixed with the cell suspension and are put  through a column (Diogo et al. 2012). 
A magnetic field is applied to the cells and the cells with a particular phenotype stay in 
the column (Diogo et al. 2012). The magnetic field is then removed and the cells can elute 
out of the column (Diogo et al. 2012).  
Affinity chromatography is a powerful and is widely used as a separation technique. This 
technique has the potential of separating different cell types. The potential issues 
associated with affinity chromatography  include high shear stress and low throughput 
(Diogo et al. 2012). 
1.5.4 Integrated technologies  
Over the past few years, fully integrated technologies have become available for the 
manufacture of cell therapy products. These technologies include the Prodigy® (Miltenyi 
Biotec, Bergisch Gladbach, Germany) and the Octane Cocoon® (Octane Biotech, 
Ontairo, Canada). The Prodigy® is an automated integrated platform which encompasses 
a cell culture and centrifugation chamber with a capacity of 400ml (Apel et al. 2013). 
This integrated platform is able to carry out multiple manufacturing steps such as: PBMC 
enrichment, cell activation, cell culture, cell wash and formulation (Apel et al. 2013). 
Little information is currently available regarding the Octane Cocoon technology. This 
technology can be used for customised cell culture and tissue engineering (Octane n.d.). 
One of the key differences between the Prodigy® and the Octane Cocoon® is that the 
latter can also be used for cell culture on a scaffold (Octane n.d.). 
1.6 Challenges to commercialisation and future trends for CAR T-cell and MSC-
based cell therapy products 
1.6.1 Clinical performance  
Demonstrating good clinical performance is crucial for the market acceptance of cell 
therapy products (Webster 2016).  In contrast with traditional drugs, cell therapy clinical 
trials are carried out in patients as opposed to healthy volunteers, due to the possible risks 
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associated with these therapeutics  (Mount et al. 2015a). Hence selecting the correct 
patients may reduce the risks of adverse effects and enhance clinical performance (Mount 
et al. 2015a). Moreover, the patients treatment history is also likely to affect the 
performance of the treatment, as the pre-conditioning regime has shown to have an effect 
on the success of cell therapy products (Han et al. 2013). Furthermore, the delivery mode 
of the cell therapy will have a high influence on the performance of the cell therapy 
product as well as in potential advert effects (Bang et al. 2016; Wei et al. 2013a). 
In MSC-based therapies the type of cells used affects the potency and proliferation of 
cells (Jin et al. 2013; Wang et al. 2009). CAR T-cells are distributed across the body after 
infusion, and exhibit persistence for long-term identification and destruction of cells 
which express the target tumour antigen (Sentman 2013). Factors influencing the 
persistence of the CAR T-cell products include the constitution of the product itself  
(Barrett et al. 2015). For example, historically, T-cell therapy products were composed 
of differentiated cytotoxic T-cells (CD8+ T cells ); although these cells have high toxicity 
against tumours, they lacked proliferative capacity in vivo, and hence, post-infusion 
resistance was generally low (Barrett et al. 2015). Current attempts to overcome this 
limitations, include the use of T-helper cells (CD4+ cells) to supply growth factors for 
higher resistance of CD8+ cells in vivo (Barrett et al. 2015). 
Significant challenges have been reported when using CAR T-cell therapies in solid 
tumours (Guo et al. 2016; Walker & Johnson 2016a; Han et al. 2013; Gilham et al. 2012) 
including understanding  the mechanisms of  T-cell trafficking required in order to supply 
enough CAR T-cells to the tumour site (Gilham et al. 2012; Walker & Johnson 2016a; 
Newick et al. 2017; Guo et al. 2016; Webster 2016; Han et al. 2013). In solid tumours, T-
cell trafficking is critical and is dependent on the relationship between the adhesion to 
receptors in the tumour endothelium, the CAR T-cell, the chemokines produced by the 
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tumour and the chemokine receptor on the CAR T-cell (Newick et al. 2017). Furthermore, 
the microenvironment in solid tumours is often immunosuppressive, which caused the 
first generation CAR T-cell products to be short-lived, resulting in less significant 
improvements in patients in solid tumour clinical trials versus blood cancers clinical trials 
using CAR T-cell products  (Newick et al. 2017; Walker & Johnson 2016a; Guo et al. 
2016; Webster 2016; Gilham et al. 2012).  
In order to overcome the persistence, safety and effectiveness hurdles of CAR T-cell 
therapies, companies such as Juno Therapeutics (Seattle, WA, USA) and Cellectis (Paris, 
France )  have been developing second  and third-generation CARs,  (Han et al. 2013; 
Webster 2016). Some of these novel CARs include solid tumours co-stimulatory 
molecules such as CD28, 4-1BB, and OX40 (Morgan et al. 2010b; Beatty et al. 2014; 
Ahmed et al. 2015). Studies using second-generation CAR T-cells products have 
indicated that these treatments can be efficacious and safe against solid tumours (Beatty 
et al. 2014; Maus et al. 2013; Katz et al. 2015). Additional features of new generation 
CARs include the incorporation of  safety mechanisms (kill switch) in order to damp the 
adverse effects of CAR T-cell products (Webster 2016). 
1.6.2 Adverse effects  
As previously mentioned, MSCs have low immunogenicity and are short-lived once 
transplanted into the patient (Wei et al. 2013a; Le Blanc 2003; Trounson & McDonald 
2015). However, adverse effects have been reported with these type of therapies, as they 
are involved in tumour modulation. These side effects include enhancement of tumour 
growth and metastasis when MSC are administered to oncology patients (Wong 2011). 
In CAR T-cell therapy, severe adverse effects have also been reported. The most notable 
side effect of the use of CAR T-cells is cytokine release syndrome (CRS), which are 
typically more severe in treatments with high dose, due to the high number of  CAR T-
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cells and their high proliferation rate  (Barrett et al. 2015; Sentman 2013; Guo et al. 2016). 
These reactions are independent from the specificity of the antigen of the CAR T-cells 
used, however, the likelihood of a patient developing CRS is dependent on the target 
indication (e.g. ALL shows higher risk of CRS than CLL) (Barrett et al. 2015; Sentman 
2013). The severity of these CRS reactions can vary from fever to respiratory failure 
(Barrett et al. 2015). Moreover, if  a high risk of developing  CRS after CAR T-cell 
infusion persists, the use of CAR T-cell therapies may only be employed  in extreme cases 
where patients have failed to respond to all other therapies, decreasing the target market 
for these therapies (Webster 2016). Furthermore, additional side effects of the use of CAR 
T-cells include neurologic toxicities  and “on target” toxicities (toxicities which are 
related to the antigen specificity of the CAR T-cells) (Barrett et al. 2015; Morgan et al. 
2010b).   
1.6.3 Manufacturing process and supply chain 
Cell therapy products are complex, very sensitive to environmental changes and require 
multiple expensive biological agents, and as such their manufacturing process presents 
multiple challenges (Ratcliffe et al. 2011). The current cell therapy manufacturing 
processes are highly manual, which makes them highly variable and susceptible to 
operator error (Lopez et al. 2010). The chances for operator error are bound to increase 
with increasing batch size, as more manipulations are required. Furthermore, other 
sources of variability are present in cell therapy manufacturing such as the cell source, 
age and health of the donor, the heterogeneity of the cell bank and reagents used (e.g. 
serum) (Heathman et al. 2015; Lapinskas 2010; Lopez et al. 2010; Christodoulou et al. 
2013). Variation is particularly present during the differentiation process of MSC cells as 
this process requires the cells to go through multiple stages including a number of media 
exchange steps used to add different process components (Brandenberger et al. 2011).  
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Additional hurdles surrounding the manufacture of MSCs are related to the scalability of 
current technologies (Chereau 2011; Heathman et al. 2015). Since MSCs are anchorage-
dependent, if  planar technologies are employed (e.g. cell factories and T-flasks), the 
number of cell culture vessels required in parallel per batch would rapidly increase and 
become unmanageable at very large cellular demands (Simaria et al. 2014b). This would 
result in a high facility footprint and consequently high capital investment. The severity 
of this scalability issue depends on the indication being targeted (Prieels et al. 2012). For 
low dose indications (~1×107 cells) such as low back pain (Pang et al. 2014; 
GlobeNewswire 2016b)  cell culture flasks may suffice; these multi-layer vessels have 
the adequate capacity to produce cell numbers as high as 400B cells per batch (Rowley 
et al. 2012). These vessels however, employ open processing, which demand for 
expensive cleanrooms (Fitzpatrick 2008), increasing the initial investment required. 
For treatments such as GvHD or heart disease with higher dose sizes (108-109cells per 
patient) (Hare et al. 2009; Introna et al. 2014; Lazarus et al. 2005; Lin & Hogan 2011; 
Bell Potter 2011; ClinicalTrials.gov 2016) however, larger cell culture vessels would be 
required. Moreover, increasing the annual demand (and hence the batch size) reduces the 
number of candidate technologies for both cell culture and DSP applications (Hassan et 
al. 2015; Simaria et al. 2014b). High annual demands require the use of stirred tank 
bioreactors with microcarriers, which will allow for  batch sizes of trillion of cells to be 
achieved (Rowley et al. 2012; Simaria et al. 2014b), while maintaining optimal and 
controlled physiochemical conditions and environment for cell growth (Wendt et al. 
2009). The use of microcarriers in suspension carries its own hurdles, as the cells must 
be separated from the microcarries after the expansion step. Moreover, the fact that cell 
separation is carried out using enzymatic intervention, puts an additional strain on the 
downstream process, as enzymatic treatment must be quenched rapidly to avoid damage 
to the cells (Lapinskas 2010; Raviv & Karnieli 2014). The time between cell detachment 
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and final formulation typically varies from less than 1 hour to up to 4 hours (Lapinskas 
2010; Raviv & Karnieli 2014; Hassan et al. 2015).  
The production of autologous CAR T-cell products requires complex logistics, hence 
successful coordination between the collection centre, the manufacturing site and the 
administration centre is vital (Levine et al. 2017; Sharpe & Mount 2015b; Mount et al. 
2015b). Moreover, the complexity of CAR T-cell products makes it so these products will 
only be available in specific clinics (Flinn et al. 2016), as variability at point of care is 
likely to occur due to differences in thawing technique across physicians (Davie 2013; 
Trainor et al. 2014; Flinn et al. 2016).  
Manufacturing challenges related to autologous CAR T-cell manufacture include 
significant batch-to-batch variability attributed to the fact that each batch uses cells from 
a different patient  (Levine et al. 2017; Sharpe & Mount 2015b; Webster 2016).  This 
makes standardization, scheduling and quality control of CAR T-cell processes 
challenging (Webster 2016). Hence, CAR T-cell therapies would highly benefit from the 
development of optimized protocols for product manufacture from sample collection to 
final formulation (Sharpe & Mount 2015b).  
To date, CAR T-cell therapy have only been used for in a smaller number of patients 
hence, the logistics and manufacturing challenges will become more apparent as the 
process is scaled-out in order to meet higher clinical demands (Levine et al. 2017). 
Moreover, as the number of CAR T-cells candidate therapies increases, so does the 
demand for viral vector stocks. Hence, higher  performance in viral vector transduction 
must be achieved and processes for viral vector manufacture must be optimized in order 
to increase the cost-effectiveness of products that require viral vectors for gene editing 
(Sharpe & Mount 2015b; B Levine 2015).  
In order to overcome some of the key challenges characteristic of autologous products, 
companies such as Cellectis are investing in allogeneic CAR T-cell therapies as these 
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could potentially be readily available to the patients  (Webster 2016). These novel CAR 
T-cell therapy products will allow for cell bank formation and the use of a scale-up 
approach to product manufacture, which may result in lower manufacturing COG (Mount 
et al. 2015b). 
Different cell therapy products have different formulations and therefore require different 
storage and transportation arrangements. An example of this is the final form of 
ChrondoCelect® versus Provenge® and Prochymal®. ChrondoCelect® is stored at room 
temperature whilst Provenge®  requires cold storage and must be transported in a sealed 
container under 18 hours, making the transportation process significantly more 
challenging (Coopman & Medcalf 2008; Harvard Medical School 2010). Prochymal® on 
the other hand is a cryopreserved product stored at -135°C which allows for a shelf-life 
of up to 2 years (Kebriaei et al. 2009).  
Using methods to extend product shelf-life has significant benefits in autologous 
processes as cells can be preserved prior to cell culture. This allows for  the cell collection 
to be carried out in multiple occasions, in cases where the patient is incapable of supplying 
sufficient cells at once (Coopman & Medcalf 2008). This was the case of 25% of patients 
which were treated with Provenge® (Coopman & Medcalf 2008). Cryopreservation often 
relies on the use of DMSO. The use of DMSO has shown to negatively affect the cells at 
positive temperatures depending on length of exposure and concentration (Coopman & 
Medcalf 2008). This can be manifested in loss of cell viability, which has been shown to 
drop by as much as 30% post cryopreservation (Ostrowska et al. 2009). Furthermore, the 
use of controlled rate freezers for cryopreservation also poses challenges in  maintaining 
temperature uniformity in multiple vials at commercial scale manufacture (Thirumala et 
al. 2013). Alternative methods for short-term cell preservation include hypothermic 
storage. This method allows for cell preservation whilst keeping them  in positive 
temperatures (Coopman & Medcalf 2008). 
82 
 
1.6.4 COG and reimbursement  
At present, there is a general trend in which companies do not heavily invest in the 
translational process before clinical success is seen, in order to minimise risks (Mount et 
al. 2015b). Investing in process optimisation requires significant funds and may delay the 
time to market (Coopman & Medcalf 2008). However, if the manufacturing issues related 
to technology scalability, supply chain, product stability, robustness etc. are not 
considered early in the process development the  selling price of the cell therapy product 
may exceed the pricing threshold set by the payers (Mount et al. 2015b).  For example, 
Dendreon used a manual and non-closed process for the manufacture of the autologous 
product Provenge®. This product required a facility footprint as high as 16,723m2 
(Dodson & Levine 2015b). The high COG associated with this manufacturing process 
cause the selling price to reach $93,000USD (Dodson & Levine 2015b). Moreover, 
estimating the annual sales in the cell therapy industry is challenging. For example, in 
2009 only 2% of the projected market for cell therapy products was captured in the USA 
(Mason et al. 2011).  Another example of this challenge in estimating market penetration 
is the significantly lower sales seen for the Provenge®, where the company foreseen sales 
as high as $400M USD but only $68.6M USD in sales were achieved (Timmerman 2011). 
In addition to challenges in market forecast, securing adequate reimbursement for cell 
therapy products is also difficult due to the fact cell therapy products will likely be more 
expensive than traditional drugs  (Dodson & Levine 2015b). 
1.7 Cell therapy facilities 
1.7.1 Introduction to single-use technologies 
Single-use technologies (SUTs) were first introduced in the market 1970’s in the form of 
filters and capsules (Kinsella & Dewan 2015; Lopes 2015). Ever since, SUTs have 
increasingly been employed at different stages of product development (Guldager 2010; 
Pharma IQ 2013; Sandstrom n.d.; Levine et al. 2012; Tiene 2016; Geipel-Kern 2009). 
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The SUTs now available in the market include storage and mixing bags, bioreactors, 
downstream processing solutions etc. (Barak & Bader 2008; Flaherty & Perrone 2012; 
Jacquemart et al. 2016; Kinsella & Dewan 2015; Pollock et al. 2013; Rayner 2010; 
Sargent 2013; Lopes 2015; Shukla & Gottschalk 2013; Tiene 2016). The SUT market 
was estimated at $1.7B USD in 2014 (Chapman & Krishnan 2010) and foreseen to grow 
beyond 100’s of billions of  dollars by 2019 (Pharma IQ 2013; Langer & Rader 2014) as 
biotech companies as large as Shire, now utilize SU bioreactors for commercial scale 
product manufacture (Levine et al. 2012). Furthermore the highest sales seen in  the SUTs 
market are for technologies used for product manufacture during R&D (Langer & Rader 
2014). In commercial scale manufacture DSP SUTs are more popular than upstream 
process (USP) SUTs (Langer & Rader 2014). 
1.7.2 Pros and cons of single-use facilities 
Multiple benefits of switching to single-use manufacture have been reported (Rogge et 
al. 2015; Novais et al. 2001; Barak & Bader 2008; Guldager 2010; Levine et al. 2012; 
Stock R. 2011; Rayner 2010; Haigney 2016; Eibl & Eibl 2010; Geipel-Kern 2009; 
Sargent 2013; Tiene 2016; Whitford 2010; Flaherty & Perrone 2012; Shukla & 
Gottschalk 2013; Lopes 2015; biopharm services Limited 2014; Sandstrom 2009; Langer 
& Rader 2014). These benefits include the removal of the cleaning in place (CIP) and 
sterilization in place (SIP) operations, which also ease the cleaning and sterilizing 
validation processes (Rogge et al. 2015; Barak & Bader 2008; Levine et al. 2012; Rayner 
2010; Haigney 2016; Tiene 2016; Flaherty & Perrone 2012). Reducing CIP  and SIP 
operations was revealed to be the main reason that drove companies to implement SUTs 
in a survey carried out by the Bio-Process Systems Alliance (Geipel-Kern 2009). Doing 
so also reduces the changeover time between batches and products, which eases multi-
product manufacture (Rogge et al. 2015; Barak & Bader 2008; Haigney 2016; Flaherty 
& Perrone 2012; Lopes 2015). The change-over process  can take over two weeks, hence 
84 
 
reducing this duration of this process would benefit the productivity of the facility (Levine 
et al. 2012). Furthermore removal of CIP and SIP cycles decreases the water usage and 
water waste, decreasing the liquid waste disposal costs (Rogge et al. 2015; Barak & Bader 
2008; Haigney 2016; Geipel-Kern 2009; Flaherty & Perrone 2012; Cox et al. 2008). 
Additional benefits to SUTs include the reduced risk for contamination, increasing the 
batch successful rate (Rogge et al. 2015; Barak & Bader 2008; Haigney 2016; Geipel-
Kern 2009; Tiene 2016; Flaherty & Perrone 2012; Lopes 2015; Guldager 2009). Single-
use technologies  also ease the creation of closed systems which increases the flexibility 
of facilities, as equipment modules can easily be moved in and out of processing rooms  
(Stock R. 2011; Levine et al. 2012; Sargent 2013; Geipel-Kern 2009; Flaherty & Perrone 
2012; Lopes 2015; Guldager 2009; Rogge et al. 2015). Moreover closed SUTs ease the  
decentralisation of product manufacture and capacity expansion (Whitford 2010). The 
use of movable modules can also decrease the overall project time  due to the reduction 
in installation and procurement time  as well as ease qualification and commissioning, 
and hence speedup commercialisation (Rogge et al. 2015; Levine et al. 2012; Sargent 
2013; Lopes 2015; Barak & Bader 2008).  
Multiple sources have reported lower capital investments achieved when using SUTs 
(Barak & Bader 2008; Rogge et al. 2015; Levine et al. 2012; Guldager 2010; Sargent 
2013; Tiene 2016; Geipel-Kern 2009; Whitford 2010; Lopes 2015; Eibl & Eibl 2010; 
Novais et al. 2001; Guldager 2009). This is due to the reduced requirement for piping and 
support facilities (media and buffer pep, steam facilities etc.), as well as installation costs 
and commissioning costs (Barak & Bader 2008; Rogge et al. 2015; Levine et al. 2012; 
Guldager 2010; Sargent 2013; Tiene 2016; Geipel-Kern 2009; Whitford 2010; Lopes 
2015; Eibl & Eibl 2010; Novais et al. 2001; Guldager 2009). Furthermore, SU facilities  
are likely to operate at smaller scales than traditional biopharma stainless steel (SS) 
facilities (Rogge et al. 2015), which will result in lower equipment costs (Sargent 2013) 
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and smaller facility footprints (Guldager 2010; Rayner 2010; Flaherty & Perrone 2012; 
Cox et al. 2008; Lopes 2015).  
Disadvantages of single-use facilities include the poor standardization of  SU products, 
higher solid waste, scale and configuration restrictions, lower performance and source 
availability (Shukla & Gottschalk 2013; Rogge et al. 2015; Levine et al. 2012; Langer & 
Rader 2014; Flaherty & Perrone 2012). Furthermore leachables and extractables are a 
hurdle with SUTs (Flaherty & Perrone 2012; Levine et al. 2012; Langer & Rader 2014). 
When considering operational costs, sources show conflicting conclusions on the overall 
cost savings associated with the use of SUTs. Arguments for higher operating costs  with 
SUTs include the higher consumables costs  and costs associated with the disposal of 
consumables (Levine et al. 2012; Barak & Bader 2008; Eibl & Eibl 2010; Novais et al. 
2001). Arguments for lower operating costs include cost savings in quality control 
operations as well a labour, water and cleaning reagents (Geipel-Kern 2009; Cox et al. 
2008; Novais et al. 2001; Eibl & Eibl 2010; Haigney 2016).  
1.7.3 Single-use facilities in cell therapy 
Cell therapy facilities will likely be considerably different from traditional biotech 
facilities as the uniqueness of cell therapy processes requires specific facility layouts 
(Bozenhardt 2017). For example cell therapy products are usually manufactured using 
SUTs, hence CIP & SIP operations are reduced and therefore the requirement for process 
utilities is lower (Bozenhardt & Bozenhardt 2017). Table 1.6 shows examples of cost and 
footprint of current cell therapy facilities. 
Cell processing must be carried out in facilities operating under current Good 
Manufacturing Practice (cGMP) and under stringent quality control (QC) and quality 
assurance (QA) procedures. Such procedures should monitor and control all product-
related activities within the facility including sample arrival, product manufacture and 
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storage (Giancola et al. 2012). Quality assurance under cGMP requires a team with 
diverse expertise in order to manage different aspects of the manufacturing process such 
as resource requirement, standard operating procedures (SOPs), equipment monitoring, 
product storage and tracking (Giancola et al. 2012). Furthermore, such facilities must 
include segregated areas such as support laboratory areas, storage warehouse, product 
support areas etc.  (Giancola et al. 2012). 
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Table 1.6 Examples of current cell therapy facilities  
Company Location 
Cost 
$(M) 
Total 
size (ft2) 
Build/Purchase Details 
Argos 
Therapeuticsa 
Durham, NC,USAa 57a 100,000b Buildb 
Support automated 
production of 
personalized 
immunotherapy 
product candidatesa 
UC Davis/ 
California 
Institute of 
Regen Medc 
Sacramento,CA,USAc 62c 90,000c Buildc 
Includes research 
and laboratory 
facilities for 
clinical trial 
product 
manufacturec 
Bone 
Therapeuticsd 
Gosselies, Belgiumd 11.03d 32,300e Buildd,e 
Commercial scale 
manufacture of cell 
therapies targeted 
at bone fracturesd 
PharmaCell 
B.V. - 
Advanced 
Therapiesf 
Maastricht,Netherlandsf 6.34f 15,500g 
Purchased from 
TiGenixf 
Manufacture of 
ChrondoCelectf 
Novartish New Jersey, NJ,USAh 43h 173,000h 
Purchased from 
Dendreonh,i 
Manufacture of 
personalised 
products from the 
collaboration with 
Upenni 
Kite Pharmaj Netherlandsk 21j - 
Purchased from 
T-Cell Factory 
B.V.k 
Discovery and 
development of 
TCR productsl 
Pluristem 
Therapeuticsn 
Haifa,Israeln 6.2n - Buildn,m 
Production of 
placenta expanded 
cellsm 
Xcyte 
Therapeuticso 
Bothell, WA, USAo,p 4o 40,500p Buildo 
Production of T-
cell products for 
clinical trialsp 
Aastromq  
Biosciencesq 
Ann Arbor,MI,USAq 1.4q 30,000q Build 
Production of 
autologous 
products for tissue 
repairr 
Cardio 3 
Biosciences 
(now Celyad)s 
Minesota, MN,USAs 1.5s 15,000s Build 
Development of 
autologous product 
for heart failures 
University of 
Pennsylvaniat 
Pennsylvania,USAt 27t 30,000u Buildt 
Development of 
personalised cancer 
therapiest 
Cell Medicav London,UKv 4.59v 11,621v Build 
Personalised T-cell 
productsv 
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As the final product cannot be sterilized, a risked-based approach is employed in 
maintaining product quality. The purpose of this is to avoid contamination of the product 
(Dietz et al. 2007). Contamination can occur due to the materials used (raw materials and 
consumables), environmental changes and other products (cross-contamination) among 
other reasons (Giancola et al. 2012). Effective sterilization of all materials which come in 
contact with the product is required as well as  the use of ascetic techniques (Giancola et 
al. 2012; Dietz et al. 2007). For the successful implementation of ascetic techniques, these 
must be considered not only during operation of cGMP facilities but also during facility 
design and construction (Dietz et al. 2007). Aseptic techniques require the control of the 
facility environment (Giancola et al. 2012) (e.g. pressure, temperature and humidity etc.), 
as failure to do so may influence contamination by microorganisms and jeopardise the 
Masthercelx Brussels, Belgiumx 5.84w 6,456x Buildx 
Contract 
manufacturer 
Dendreony Atlantay 80z 200,000z Buildz 
Autologous 
dendritic cells 
manufacturez 
aDeBruyn 2016 
bArgos therapeutics 2014 
cRobertson 2010 
dBone therapeutics 2013 
eFlandersbio 2015 
fGlobeNewswire 2014 
gBrennan 2015 
hStaton & Palmer 2012 
iNew Jersey business 2012 
jHollandBio n.d.  
kInvestHolland 2015 
lGarde 2015 
mDirks 2011 
nStreetInsider 2012 
oPrinceton 2004 
pBerenson 2003 
qKavanaugh 2007 
rGlobeNewswire 2010 
sAreadevelopment 2015 
tPenn Medicine News 2016 
uTradeline 2016  
vCell Medica 2014 
xMaSTherCell n.d.  
wPersonal contact with Eric Matthieu (COO, Masthercel ) 
yBzjournals 2009 
zCarroll 2009 
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maintenance of low particle counts in the air (Giancola et al. 2012; Dietz et al. 2007). In 
order to maintain low particle count in the air, special cleaning schedules and air filters 
and regular maintenance are implemented which are part of the heating, ventilation and 
air conditioning systems (HVAC) (Dietz et al. 2007).  
Different degrees of environmental control strategies are applied to different area 
classifications and have different building and running costs (Chester 2008; Barak & 
Bader 2008). For example, a Grade B (ISO 7) cleanroom may require 50 air changes per 
hour, whereas a grade D clean room (ISO 9)  only requires 12 (Barak & Bader 2008). 
Table 1.7 shows how the facility costs/ft2 varies with area classification. 
Furthermore, process flow and appropriate isolation is also important to be considered in 
order to avoid possible cross-contamination (Giancola et al. 2012; Dietz et al. 2007). To 
do so separation of materials and staff, appropriate gowning as well as unidirectional flow 
of both staff and materials is required (Giancola et al. 2012; Dietz et al. 2007). Moreover, 
additional segregation can be achieved through the use of airlocks, these are used in order 
to avoid air turbulence and maintain pressure across cleanrooms area classifications 
(Dietz et al. 2007). 
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Table 1.7 Cleanroom costs ($ per ft2) 
 
1.7.4 Estimating costs in single-use facilities 
The use of SUTs will have a significant  effect on the  layout of a given facility, as 
parameters such as facility footprint of the facility, the HVAC and utilities requirements, 
workflows, storage space, automation design and height of the room will be affected by 
the implementation of these technologies (Levine et al. 2012; Barak & Bader 2008; Rogge 
et al. 2015; Guldager 2009). Traditionally, fixed capital investment (FCI) for 
pharmaceutical facilities was calculated using the “Lang factor method”. When using this 
method, a ratio between the equipment costs (including utility costs)  and all the other 
costs included in the total FCI was evaluated based on historical projects (Lang 1948). 
These costs included: equipment, piping, instrumentation, electrical work, building, 
utilities, site development and auxiliary buildings (Coulson & Richardson 2005). 
Additional factors were also applied in order to account for design and engineering, 
contractors fees as well as contingency (Lang 1948). The total multiplier was then 
calculated to be 3.10 for solids facilities, 3.63 for solid-fluid facilities and 4.74 for fluid 
facilities (Lang 1948). In biopharmaceutical protein facilities, higher “Lang factors” of 6-
 
Barnoon 
Barak 
(2008) 
Chester 
(2008) 
Gering & 
Campesi 
(2013) 
Gering & 
Campesi 
(2013) 
Petrides et al 
(2015) 
eXmoor 
Pharma 
Concepts 
(2018)*  
Mechanical rooms 
(utilities) 
    41-82  
Office space 210    68-82 124 
Laboratory 360    136-273 440 
Class 100,000 420    273-341 440 
Class 10,000 465 500 530-662 540-634 341-473 529 
Class 1000 525 700 692-795 704-810 607-818 721 
Class 100  900 877 -1,000 894-1,100 818-1,091  
* Personal communication (Andrew Besso, eXmoor Pharma Concepts, Bristol, UK 
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8 were typically applied for FCI estimation (Novais et al. 2001). To date, this calculation 
method has yet to be adapted to cell therapy facilities. 
Over the years, multiple publications have emerged on FCI estimates for chemical and 
biochemical facilities using different methods for capital investment calculation (Coulson 
& Richardson 2005; Peters & Timmerhaus 1991; Pavlotsky 2004; Novais et al. 2001; 
Brennan & Golonka 2002; Petrides et al. 2015; Sinclair & Monge 2005). Figure 1.13 
summarises the normalised FCI breakdown of these different methods.  
All FCI estimates are however subjective to variability. For example, the location of the 
facility will have a great impact in the costs estimates (Barak & Bader 2008; Peters & 
Timmerhaus 1991; Seider et al. 2003; Flaherty & Perrone 2012). Hence, companies may 
apply a geographic location factor in order to account for these differences (Peters & 
Timmerhaus 1991; Seider et al. 2003). These factors vary between 0.85 and 1.25 (Seider 
et al. 2003). The location with the lowest geographic factor is India followed by Mexico 
and the Southwest of the US, whilst the places with the highest factors are the US west 
coast, western Europe and the Midwest (US) and Japan (Seider et al. 2003). 
Figure 1.13 Example of current facility costs breakdown. Sources: D. J. Brennan & 
Golonka, 2002; Coulson & Richardson, 2005; Eibl R., 2010; Novais et al., 2001; 
Pavlotsky, 2004; Peters & Timmerhaus, 1991; Petrides et al., 2015; Sinclair & Monge, 
2005. SS = stainless steel, SU = single use. 
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Table 1.8 Capital investment and footprint comparison between single-use and stainless steel systems 
 
Levine et al (2012) 
(Based on a modular and single-use 
facility) 
Eibl (2010) 
Rogge  &  
Müller 
(2015) 
Sinclair & Monge (2005) Novais et al (2001) 
Product MAb MAb Non specified 
Mammalian cell-based 
protein 
E. coli process 
Single use 
components  
Non specified 
Bioreactors and 
centrifugation units & 
support system  
Bioreactors 
transwall transfer and & 
aseptic connectors 
All equipment parts in 
direct contact with the 
product 
Bioreactor scale  1000L 1000L 
2000L 
(SUTs) 
3000L (SS) 
1000L 300L 
Change in Capex 
w.r.t. SS 
-13% -27% -52% -41% -42% 
Reasoning  (based on equipment reduction) 
-37% Utilities 
-37% Automation & 
instrumentation 
-80% Piping & 
insulation 
-38% Engineering 
costs 
+7% Building costs 
+ 2% Start-up costs 
- 
-45% Process equipment 
-49% Installation 
- 22% Building costs 
-54% Engineering 
Validation 
-80% Equipment & 
process utilities 
-60% Piping, insulation& 
Installation 
-34% Control and 
instrumentation 
- 20% Building costs 
-50% Engineering costs 
-25% Site management 
-50% Validation 
Change in COG 
w.r.t. SS 
-10% +13% -18% -17% +75% 
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Levine et al (2012) 
(Based on a modular and single-use 
facility) 
Eibl (2010) 
Rogge  &  
Müller 
(2015) 
Sinclair & Monge (2005) Novais et al (2001) 
Reasoning  
-30% Labour costs 
-20% Material costs 
+5% Labour 
+51% Consumables 
+60 Waste disposable 
-63% labour 
-88% 
materials 
+28% 
consumables 
-23% Labour 
-9% Materials 
-50% Waste treatment 
+80% Consumables 
-50% Utilities 
+1549% Materials 
Change in facility 
footprint w.r.t. SS 
-11% (based on footprint reductions of 
different facility areas) 
+7%  
-22% (assumed as 
function of shell costs) 
Reduced 
Reasoning 
-40% in C grade area 
-37% in D grade area 
Lower pipe footprint 
Increase in CNC area 
+16%Buffer holding 
+ 390% Cold rooms 
+50% Corridors 
- 8% Support areas 
- - - 
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Publications comparing the capital investment of SU facilities versus SS facilities include  
Novais et al. (2001), Sinclair & Monge (2005) and Eibl  (2010). The results attained in 
these comparisons as well as the rationale behind them are summarized in Table 1.8.    In  
Novais et al. (2001), they based their calculations on an E. coli based product with the 
same annual demand in both SU and SS scenarios. Moreover, in this publication number 
of assumptions were made in order to investigate how the different components of the 
FCI would change with the use of SUTs.  
Sinclair & Monge (2005) uses a conceptual disposable facility design where SS auxiliary 
equipment was replaced by SUTs. The “Lang factor” method was used to calculate the 
different components of the FCI by adapting this factor to more recent projects. Eibl  
(2010) describes a case study based on a monoclonal antibody (mAb) process with 1,000L 
scale for both SU and SS facilities. The costs calculations were carried out using an 
internal database. 
1.7.5 Implementation of automation in cell therapy facilities 
Automation allows for the removal of multiple labour intensive steps (Hampson 2015; 
Harris et al. 2016). The implementation of automated systems is expected to ease multi-
site manufacture, and potentially ease process validation (Harris et al. 2016). A recent 
survey has revealed that 80% of  companies  developing cell therapy products employ 
manual operations during pre-clinical studies (Hanrahan 2016). This number is reduced 
to 50% for companies which are currently in the early stages of the clinical trials  
(Hanrahan 2016). Furthermore, the same survey revealed that 80% of cell therapy 
companies plan to move towards automated solutions during commercial manufacture 
(Hanrahan 2016). Automated platforms currently available in the market include the 
CompacT SelecT® (TAP Biosystems Grantham Cl, Royston, UK) and the Prodigy®. For 
bespoke automated solutions companies can opt for specific platforms such as the ones 
provided by Invetec (Australia) (Mount et al. 2015a). 
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Automation can be employed in multiple stages of the manufacturing process including 
cell culture and downstream processing (Andon 2017).  It allows for high quality products 
to be manufacture faster, more robustly and reproducibly, by reducing chances of operator 
related error (Harris et al. 2016; Hümmer et al. 2016; Invetech n.d.; Andon 2017; 
Hampson n.d.; Trainor et al. 2014). Operator variability can occur during multiple stages 
of product manufacture and testing. For example, in cell counting the tests results rely 
heavily on the opinion of the operator, as the operator must physically count the cells 
stained with trypan blue  (Harris et al. 2016). Therefore,  by implementing automation in 
analytical testing these tests can be carried out continuously and reliably (Harris et al. 
2016). Moreover, automation allows for the use of closed systems which shield the 
product from contaminants from personnel and environment (Harris et al. 2016; Hampson 
n.d.). This reduces the need of building cleanrooms with high ISO qualification, which 
may reduce capital investment and project timelines (Hampson n.d.). 
Issues related with process scalability can also be addressed with automation  especially 
in patient specific products where the manufacturing model is scale-out (Andon 2017; 
Invetech n.d.).  When using a scale-out model, automation enables higher throughput to 
be achieved (Harris et al. 2016). Furthermore automation can increase the process 
efficiency and possibly reduce costs and facility footprint (Harris et al. 2016; Hümmer et 
al. 2016; Andon 2017; Invetech n.d.; Nelsen 2017; Hampson n.d.; Trainor et al. 2014).  
The cost-benefit of automated manufacture was highlighted in the survey described in 
Hanrahan (2016), where the author reports costs reductions between 40% and 90% with 
automated technologies. The costs benefits of automation were also captured in Invetech 
n.d., where replacing manual processing with automation  in the manufacturing process 
of a patient specific therapy, resulted in annual savings of $105M USD. Additional areas 
that could economically benefit from the implementation of automation include data 
collection and record keeping (Hampson n.d.; Trainor et al. 2014; Andon 2017).  
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Challenges to the implementation of automation in cell therapy processes include 
availability of automated platforms, as current automated solutions are limited and single-
sourced (Harris et al. 2016; Hampson 2015), which increases risk of interrupted supply. 
Moreover cell therapy processes and products are complex and vary significantly, and in 
some cases are personalised,  which brings an additional challenge to developing 
automated technologies to accommodate such variability (Harris et al. 2016). 
Furthermore development costs of automated platforms are high  (Harris et al. 2016; 
Hampson 2015; Nelsen 2017). Alternatively, companies may opt to implement 
automation later within the process development or even during commercialisation. 
When doing so, it is important to consider potential regulatory implications as 
comparability will have to be demonstrated (Harris et al. 2016; Hampson 2015; Hampson 
n.d.).  
1.7.6 Decentralised manufacture  
In centralised manufacture the market is supplied by  a single GMP facility and all major 
manufacturing processes are carried out within the facility (Davie 2013; Bersenev 2016b). 
This approach has been applied in traditional pharma and biopharma industry by 
companies such as Novartis (Basel, Switzerland) and Kite pharma (Santa Monica, CA, 
USA) (Bersenev 2016b; Rafiq 2016).  One of the key benefits of centralised product 
manufacture are the economies of scale, mainly due to the fact that overhead costs are 
distributed across a higher number of doses (Medcalf 2016; Rafiq 2016). However, in  
autologous cell therapy bioprocessing, these economies of scale are minimal, as the 
manufacturing model applied to these therapies is scale-out as opposed to scale-up, and 
hence the benefit of centralised manufacture are lower (Walker & Johnson 2016b; Rafiq 
2016). 
Key disadvantages related to centralised manufacture include the fact that centralisation 
limits market access as the same facility will have to be compliant with multiple 
97 
 
regulatory bodies (Medcalf 2016). Shipping the product through long distances between 
the administration site and the manufacturing site may also pose some challenges as the 
product must be maintained at formulation temperature (4 °C if fresh and -15 °C to – 25 
°C if cryopreserved) (Rafiq 2016). Moreover, cold chain transportation is expensive 
adding to the high COG of cell therapy products (Rafiq 2016). Furthermore delays and 
even product loss may occur when shipping products across long distances (Trainor et al. 
2014; Medcalf 2016).  
Market uncertainties seen in the cell therapy industry require cell therapy facilities to be 
flexible in order to avoid low facility utilization (if the market demand is overestimated) 
or failure to meet market demand (if the market demand is underestimated) (Trainor et al. 
2014; Medcalf 2016). This flexibility is challenging to achieve with centralised facilities 
(Trainor et al. 2014; Medcalf 2016).   
Decentralised manufacture is a possible solution to some of the challenges associated 
with centralised manufacture. In decentralised manufacture, the product manufacture is 
spread over multiple manufacturing sites which are closer to the administration site and 
hence the patient itself (Rafiq 2016)(Davie 2013)(Davie 2013). Although this business 
model has been successfully adopted by other healthcare industries such as blood and 
bone marrow (Davie 2013), when considering a decentralised manufacture, the question 
arises of what is the optimal number of manufacturing sites (Walker & Johnson 2016b).  
Decentralising the manufacture of cell therapy products will solve some of the issues 
mentioned above by easing product manufacture in response to market demand as well 
as ease tracking and labelling of samples and products (Medcalf 2016; Coopman & 
Medcalf 2008; Rafiq 2016). Moreover, decentralised manufacture allows for 
uninterrupted market supply in case of facility shutdown due to unforeseen events such 
as a fire, staff strike or natural disaster (Medcalf 2016; Rafiq 2016). 
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Challenges associated with the implementation of multi-site manufacture include higher 
FCI and technology transfer costs  as well as regulatory hurdles, as regulators will require 
proof that the product meets the requirements across sites through bridging studies  
(Trainor et al. 2014; Coopman & Medcalf 2008; Davie 2013; Rafiq 2016; Hourd et al. 
2014).  Moreover it is important to identify the party responsible for product release;  in 
centralised manufacture, it would be the inventor company (Coopman & Medcalf 2008). 
In multi-site manufacture however the complexity in establishing accountability increases 
(Coopman & Medcalf 2008; Medcalf 2016).  
As previously mentioned,  traditional cell therapy processes are labour intensive and 
therefore prone to variability (Trainor et al. 2014). The use of fully automated platforms 
at the point of care has been explored as a possible solution to some of the issues 
characteristic of centralised manufacture. This automated decentralised manufacturing 
model would allow for all process steps to be carried out in a single “GMP-in-a-box” 
equipment unit which includes environmental controls and therefore dismisses the need 
for expensive cleanroom space (Trainor et al. 2014; Bersenev 2016b; Porwollik 2016; 
Hourd et al. 2014). Moreover, the use of closed and automated systems may ease some 
of the regulatory issues related to multi-site manufacture (Trainor et al. 2014). 
The Prodigy® system has been proposed as one of such “GMP-in-a-box” platforms 
(Medcalf 2016; Bersenev 2016b). However this technology is not yet suitable for end-to-
end manufacture and testing of cell therapy products as it does not perform automated 
product testing (Medcalf 2016; Bersenev 2016b).  
1.8 Decisional tools  
1.8.1 Introduction to decisional tools & decisional tools in bioprocessing  
1.8.1.1 Decisional tools overview  
Decisional tools or decision support tools are tools that provide guidance during decision-
making through guidelines, analysis or procedures (Sullivan 2002). This guidance can be 
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in a form of a software or in the written format (Sullivan 2002). Such tools have been 
previously employed in multiple sectors including environmental policy making, 
medicine, and finance (Tsang et al. 2004; Donnan et al. 2009; Elghali et al. 2008).  
Decisional tools are different than computer  models, as computer models provide 
solutions as technical variables such as time, flowrate etc.,  while decisional tools give 
solutions as decision variables such as risk  (Sullivan 2002). For example, if the optimal 
batch size for a cell therapy product is to be evaluated, the COG can be evaluated using a 
computer model. However this information alone is not enough to decide on the optimal 
batch size, knowledge on risk of batch failure, process variations etc. can be added to the 
COG to form a more complete analysis. This type of analysis can be achieved through 
the use of decisional tools. 
1.8.1.1 Decisional tools in bioprocess  
There are numerous publications on the subject of decisional tools in bioprocessing. The 
UCL Biochemical Engineering department has made notorious contributions to the 
biopharmaceutical industry by developing and using decisional tools to address critical 
questions in the sector. These questions were addressed by introducing  risk-based 
methods to evaluate optimal manufacturing strategies for biopharmaceutical products, 
considering multiple parameters such as time, COG, robustness and net present value 
(NPV) (Lim et al. 2006; Pollock et al. 2013; Yang et al. 2014). Additional case studies 
carried out by the same group include using advanced tools to debottleneck processes in 
order to avoid product waste by anticipating facility sizing issues (Lim et al. 2006).  
1.8.2 Decisional tools in cell therapies 
As seen throughout this chapter there are multiple parameters to be considered when 
bringing a novel cell therapy product to market. Figure 1.14 shows an example of 
constraints and uncertainties related to the development and commercialisation of cell 
therapy products.  
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A limited number of  publications are now available in the topic of decisional tools in cell 
therapy.  Simaria et al (2014) evaluated the optimal technology to be employed in 
different commercialisation scenarios for the production of MSCs. This was done by 
coupling an optimization algorithm and a bioprocess economics model. The results 
clearly shown the limits of current technologies for MSC expansion and the R&D 
development required for these to fulfil future market demands. The authors also identify 
the cost drivers affecting the different technologies for adherent cell culture, as well as 
some of the critical characteristics which make microcarrier-based cell expansion more 
cost-effective than planar options. This study was extended in Hassan et al (2015) in order 
to model the whole manufacturing process of allogeneic MSC products, and capture the 
economic benefit of different downstream process technologies for wash and 
concentration of MSCs. This study has revealed that the downstream process may account 
for 20% - 80% of the COG/dose depending on the technology and the commercialisation 
scenario selected.  
The economic impact of process changes at different stages of the development pathway 
was explored in Hassan et al (2016). This study has shown that the benefit of changing 
technologies at different stages of the process development and commercialisation is 
dependent on the metrics being considered (e.g. NPV and COG). The study revealed that 
from a total costs point of view, it is optimal to change technologies earlier in the process 
development in order to avoid additional costs that comparability studies may incur. 
However, from an NPV point of view, it is optimal to make changes post market approval 
in order to avoid prolonging the time-to-market. 
Jenkins et al (2016) explores the costs and operational benefits of using fully automated 
platforms for the manufacture of autologous iPSCs. This study has indicated that the 
relative cost-effectiveness of automated systems highly depended on the number of doses 
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manufactured per year. Moreover, this study indicated that automated processes for the 
manufacture of iPSC cells are more robust than manual processes.  
1.8.3 Computational methods 
1.8.3.1 Bioprocess economics model 
Bioprocess economics models have been employed in multiple studies in order to 
evaluate the cost-benefit of different strategies for product manufacture for both 
traditional biopharmaceutics and cell therapies. Bioprocess economics models are 
capable of simulating whole manufacturing processes and address questions such as: 
benefit of perfusion vs fed-batch cell culture and the cost-benefits of single-use stainless 
steel technologies (Pollock et al. 2013; Novais et al. 2001).  Common metrics used in 
order to estimate the cost-benefit of different manufacturing strategies include COG, NPV 
and FCI (Wen et al. 2015; Pollard et al. 2016).  
COG is the most widely used metric  and includes all the costs related to manufacturing 
the product including direct and indirect costs (Wen et al. 2015; Pollard et al. 2016). In 
cell therapy COG have been used in order to determine the optimal technologies to be 
employed in the manufacture of allogeneic adherent cells (Simaria et al. 2014a; Hassan 
et al. 2015). FCI is the initial capital investment, which a company must spend in order 
to build and open a facility for product manufacture. This metric is yet to be utilized 
explicitly in cell therapy publications, however this metric has been employed in 
bioprocess in order to estimate the benefits of single-use technologies (Novais et al. 
2001). NPV is a metric which considers costs and capital investment as well as risks and 
future cash flows (Wen et al. 2015). In cell therapy this metric has been employed in 
determining the economic impact of modifying the process at different stages of the 
process development and commercialisation (Hassan et al. 2016).  
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Publications on process economics models applied to cell therapy product include Malik 
(2012), where the author describes a cost comparison between autologous and allogeneic 
MSC-products. In this publication a number of simple assumptions were made to 
compute the COG, for example, the production costs (expansion and recovery) for both 
the autologous and allogeneic processes where the same. In real life, however, these costs 
would differ as economies of scale can be achieved in allogeneic cell therapy 
manufacture.  Despite these assumptions, the cost per dose of autologous products were 
considerably higher than for the allogeneic products. This was due to the fact that cell 
therapy products must be tested after tissue acquisition and before product release. Since 
each batch requires a different donor in autologous processing, these products become 
immediately more expensive due to the higher testing costs per dose. This analysis 
although simplistic illustrates that one of the biggest bottlenecks of autologous cell 
therapy production is the additional testing costs. It however does not capture additional 
hurdles associated with autologous manufacture such as higher facility footprint, higher 
FCI etc. 
Abou-El-Enein et al. (2013) describes a model for COG estimation, performance analysis 
and GMP facility optimisation by using a clean room assessment technique (CTAT) in 
an existing facility. The model recognises the core processes within the facility, and 
attributes to them a value, which represents the fixed manufacturing costs. The model 
then identifies the supporting processes within the facility, which represent the direct 
costs. The results shown that the costs comparison between the costs predicted by the 
model and the actual costs of the facility did not differ considerably.  
 
Dutton & Fox (2006) have compared the manufacturing costs of manual, automated and 
glovebox isolated process for two different scales using a life cycle costs analysis (LCC). 
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The results of this study have confirmed the cost-benefits of automated platforms for cell 
therapy manufacture. These benefits increase with increasing scale of production. The 
technology used for cell culture in for this comparison was roller bottles, which may not 
be suited for large scale production of cell therapy products. 
 The benefits of automation in autologous cell therapy processing is also highlighted in a 
case study carried out by Invetech (Melbourne, Australia). This study has revealed that 
automating manufacturing processes could result in a 40% COG reduction. Such costs 
reductions were more pronounced in larger patient demand scenarios. The study also 
shown that when automation is employed, the cost categories with the highest reduction 
were : facility depreciation, reagents, labour and gowning. Whilst equipment depreciation 
and consumable costs increased with the implementation of automation (Inventech n.d.). 
Figure 1.14  Key decisions, uncertainties, constraints and metrics when bringing a novel 
cell therapy product to market. Adapted from Farid (2012). 
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Karnieli (2015) evaluated the material costs reduction and facility footprint requirement 
when moving from a 2D disposable system to a non-disposable packed bed system for 
adherent cell manufacture. This article has revealed that serum is a significant contributor 
towards COG. Furthermore, this study has shown that when switching to multi-use 
packed bed systems, cost, personnel requirement and facility footprint reductions are 
achieved. 
1.8.3.2 Brute force search  
Brute-force search tools are a useful tool for process optimization. When using brute force 
to select the optimal solution to for a case study, the computer model will screen through 
all possible combinations, verify if they meet the criteria established by the user (e.g. 
maximum number of cell culture vessels per batch), and then select the optimal solution 
according to the desired parameter(s) (e.g. minimum COG) (Sui 2007). In cell therapy, 
this method has been used in order to rapidly screen through combinations of technology 
candidates and mode of operations and (manual vs automated), with the aim of selecting 
the optimal solution for the expansion and differentiation of iPSCs under different 
commercialisation  scenarios (Jenkins et al. 2016). 
1.8.3.3 Monte-Carlo simulation 
Monte-Carlo simulations mimic complex processes and providing solutions in terms of a 
probability distribution of desired parameters (e.g. COG) which are dependent on 
multiple random distributions of intendent parameters (e.g. cell harvest density, process 
yield etc.) (Fang & Boas 2009; Harrison 2010). This approach was also employed in 
Jenkins et al (2016) in order to evaluate the robustness of automated versus manual 
platforms. 
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1.8.3.4 Multi attribute decision-making 
Multi-attribute decision making is a method used to enable decisions to be made 
considering multiple tangible and intangible variables (e.g. COG and ease of operation) 
(Farid 2012; Pollock et al. 2013; Rao 2007). This method, has been employed in 
bioprocess case studies in order to evaluate the benefit of SUTs versus SSTs as well as 
the benefit of fed-batch vs perfusion cell cultures (Farid 2012; Pollock et al. 2013). The 
parameters considered in these analyses were: COG, FCI, construction time, project 
throughput criterion, online fermentation control, operational flexibility, ease of 
validation cleaning, leachable validation, ease of scale-up, reliance on suppliers, water 
and consumables environmental rating, batch to batch variability, ease of control and ease 
of development (Farid 2012; Pollock et al. 2013). 
1.9 Aims and organisation of thesis 
The previous sections of this chapter have underlined several features of cell therapy 
products including their therapeutic potential, market value, current products available in 
the market, manufacturing process and technology availability for cell therapy 
manufacture as well as challenges facing cell therapy developers with emphasis on MSC-
based and CAR T-cell-based products. This chapter has also described the previous use 
of decisional tools in providing key insights to some of these challenges. Articles 
describing the use of decisional tools to address challenges related to MSC manufacture 
have focused on assessing the cost-benefit of different upstream and downstream 
technologies for MSC manufacture over several years as well as the effect of switching 
between technologies at different stages of the process development pathway. These 
studies have not yet captured the less tangible operational aspects of technologies for 
MSC manufacture (e.g. robustness, resource requirement, ease of validation, ease of 
operation, ease of development).  
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Moreover, there are currently no published studies on the use of decisional tools to help 
design and optimize manufacturing strategies for autologous CAR T-cell therapies. 
Furthermore, all studies using decisional tools to address questions in the cell therapy 
sector have employed methods for computing capital investment characteristic traditional 
biopharmaceutical facilities. As previously explained, cell therapy facilities will likely 
differ from traditional biopharmaceutical facilities, hence these methods for capital 
investment estimation may not be suited for cell therapy facilities. 
This thesis aims at illustrating the role of decisional tools in enabling successful 
commercialisation of cell therapy products by providing insights to some of the critical 
questions facing cell therapy developers with the example of MSC-based and CAR T-cell 
therapies.   
Chapter 2 describes the advanced integrated bioprocess economics tool used to generate 
the results seen in Chapter 3 to Chapter 5. This tool incorporates a fixed capital 
investment model, a bioprocess economics model coupled with brute-force optimization, 
a robustness model, a multi-attribute decision making model and a net present value 
model.  
Chapter 3 describes the use of the fixed capital investment model described in Chapter 
2 to provide a detailed factorial methodology for estimating FCI and footprint for bespoke 
cell therapy facilities that accounts for technology-specific factors such as cleanroom 
classifications and facility layout.  Chapter 4 uses the advanced decisional tool described 
in Chapter 2 to provide a novel integrated approach to evaluate the cost and operational 
benefit of technologies for MSC manufacture across different scenarios and identifies 
performance targets that must be met in order to enhance the commercial feasibility of 
cell therapy products. Chapter 5 describes the first in-depth economic study on CAR T-
cell therapy products with insights at both technology level and an enterprise’s facility 
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configuration level. Chapter 6 summarises the key conclusions and contributions from 
the case studies described in Chapter 3 to Chapter 5 and discusses possible avenues to 
extend these case studies and  Chapter 7 highlights the process for validating cell therapy 
products as well as some of the key challenges associated with this process. 
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Chapter 2: Materials and Methods 
 
2.1 Introduction  
As described in Chapter 1, companies developing cell therapy products face multiple 
questions and challenges. Such questions include the selection of the optimal 
manufacturing strategy for these unique products considering economic and operational 
features of different manufacturing platforms, autologous versus allogeneic product 
manufacture and the benefits of multi-site product manufacture. This chapter describes 
the integrated decisional tool developed to tackle such questions whilst capturing the 
technical, economic and risk specificities of cell therapy manufacture. The application of 
the tool to industrially-relevant case studies is described in Chapters 3-5.  
The remainder of this chapter is structured as follows. Section 2.2 describes the overall 
architecture of the advanced decisional tool. Sections 2.3-2.7 provide a more detailed 
description of each of the components in the decisional tool. The final section (Section 
2.8) describes the methods  used for the collection of the data used in the results chapters. 
2.2 Tool architecture  
The advanced decisional tool was developed to comprise the following components: a 
database, a fixed capital investment (FCI) model, a process economics model, brute force 
optimization, a multi-attribute decision making (MADM) model, a robustness analysis 
model and a risk-adjusted cash flow  model. The tool architecture is summarised in 
Figure 2.1.  
The information from the database provides the relevant assumptions used during the 
different case studies.  The FCI model described in Section 2.3 is used to compute the 
facility footprint and FCI of cell therapy facilities across multiple commercialisation 
scenarios, considering parameters such as technology selection, facility location and 
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cleanroom classification. Both FCI and facility footprint are used by the bioprocess 
economics model and by the risk-adjusted cash flow model to evaluate the cost of goods 
(COG) per dose (Section 2.4) and risk-adjusted net present value (rNPV) (Section 2.7) 
respectively.  
The bioprocess economics model described in Section 2.4 uses a series of advanced 
equations to carry out mass balance and equipment sizing in order to evaluate resource 
requirement and COG for different manufacturing strategies across multiple 
commercialisation scenarios. This model is coupled with brute force optimization, which 
is used to evaluate rapidly the suitability of different manufacturing strategies for the 
selected commercialisation scenarios.  
Section 2.5 describes a multi-attribute decision making model that was used to evaluate 
manufacturing platforms by considering both operational and economic attributes. The 
robustness of different manufacturing strategies was captured using the Monte Carlo 
model described in Section 2.6. In order to evaluate the economic benefit of different 
commercialisation strategies over the lifecycle of a cell therapy product, a net present 
value model was developed; this is described in Section 2.7.  
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Figure 2.1  Schematic representation of the integrated bioprocess economics tool. This tool encompasses a database, a fixed capital 
investment model, a process economics model coupled with brute force optimization, a multi-attribute decision making tool, a Monte-
Carlo model and a net present value model. 
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2.3 Technology-specific detailed factorial method for fixed capital investment 
estimation 
2.3.1 Method overview   
Since cell therapy products cannot be sterilised at the end of the manufacturing process 
(Dietz et al. 2007), they will likely employ single-use technologies and hence the facilities 
will differ from traditional stainless steel facilities (Bozenhardt 2017). Furthermore, the 
cost of different cell culture technologies (e.g. multilayer vessels such as Cell Factories® 
(Nunc, Roskilde, Denmark/Thermofischer, Waltham, MA, USA) versus integrated kits 
such as Prodigy® (Miltenyi Biotec, Gladbach, Germany)) can vary widely in the cell 
therapy sector; hence, the use of a common “Lang factor” for all cell therapy facilities 
can be inappropriate. Therefore, traditional methods for FCI estimation may not apply to 
cell therapy facilities. This section describes a novel detailed factorial methodology for 
estimating FCI and footprint for bespoke cell therapy facilities that accounts for 
technology-specific factors for key cell culture technologies as well as the implications 
of single-use technologies, open versus closed operations and the commercialisation 
scenario selected. This was used to derive benchmark values for short-cut cost and area 
factors for typical cell therapy facilities according to the technologies selected. This 
method was used to compute FCI and facility running costs in Chapter 3 and Chapter 
5. 
The short-cut method for facility footprint and FCI estimation outlined in this section 
resembles the “Lang factor” (Lang 1948) method described in Section 1.7. When using 
the “Lang factor” method, a number was derived using historical data which when 
multiplied by the total equipment purchase costs (TEPC), provides the total capital 
investment required. This number varied between 3.10 and 4.74 for chemical facilities 
depending on the type of product manufactured within the facility (Lang 1948). In the 
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method described in this chapter, a single number which provides a ratio between the 
main process equipment costs (e.g. skids, incubators and biosafety cabinets), and the total 
costs is also estimated. However, this ratio varies according to the technologies used for 
cell therapy manufacture, the location of the facility, the commercialisation scenario, the 
type of project and cleanroom classification. The same parameters were also considered 
to provide a ratio between the reciprocal facility footprint and main process equipment 
costs in order to enable the user to estimate the footprint of a cell therapy facility using 
only the costs of the main process equipment. This novel short-cut method is summarised 
in Figure 2.2. 
 
2.3.2 Model overview 
Section 2.2.1 described a novel method for evaluating facility costs and facility footprint 
for cell therapy facilities.  In order for this method to be adopted, cost factors and area 
factors for multiple hypothetical facilities had to be derived. This was done using a fixed 
capital investment model summarised in Figure 2.3. 
Figure 2.2 Schematic representation of the short-cut method used to calculate facility 
footprint and facility costs. A cost factor is multiplied by the total process equipment 
purchase costs to provide the fixed capital investment. The total process equipment 
purchase costs are divided by an area factor to calculate the facility footprint. 
 
113 
 
 
Figure 2.3 Schematic representation the detailed factorial method used to compute a) FCI 
and b) facility footprint. 
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2.3.2.1  Area factor 
The area factor (Fa) is calculated by dividing the total process equipment costs (Cpe) by 
the total facility footprint (ab). The total process equipment costs are given by the sum of 
the number of units of each type of equipment required multiplied by the cost per 
equipment unit. 
𝐶𝑝𝑒  =  ∑ 𝐶𝑝𝑒𝑖 ×  𝑁𝑝𝑒𝑖
𝑖=𝑛
𝑖=1
 
 (2.1) 
where 𝐶𝑝𝑒𝑖 = cost per unit of process equipment i 
 𝑁𝑝𝑒𝑖 = no of units of process equipment i required  
The facility footprint is given by the sum of the footprint of the different sections within 
the facility. Six main sections were identified, as these are likely to have different 
cleanroom classifications. These sections were: product manufacture am, clean circulation 
space ac, product testing at, waste circulation space aw, general space ag and plant space 
ap. The product manufacture area, am, corresponds to the main processing area where all 
product manufacture operations take place including inoculation, cell culture, 
downstream processing and formulation and fill. These operations are carried out in 
cleanrooms which have the highest ISO qualification within the facility. The clean 
circulation space ac corresponds to the airlocks and corridors that separate the product 
manufacture area and the general area within the facility as well as janitor rooms required 
for clean areas. The product testing area, at, includes the space required for QC labs, 
microbiology labs, polymerase chain reaction (PCR) rooms, janitor rooms for laboratories 
as well as the corridors and personnel and material airlocks. The waste circulation area 
includes waste disposal rooms, corridors and personnel changing rooms. The general 
space within the facility comprises the logistics rooms, meeting rooms, offices, cold 
rooms, general corridors, loading docks, WC, staircases, facility receptions and janitor 
rooms for general areas. The plant area is where the utilities reside ( including the HVAC 
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systems); this area is smaller in SU facilities than in stainless steel (SS) facilities as CIP 
and SIP activities are reduced (Barak & Bader 2008; Rogge et al. 2015; Levine et al. 
2012; Guldager 2010; Sargent 2013; Tiene 2016; Geipel-Kern 2009; Whitford 2010; 
Lopes 2015; Eibl & Eibl 2010; Novais et al. 2001; Guldager 2009). Moreover, this model 
assumes that no media and buffer preparation is carried out within the facility, such that 
the materials are pre-formulated before arriving to the manufacturing site further reducing 
the plant area and increasing the storage space required. 
The product manufacture area is calculated using the footprint of the main process 
equipment, ape, and the ratio between the footprint of the main process equipment and the 
product manufacture area; this ratio is retrieved from a database: 
 
The total footprint of the main process equipment is calculated in a similar manner as the 
total costs of the main process equipment, by the sum of the number of units of each type 
equipment required multiplied by the footprint per unit of equipment. 
𝑎𝑝𝑒  =  ∑ 𝑎𝑝𝑒𝑖 × 𝑁𝑝𝑒𝑖
𝑖=𝑛
𝑖=1
 
 (2.3) 
where 𝑎𝑝𝑒𝑖 = footprint per unit of  process equipment i 
 𝑁𝑒𝑖 = no of units of process equipment i required  
  
All other sections within the facility ax (apart from personnel and materials airlocks) are 
calculated as a function of the product manufacture area and a ratio between the product 
𝑎𝑚  = 𝑎𝑝𝑒 × 𝑟𝑚/𝑒   (2.2) 
where 𝑎𝑃𝑒 = total footprint occupied by process equipment   
 𝑟𝑚/𝑒 = ratio between product manufacture area and 
total footprint of the process equipment   
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manufacture area and the footprint of that particular section. The personnel and materials 
airlocks were assumed to have a fixed footprint. As one personnel and materials airlock 
were attributed for each processing room and laboratory, the number of airlocks becomes 
a function of the number of processing rooms and labs within the facility. 
𝑎𝑥  = (𝑎𝑚 × 𝑟𝑥/𝑚 )  (2.4) 
where 𝑎𝑥  = footprint of manufacturing section x (e.g. 
clean circulation space, product testing area, 
waste circulation space, general area and plat 
area) 
 𝑎𝑚 = product manufacture area  
 𝑟𝑥/𝑚 = ratio between footprint of section x and 
footprint of product manufacture area  
 
The area factor is then calculated as follows: 
𝐹𝑎  =
𝐶𝑝𝑒
∑ 𝑎𝑚, 𝑎𝑐, 𝑎𝑡, 𝑎𝑤, 𝑎𝑔, 𝑎𝑝, (𝑁𝑝𝑟 + 𝑁𝑙𝑎𝑏) × (𝑎𝑃𝐴𝐿 + 𝑎𝑀𝐴𝐿)
 
 (2.5) 
where 𝑁𝑝𝑟 = no of processing rooms 
 𝑁𝑙𝑎𝑏 = no of labs  
 𝑎𝑃𝐴𝐿 = footprint per personnel airlock   
 𝑎𝑀𝐴𝐿 = footprint per material airlock  
 
2.3.2.2 Cost factor  
The cost factor is calculated by dividing the sum of all the costs included in the FCI by 
the main process equipment costs Cpe. FCI can be divided into direct FCI (i.e. fixed plat 
costs) and non-direct FCI. The different costs included in the direct FCI calculation were 
the main process equipment costs Cpe, process support equipment costs Cse, QC 
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equipment costs CQC, logistics equipment costs Cle, environment monitoring systems 
(EMS) CEMS, main process equipment installation costs Cie, building shell costs Cbs, 
building fit-out cots Cbf, contractor fees Cc, land costs Cl and  yard improvement costs 
Cy. Non-direct cost categories included in the FCI calculation were project design, 
engineering management and consultant fees Ceng and contingency costs Ccon.  
The process support equipment costs Cse include the costs of benchtop centrifuges, 
pumps, weighting equipment, trolleys, wracks, shelves etc. These costs are calculated by 
multiplying the product manufacture area am by the process support equipment costs per 
m2 of product manufacturing area cse.  
𝐶𝑠𝑒  = 𝑎𝑚 × 𝑐𝑠𝑒   (2.6) 
where 𝑐𝑠𝑒  = process support equipment costs per m
2 of 
product manufacture area   
A similar method was employed in evaluating the equipment logistics costs, Cle, where 
the total footprint of the product manufacture area am is multiplied by the costs of logistics 
equipment per m2 of product manufacture area, cle. The logistics equipment include 
fridges, freezers and roller racking.  
 
 
𝐶𝑙𝑒  = 𝑎𝑚 × 𝑐𝑙𝑒   (2.7) 
where 𝑐𝑙𝑒  = logistics equipment costs per m
2 of product 
manufacture area   
QC equipment include filter integrity testers, incubators, fluorescence-activated cell 
sorting (FACS) systems, PCR systems, high liquid performance chromatography systems 
(HPLC) among other technologies. The QC equipment costs are not dependent on the 
118 
 
facility footprint or on other equipment costs. The QC equipment costs are calculated 
under the assumption that each QC lab would include one unit of each different type of 
equipment necessary for QC testing. The equipment costs per QC lab are then added 
together and multiplied by the number of QC labs within the facility. This is given by the 
number of batches being manufactured in parallel divided by the maximum number of 
batches which a QC lab can process in parallel.   
𝐶𝑄𝐶 =  
(𝑐𝑄𝐶 × 𝑁𝑏𝑎𝑡𝑐ℎ)
𝑁𝑏𝑎𝑡𝑐ℎ𝑀𝐴𝑋
 
 (2.8) 
where 𝑐𝑄𝐶 = QC equipment costs per lab 
 𝑁𝑏𝑎𝑡𝑐ℎ = no of batches in parallel  
 𝑁𝑏𝑎𝑡𝑐ℎ𝑀𝐴𝑋 = maximum no of batches in parallel per QC lab   
 
The EMS costs are calculated by adding the costs of the central monitoring unit and the 
costs of the monitoring probes in the product manufacture area and airlocks. The model 
assumes that the measurements taken for environment monitoring within a given facility 
were pressure, humidity, temperature and number of air particles. The minimum number 
of probes required to monitor the number of particles per unit volume of air is calculated 
as the square root of the product manufacture area and airlock area rounded up to the 
nearest whole number. This measurement is only necessary in B grade rooms. The 
minimum number of probes per room and airlocks for all other measurements is one.  
𝐶𝐸𝑀𝑆 =  𝑐𝐶𝑈 + (𝑁𝑟𝑜 × 3 × 3)
+ (√𝑎𝑚 + ((𝑎𝑃𝐴𝐿 +  𝑎𝑃𝐴𝐿) × 𝑁𝑟𝑜)
2
) 
 (2.9) 
where 𝑐𝐶𝑈 = central monitoring unit costs    
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 𝑁𝑟𝑜 = no of processing rooms  
 𝑎𝑚 = product manufacture area  
 𝑎𝑃𝐴𝐿 = footprint per personnel airlock   
 𝑎𝑀𝐴𝐿 = footprint per material airlock  
 
In the above equation, when calculating the number of probes, the number of product 
manufacture rooms, Nro, is multiplied by 3 to account for the number of personnel and 
materials airlocks leading into these rooms. This number is multiplied again by 3 to 
account for the fact that three different probes are required per manufacturing room and 
airlocks for measures of humidity, temperature and pressure. 
The process equipment installation costs Cie are calculated by multiplying the number of 
process equipment units by the installation costs per unit cie. 
𝐶𝑖𝑒 =  𝑁𝑒 × 𝑐𝑖𝑒  (2.10) 
where 𝑁𝑒 = no of equipment units     
 𝑐𝑖𝑒 = installation costs per equipment unit   
 
The building shell costs Cbs are given by the sum of the footprint of all the sections within 
the facility previously highlighted multiplied by the shell costs per m2: 
𝐶𝑏𝑠 =  𝑎𝑏 × 𝑐𝑏𝑠  (2.11) 
where 𝑎𝑏 = total building footprint     
 𝑐𝑏𝑠 = shell costs per m
2    
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The building fit-out costs Cbf include the majority of the building-related costs; these 
include partitions, floors, ceilings, air conditioning, duct work, electrical distribution, 
lighting, controls and monitoring, pipework and insulation etc. Given that different 
sections within a cell therapy facility may have different ISO classifications, the building 
fit-out costs is given by the sum of the fit out costs of the individual sections within a 
facility.  
𝐶𝑏𝑓 =  ∑ 𝑐𝑏𝑓𝑥
𝑥=𝑛
𝑥=1
× 𝑎𝑥 
 (2.12) 
where 𝑐𝑏𝑓𝑥 = fit-out costs per m
2 for facility section x     
 𝑎𝑥 = footprint of facility section x    
 
The contractor fees Cc are calculated as a percentage of the facility fit out costs:  
𝐶𝑐 =  𝐶𝑏𝑓 × 𝑟𝐶𝑐/𝐶𝑏𝑓  (2.13) 
where 𝐶𝑏𝑓 = facility fit-out costs      
 𝑟𝐶𝑐/𝐶𝑏𝑓 = ratio between contractor fees and facility fit-
out costs     
 
Both land costs Cl and yard improvement costs Cy were calculated as a function of the 
building shell costs 
𝐶𝑙 =  𝐶𝑏𝑠 × 𝑟𝐶𝑙/𝐶𝑏𝑠  (2.14) 
where 𝐶𝑏𝑠 = building shell costs       
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 𝑟𝐶𝑙/𝐶𝑏𝑠 = ratio between land costs and building shell 
costs      
 
𝐶𝑦 =  𝐶𝑏𝑠 × 𝑟𝐶𝑦/𝐶𝑏𝑠  (2.15) 
where 𝐶𝑏𝑠 = building shell costs       
 𝑟𝐶𝑦/𝐶𝑏𝑠 = ratio between yard improvement costs and 
building shell costs      
 
The project direct costs is a sum of all the costs parameters described until this point (the 
main process equipment costs, process support equipment costs, QC equipment costs, 
logistics equipment costs, EMS costs, main process equipment installation cost, building 
shell costs, building fit out costs, contractors fees, land costs and  yard improvement 
costs). Design, engineering management and consultant fees Ceng are calculated as a 
function of the total direct costs. 
𝐶𝑒𝑛𝑔 =  (∑ 𝐶𝑝𝑒 , 𝐶𝑠𝑒 , 𝐶𝑙𝑒 , 𝐶𝑄𝐶 , 𝐶𝐸𝑀𝑆 , 𝐶𝑖𝑒 , 𝐶𝑏𝑠, 𝐶𝑐, 𝐶𝑙, 𝐶𝑦) ×  𝑟𝐶𝑒𝑛𝑔/𝐶𝑑  
 (2.16) 
where 𝑟𝑒𝑛𝑔/𝐶𝑑 = ratio between design, engineering 
management and consultant fees costs and 
direct costs  
 
The contingency costs are costs attributed to potentially unforeseen events which may 
increase the fixed capital investment and/or delay the process such as strikes and natural 
disasters. These costs are calculated as a function of the total project costs (direct costs 
plus design, engineering, management and consultant fees): 
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𝐶𝑐𝑜𝑛 =  (∑ 𝐶𝑝𝑒, 𝐶𝑠𝑒 , 𝐶𝑙𝑒 , 𝐶𝑄𝐶 , 𝐶𝐸𝑀𝑆, 𝐶𝑖𝑒 , 𝐶𝑏𝑠, 𝐶𝑐, 𝐶𝑙 , 𝐶𝑦, 𝐶𝑒𝑛𝑔) ×  𝑟𝐶𝑐𝑜𝑛/𝐶𝑡𝑜𝑡  
 (2.17) 
where  𝑟𝑐𝑜𝑛/𝑡𝑜𝑡 = ratio between contingency costs and total 
project costs   
 
2.4 Process economics model  
The process economics model used to compute the COG associated with different 
manufacturing strategies was developed in Microsoft Excel (Microsoft® Corporation, 
Redmond, WA) as this programme offers a user friendly interface. This model uses a 
similar approach to those published in Hassan et al (2015) and Simaria et al (2014) to 
simulate the manufacturing process of cell therapy products across multiple 
commercialisation scenarios selected by the user.   The process economics model mimics 
single product cell therapy facilities manufacturing autologous or allogeneic cell therapy 
products. The facilities modelled produce multiple batches with durations defined by the 
user. This model is capable of evaluating the economic and operational benefits of 
multiple process designs by carrying out detailed mass balance and equipment sizing for 
each of the process unit operations within the manufacturing process of cell therapy 
products, while accounting for possible product losses characteristic of the different unit 
operations.   
The scope of the processes captured in this bioprocess economics model includes all 
manufacturing unit operations carried out between tissue acquisition and the final 
formulation of the product. The process sequence and length as well as the resource 
requirement for each unit operation are dependent on the cell therapy product being 
manufactured and were selected with the product purity, potency and viability in mind. 
The mass balance and equipment sizing results are used to estimate COG for different 
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types of cell therapy products (e.g. autologous v allogeneic, adherent v suspension cell 
culture etc.).  
2.4.1 Mass balance & equipment sizing  
Multiple unit operations are used during cell therapy manufacture. The specific aim of 
each of these unit operations have been described in detail in Chapter 1 Section 1.4.  
Throughout the manufacturing process for cell therapy products, the cells go from one 
unit operation to the other with product loss occurring during most unit operators. Hence, 
the number of cells loaded into a particular unit operation are the same as the cells that 
exit the previous unit operation. The cells exiting a unit operation n are calculated as: 
𝑁𝑐𝑜𝑢𝑡  = 𝑁𝑐𝑖𝑛 × 𝑌𝑛  (2.18) 
where 𝑁𝑐𝑜𝑢𝑡   = no of cells exiting the unit operation n  
 𝑁𝑐𝑖𝑛 = no of cells entering the unit operation n 
 𝑌𝑛 = yield of the unit operation n  
 
The step yield of each different unit operation is retrieved form the database and can be 
found in Chapter 4 and Chapter 5. In order to account for cell losses suffered during the 
manufacturing process and hence ensuring that the adequate demand is fulfilled, the 
number of cells initially loaded into the process is calculated by applying a redundancy 
ratio in order to consider issues that may occur during product transportation or 
administration which have been described in Chapter 1 Section 1.6: 
𝑁𝑐𝑖𝑛
0  =
𝑁𝑐𝑡𝑎𝑟𝑔𝑒𝑡 ×  𝑟𝑟
(𝑌𝑛0 ×  𝑌𝑛1 … .× 𝑌𝑛)  × 𝑒𝑘×(𝑡−1)
 
 (2.19) 
where 𝑁𝑐𝑖𝑛
0  = no of cells initially loaded into the process  
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 𝑁𝑐𝑡𝑎𝑟𝑔𝑒𝑡  = target no of cells at the end of the 
manufacturing process  
 𝑟𝑟 = redundancy ratio (autologous CAR T-cell 
manufacture only)  
 𝑌𝑛 = yield of each process step 
 𝑘 = exponential constant   
 t = no of cell culture days 
 
Due to the limitations in capacity of current technologies for allogeneic cell therapy 
manufacture, it is likely that a high number of batches will be required in order to fulfil 
large annual demands (Chereau 2011; Heathman et al. 2015; Simaria et al. 2014b). In 
autologous cell therapy manufacture, each patient represents one batch. Hence, in high 
annual demand scenarios a very high number of batches will also be required. If the 
number of batches required to fulfil a particular annual demand exceeds the maximum 
number of batches that can be processed in series within the manufacturing year, then 
parallel processing is carried out. The number of batches manufactured in parallel 
required to fulfil a particular annual demand is calculated as follows: 
𝑁𝐵𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙  =  
𝑁𝐵𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 × 𝐿𝑝𝑟𝑜𝑐
𝑌𝑀𝐹𝐺
 
 (2.20) 
where 𝑁𝐵𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙   = no of batches in parallel   
 𝑁𝐵𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 = batches per year  
 𝐿𝑝𝑟𝑜𝑐 = length of the process  
 𝑌𝑀𝐹𝐺  = Manufacturing year 
 
2.4.1.1 Reagents  
Buffers   
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Multiple buffers are required throughout the manufacturing process of cell therapy 
products. During elutriation and magnetic separation of autologous CAR T-cells, the 
quantities of buffers required are evaluated as a function of the number of cycles required 
to process the target number of cells. These buffers include: magnetic rinse buffer, 
magnetic separation buffer, NaCl and PBS. The number of cycles required to processes a 
given amount of cells is evaluated as follows: 
𝑁𝐶𝑦  =
𝑁𝑐𝑖𝑛𝑛
𝑁𝑐𝑚𝑎𝑥𝑛
  
 (2.21) 
where 𝑁𝑐𝑖𝑛𝑛 = no of cells loaded into the unit operation n   
 𝑁𝑐𝑚𝑎𝑥𝑛 = max no of cells which can be loaded per cycle 
in unit operation n  
The volume of rinse buffer, NaCl, PBS for elutriation and hydroxyethyl (Hespan) 
required can then be evaluated: 
𝑉𝑅𝑖 =  𝑁𝐶𝑦 ×  𝑉𝑅𝑖/𝑐𝑦  (2.22) 
where 𝑉𝑅𝑖  = volume of reagent i  (buffer or Hespan) 
 𝑉𝑅𝑖/𝑐𝑦 = volume of reagent i (buffer or Hespan) 
required per cycle 
Multiple steps are required for magnetic separation of T-cells including pellet 
resuspension, cell dilution, pellet dilution, column load, column wash and elution.  Hence, 
a different method is used to calculate the volume of separation buffer required: 
𝑉𝑅𝑖 =  (𝑉𝑙  +  𝑉𝑒 +  (𝑉𝑝𝑑 ×  
𝑁𝑐𝑖𝑛𝑛
𝑁𝑐𝑝𝑑𝑚𝑎𝑥
)  +  (𝑉𝑝𝑟 × 
𝑁𝑐𝑖𝑛𝑛
𝑁𝑐𝑝𝑟𝑚𝑎𝑥
)  +  (𝑉𝑐𝑑
− (𝑉𝑝𝑟 ×  
𝑁𝑐𝑖𝑛𝑛
𝑉𝑝𝑟𝑚𝑎𝑥
) )  × 𝑁𝐶𝑦  
 (2.23) 
where 𝑉𝑅𝑖 = volume of reagent i (separation buffer) 
 𝑉𝑙 = column load volume  
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 𝑉𝑒 = elution volume 
 𝑉𝑝𝑑 = pellet dilution volume  
 𝑁𝑐𝑝𝑑𝑚𝑎𝑥 = max no of cells per set of separation buffer 
for pellet dilution 
 𝑉𝑝𝑟 = pellet resuspension volume 
 𝑁𝑐𝑝𝑟𝑚𝑎𝑥 = max no of cells per set of separation buffer 
for pellet resuspension 
 𝑉𝑐𝑑 = cell dilution volume 
 
Throughout the CAR T-cell manufacturing process multiple wash and volume reduction 
unit operations are required. In order to evaluate the volume of PBS required for cell 
wash, the number of washes performed must be considered: 
𝑉𝑅𝑖 =  𝑁𝑤  × 𝑁𝐶𝑦 ×
𝑁𝑐𝑖𝑛𝑛 × 𝑌𝑛
𝐶𝑜𝑛𝑐𝑑𝑒𝑠𝑖𝑟𝑒𝑑
  
 (2.24) 
where 𝑉𝑅𝑖 = volume of reagent i (PBS for cell wash) 
 𝑁𝑤  = no of washes  
 𝑌𝑛 = yield of unit operation  
 𝐶𝑜𝑛𝑐𝑑𝑒𝑠𝑖𝑟𝑒𝑑 = desired cell concentration   
 
Furthermore, in allogeneic CAR T-cell manufacture, an electroporation unit operation is 
required. This step requires a special buffer. The volume of buffer used is evaluated 
according to the number of cells that are going through the electroporation process: 
𝑉𝑅𝑖 =  
𝑁𝑐𝑖𝑛𝑛
𝐶𝑜𝑛𝑐𝑑𝑒𝑠𝑖𝑟𝑒𝑑
  
 (2.25) 
where 𝑉𝑅𝑖 = volume of reagent i (electroporation buffer) 
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As a fluidised bed centrifuge is used for microcarrier removal, cell wash and 
concentration in allogeneic MSC manufacture, a different method was applied when 
calculating the buffer volume requirement. The buffers required for this unit operation 
are prime buffer and wash buffer. The volume of prime buffer required is calculated 
taking into account the bowl volume, number of chambers selected and holdup volume. 
𝑉𝑅𝑖 =  (𝑉𝑏𝑜𝑤𝑙  × 𝑁𝑐ℎ)  + 𝑉ℎ) × 𝑁𝐹𝐵𝐶   (2.26) 
where 𝑉𝑅𝑖 = volume of reagent i (prime buffer) 
 𝑉𝑏𝑜𝑤𝑙 = bowl volume   
 𝑁𝑐ℎ = no of chambers used   
 𝑉ℎ = holdup volume    
 𝑁𝐹𝐵𝐶  = no of fluidised bed centrifuges 
The number of fluidised bed centrifuge units required for microcarrier removal and for 
cell wash may differ and is given by:   
𝑁𝐹𝐵𝐶 =  
𝑁𝑐𝑦
𝑁𝑐𝑦𝑀𝑎𝑥
  
 (2.27) 
where 𝑁𝑐𝑦𝑀𝑎𝑥 = maximum no of cycles per fluidised bed 
centrifuge    
The maximum number of cycles per fluidised bed centrifuge is calculated according to 
the time required of each stage of the microcarrier separation, wash and concentration 
process: 
𝑁𝑐𝑦𝑀𝑎𝑥 =   
𝑉𝑖𝑛
𝑄𝑠𝑡𝑎𝑟𝑡
+  
𝑉𝑖𝑛
𝑄𝑁𝑜𝑟𝑚𝑎𝑙
+  
𝑉𝑜𝑢𝑡
𝑄𝐻𝑎𝑟𝑣𝑒𝑠𝑡
𝑇𝑚𝑎𝑥
 
 (2.28) 
where 𝑄𝑠𝑡𝑎𝑟𝑡 = starting flowrate  
 𝑄𝑁𝑜𝑟𝑚𝑎𝑙 = wash flowrate  
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 𝑄𝐻𝑎𝑟𝑣𝑒𝑠𝑡 = harvest flowrate  
 𝑉𝑜𝑢𝑡 = volume out of the FBC 
 𝑇𝑚𝑎𝑥 = maximum time allocated to downstream  
process  
If microcarriers are not used for MSC cell culture, then 𝑉𝑖𝑛 is the volume of cells attained 
from the cell culture process and 𝑉𝑜𝑢𝑡 is the volume of the cells attained from the cell 
culture process multiplied by the yield of the wash and concentration process. If on the 
other hand microcarriers are used during MSC cell culture, a two-step fluidised bed 
centrifugation is performed; the first stage is used to remove microcarriers, hence 𝑉𝑖𝑛 is 
the volume of cells attained from the cell culture process and 𝑉𝑜𝑢𝑡 is 𝑉𝑖𝑛 minus the volume 
of microcarriers. The second unit operation is used to wash and concentrate the cells 
where 𝑉𝑖𝑛 is the volume of cells loaded in the fluidised bed system minus the volume of 
microcarriers, and 𝑉𝑜𝑢𝑡 is the volume of cells required to achieve the final target 
concentration. The volume of the wash buffer required is also calculated as a function of 
the number of washes required: 
𝑉𝑅𝑖 =  ( (𝑉𝑜𝑢𝑡  × 𝑁𝑤)  + 𝑉ℎ)  × 𝑁𝐹𝐵𝐶    (2.29) 
where 𝑉𝑅𝑖 = volume of reagent i (wash buffer) required  
 𝑉ℎ = holdup volume    
 𝑁𝐹𝐵𝐶  = no fluidised bed centrifuge  
In order to cryopreserve the cells, these must first be suspended in formulation solution 
typically containing 10% DMSO. The volume of formulation solution required is the 
same as the volume out of the final wash and concentration stage. 
𝑉𝑅𝑖 =  
𝐶𝑜𝑛𝑐𝑓𝑖𝑛𝑎𝑙
(𝑁𝑐𝑖𝑛 × 𝑌)
 
 (2.30) 
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Where 𝑉𝑅𝑖 =  = volume of reagent i (DMSO containing 
solution) required  
 𝐶𝑜𝑛𝑐𝑓𝑖𝑛𝑎𝑙 = final concentration    
 𝑁𝑐𝑖𝑛 = cells into the fluidised bed centrifuge  
 𝑌 = yield of the unit operation 
Magnetic beads for isolation of specific T-cell populations 
The volume of magnetic selection beads required is calculated according to the number 
of cells being separated: 
𝑉𝑅𝑖 =  
𝑁𝑐𝑖𝑛𝑛
𝑁𝑐𝑀𝐴𝑋
 ×  𝑉𝑚𝑏  ×  𝑁𝑐𝑦   
 (2.31) 
where 𝑉𝑅𝑖 = volume of reagent i (magnetic beads)   
 𝑁𝑐𝑖𝑛𝑛 = no of T-cells loaded into the unit operation   
 𝑁𝑐𝑀𝐴𝑋 = maximum no of T-cells per set of microbeads   
 𝑉𝑚𝑏 =  volume microbeads per set    
 
CD3/CD28 nanomatrix for T-cell activation 
The volume of CD3/CD28 nanomatrix required for T-cell activation is calculated 
according to the number of cells being activated: 
𝑉𝑅𝑖 =  
𝑁𝑐𝑖𝑛𝑛
𝐶𝑜𝑛𝑐𝑛𝑎𝑛𝑜
 ×  𝑟𝑛𝑎𝑛/𝑐 
 (2.32) 
where 𝑉𝑅𝑖   =  is volume of reagent i (nanomatrix) 
required 
 𝑁𝑐𝑖𝑛𝑛 = no of cells to be activated  
 𝐶𝑜𝑛𝑐𝑛𝑎𝑛𝑜  =  is the concentration of activation 
nanomatrix   
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 𝑟𝑛𝑎𝑛/𝑐 = is the ratio between the units of nanomatrix 
and the cells added    
Viral vector for T-cell genetic modification 
The number of infectious units (IFU) for viral transduction is also evaluated as a function 
of the number of cells being transduced: 
𝑁𝑣𝑝 =  𝑁𝑐𝑖𝑛𝑛  × 𝑀𝑂𝐼  (2.33) 
where 𝑁𝑣𝑝 =  no of viral particles required 
 𝑁𝑐𝑖𝑛𝑛 = noof cells to be transduced  
 𝑀𝑂𝐼  =  no of viral particles per cell 
Retronectin for T-cell genetic modification 
The quantities of retronectin required are given in micrograms and are a function of the 
geometry of the cell culture vessel: 
𝑀𝑅𝑖 =  𝑆𝑣𝑒𝑠𝑠𝑒𝑙 ×  𝐶𝑜𝑛𝑐𝑟𝑒𝑡𝑟𝑜  (2.34) 
where 𝑀𝑅𝑖 =  mass of reagent i required (retronectin) 
 𝑆𝑣𝑒𝑠𝑠𝑒𝑙 =  size of cell culture vessel (for planar cell 
culture vessels: surface area of the based. For 
3D cell culture vessels: working volume of the 
cell culture vessel) 
 𝐶𝑜𝑛𝑐𝑟𝑒𝑡𝑟𝑜 = concentration  of retronectin required 
Cell culture media  
The cell culture media used is calculated differently for planar and 3D cell culture vessels. 
For planar cell culture vessels this is calculated a function of the surface area of the base 
of the cell culture vessel whilst for 3D cell culture vessels it is calculated as a function of 
the working volume of the vessel. Hence for planar technologies: 
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𝑉𝑅𝑖 =  ∑ 𝐶𝑎𝑝𝑢𝑛𝑖𝑡  ×  𝑁𝑒𝑥  ×  𝑁𝑢𝑛𝑖𝑡𝑛
𝑖=𝑛
𝑖=1
× 𝑟𝑚𝑒𝑑/𝑎𝑟𝑒𝑎  
 (2.35) 
where 𝑉𝑅𝑖 =  is the volume of reagent i required ( cell 
culture media) 
 𝐶𝑎𝑝𝑢𝑛𝑖𝑡 = capacity of cell culture vessels ( surface 
area) 
 𝑟𝑚𝑒𝑑/𝑎𝑟𝑒𝑎 =  is the volume of media added per unit area 
of the base of the cell culture vessel  
 𝑁𝑒𝑥 = no of media exchanges carried out  
 𝑁𝑢𝑛𝑖𝑡𝑛 = no of cell culture cell culture vessels 
required for expansion stage n  
Similarly in 3D cell culture vessels, the volume of media required is evaluated as follows: 
𝑉𝑅𝑖 =  ∑ 𝐶𝑎𝑝𝑢𝑛𝑖𝑡  ×  𝑁𝑒𝑥  ×  𝑁𝑢𝑛𝑖𝑡𝑛
𝑖=𝑛
𝑖=1
  
 (2.36) 
where 𝑉𝑅𝑖 =  is the volume of reagent i required ( cell 
culture media) 
 𝐶𝑎𝑝𝑢𝑛𝑖𝑡 = capacity of cell culture vessels ( working 
volume) 
 𝑁𝑒𝑥 = No of media exchanges carried out  
 𝑁𝑢𝑛𝑖𝑡𝑛 = No of cell culture cell culture vessels 
required for expansion stage n 
The number of cell culture vessels required for a particular expansion stage depends on 
the number of cells that must be produced and the capacity of the cell culture vessel. In 
adherent cell culture where microcarriers are not used, this is calculated as follows: 
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𝑁𝑢𝑛𝑖𝑡𝑛 =  
𝑁𝑐𝑜𝑢𝑡𝑛
𝐷ℎ𝑎𝑟𝑣𝑒𝑠𝑡
𝐶𝑎𝑝𝑢𝑛𝑖𝑡
  
 (2.37) 
where 𝑁𝑢𝑛𝑖𝑡𝑛 =  no of cell culture vessels required for 
expansion stage n  
 𝑁𝑐𝑜𝑢𝑡𝑛 = no of cells produced at the end of expansion 
stage n 
 𝐷ℎ𝑎𝑟𝑣𝑒𝑠𝑡 = cell harvest density 
 𝐶𝑎𝑝𝑢𝑛𝑖𝑡 = capacity of cell culture vessels 
When no microcarriers are used, the number Capunit corresponds to the surface area of the 
cell culture vessel. If microcarriers in stirred tank bioreactors are used on the other hand, 
the Capunit is a function of the concentration of microcarriers added to the  stirred tank 
bioreactor. The capacity of stirred tank bioreactors for adherent cell expansion is then 
given by: 
𝑁𝑢𝑛𝑖𝑡𝑛 =  𝑉𝑢𝑛𝑖𝑡 × 𝑀𝐶𝑐𝑜𝑛𝑐 × 𝐴𝑀𝑐  (2.38) 
where 𝑉𝑢𝑛𝑖𝑡  =  working volume of cell culture vessel    
 𝑀𝐶𝑐𝑜𝑛𝑐 = concentration of microcarriers in the 
bioreactor 
 𝐴𝑀𝑐 =  surface area per gram of microcarrier    
In suspension cell culture, the number of cell culture vessels required is given as function 
of the volume of the cell culture vessel as follows: 
𝑁𝑢𝑛𝑖𝑡𝑛 =  
𝑁𝑐𝑜𝑢𝑡𝑛
𝐶𝑜𝑛𝑐𝑑𝑒𝑠𝑖𝑟𝑒𝑑
𝐶𝑎𝑝𝑢𝑛𝑖𝑡
 
 (2.39) 
where 𝑁𝑢𝑛𝑖𝑡𝑛 =  no of cell culture vessels required for 
expansion stage n  
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 𝑁𝑐𝑜𝑢𝑡𝑛 = no of cells produced at the end of 
expansion stage n 
 𝐶𝑜𝑛𝑐𝑑𝑒𝑠𝑖𝑟𝑒𝑑 = desired concentration of cells at the end of 
the cell culture process  
 𝐶𝑎𝑝𝑢𝑛𝑖𝑡 = capacity of cell culture vessels (volume) 
Transcription activator-like effector nucleases (TALEN)  for genetic modification 
The quantities of TALEN reagent used during cell electroporation are given in grams and 
are calculated according to the volume of electroporation buffer used: 
𝑀𝑅𝑖 =  𝑉𝑏𝑢𝑓𝐸𝑙 × 𝐶𝑜𝑛𝑐𝑇𝐴𝐿𝐸𝑁  (2.40) 
where 𝑀𝑅𝑖 =  mass of reagent i (TALEN) required    
 𝑉𝑏𝑢𝑓𝐸𝑙 = volume of electroporation buffer  
 𝐶𝑜𝑛𝑐𝑇𝐴𝐿𝐸𝑁 = concentration of TALEN 
2.4.1.2 Consumables  
Elutriation disposable set, wash & concentration set, centrifugation tube, magnetic 
selection column 
The number of sets of consumables used a particular pre or post cell culture step equals 
the number of cycles required for that process step: 
𝑁𝑐𝑜𝑛𝑗 =  𝑁𝑐𝑦   (2.41) 
where 𝑁𝑐𝑜𝑛𝑗 =  is the no of units of disposable set j 
(Elutriation disposable set, centrifugation 
tube, magnetic selection column) 
   
Cell culture vessel 
The number of cell culture vessels required per batch has been described in 2.37 - 2.39. 
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Aseptic vials and cryopreservation bags 
The number of aseptic vials and cryopreservation bags required per batch is dependent 
on the volume per dose and the capacity of the vials/bags: 
𝑁𝑐𝑜𝑛𝑗 =  
𝑉𝑜𝑢𝑡
𝐶𝑎𝑝𝑣/𝑏
  
 (2.42) 
where 𝑁𝑐𝑜𝑛𝑗 =  no of disposable set j (aseptic vials/ 
cryopreservation bags) 
 𝑉𝑜𝑢𝑡 = volume per dose 
 𝐶𝑎𝑝𝑣/𝑏 = volume per vial/bag 
2.4.1.3 Equipment  
Dedicated equipment 
The list of dedicated equipment includes incubators and dedicated skids for cell culture 
vessels. For a particular type of dedicated equipment, the number of equipment units 
required within a facility is calculated using the number of cell culture vessels per batch, 
the maximum number of cell culture vessels that the equipment can handle and the 
number of batches being manufactured in parallel as follows. 
𝑁𝑒𝑞𝑢𝑧 =  
𝑁𝑢𝑛𝑖𝑡
𝐶𝑎𝑝𝑒𝑞𝑢𝑖
 ×  𝑁𝐵𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙   
 (2.43) 
where 𝑁𝑒𝑞𝑢𝑧 =  no of units of equipment z     
 𝑁𝑢𝑛𝑖𝑡 =  no of cell culture vessels per batch     
 𝐶𝑎𝑝𝑒𝑞𝑢𝑧 = no of cell culture vessels which a single unit 
of equipment z can hold  
 𝑁𝐵𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙   = no of batches in parallel  
Shared equipment  
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Shared equipment includes biosafety cabinets, cell wash and recovery systems, elutriation 
systems, magnetic recovery systems, electroporation systems, automated filling units, 
controlled rate freezers and shared skids for cell culture vessels. As some of these 
technologies are likely to be used in different unit operations throughout the 
manufacturing process, and the duration of these unit operations is likely to differ, the 
number of units required for shared equipment is calculated as a function of the maximum 
time for which the equipment is being used: 
𝑁𝑒𝑞𝑢𝑧 =  
𝑁𝑢𝑛𝑖𝑡
𝐶𝑎𝑝𝑒𝑞𝑢𝑗
 ×
𝑇𝑠𝑀𝐴𝑋
𝑇𝑀𝐴𝑋
 × 𝐵𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙   
 (2.44) 
where 𝑇𝑠𝑀𝐴𝑋 =  duration of the longest unit operation for 
which equipment z is used      
 𝑇𝑀𝐴𝑋 = maximum time allowed for longest unit 
operation for which equipment z is used      
 𝐵𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙 = no of batches in parallel   
 𝐶𝑎𝑝𝑒𝑞𝑢𝑗 = maximum no of cell culture vessel units that 
one unit of equipment z can handle  
2.4.1.4 Labour  
The methods used for estimating the labour requirement for CAR T-cell-based processes 
and MSC-based process differ. In CAR T-cell manufacture, the complexity of the labour-
intensive unit operations requires dedicated operators; therefore, the number of operators 
is calculated as a function of the number of batches being manufactured in parallel: 
𝑁𝑜𝑝 =  
𝑁𝑜𝑝/𝑡𝑒𝑎𝑚
𝐶𝑎𝑝𝑡𝑒𝑎𝑚
  ×  𝑁𝐵𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙  
 (2.45) 
where 𝑁𝑜𝑝/𝑡𝑒𝑎𝑚 =  no of operators per team of operators      
 𝑁𝐵𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙  = no of batches in parallel   
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 𝐶𝑎𝑝𝑡𝑒𝑎𝑚 = maximum no of batches which a team of 
operator can process in parallel   
In allogeneic MSC-based processes however, less unit operations are required and hence, 
operators are able to processes multiple batches in parallel. The number of operators 
required is calculated according to the time taken to perform the longest process unit 
operation within the manufacturing process and the maximum time allowed per unit 
operation: 
𝑁𝑜𝑝 =  𝑁𝐵𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙  ×
𝑇𝑠𝑀𝐴𝑋
𝑇𝑀𝐴𝑋
 × 𝑁𝑜𝑝/𝑡𝑒𝑎𝑚 
 (2.46) 
where 𝑁𝑜𝑝/𝑡𝑒𝑎𝑚 =  no of operators per team of operators      
 𝑇𝑠𝑀𝐴𝑋 =  duration of the longest unit operation  
 𝑇𝑀𝐴𝑋 = maximum time allowed per process unit 
operation  
 𝑁𝑜𝑝/𝑡𝑒𝑎𝑚 =  no of operators per team of operators      
 𝑁𝐵𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙 = no of batches in parallel   
2.4.2 COG 
Both indirect and direct costs were considered in this model. The direct costs include QC 
materials, transportation costs, reagents and consumables. The indirect costs considered 
were equipment and facility depreciation, equipment maintenance, utilities, cleanroom 
monitoring, labour costs and gowning costs. The materials costs for QC were assumed to 
have a fixed value per batch that depends on whether the process is autologous or 
allogeneic. Transportation costs were also assumed to be a fixed costs; this cost however 
varies with the distance between the cell therapy production site and the administration 
site. The summary of the methods used to compute both direct and indirect costs are 
summarised in Table 2.1.  Table 2.1 is used to compute the COG of mesenchymal stem 
cell-based cell therapies (Chapter 4). This table is later modified (Chapter 5 Table 5.1) 
137 
 
to capture additional calculations for costs that are more dominant in autologous CAR T-
cell processes.  
Table 2.1 Summary of the methods used to compute COG 
Cost category Value 
Direct Direct raw materials f (utilization per batch)  
QC materials f (utilization per batch) 
Indirect Depreciation FCI / depreciation period / no batches per year 
 Facility maintenance 0.1 x FCI / No batches per year 
  Labour 2.2* x No operators x annual salary   /No 
batches per year  
Cost of goods per batch Direct costs + indirect costs 
* The labour cost multiplier (2.2) corresponds to the costs related to management, 
supervisors, and quality (QC, QA and QP) labour 
 
2.4.2.1 Direct costs  
The total reagents costs were calculated by adding the multiplication of the number of 
units of each reagent required by the costs per unit of reagent. For some reagents, the 
number of units required is given as a volumetric unit such as buffers, Hespan, NaCl, 
nanomatrix, magnetic beads and media. Other reagents such as TALEN® and retronectin  
are measured in units of mass. Furthermore, reagents can also be given in terms of 
particles used, this is the case of viral vectors. The calculation of the number of units 
required for each reagent is shown in equations 2.21 to 2.40. 
𝐶𝑟 =  ∑ 𝑁𝑢𝑖 × 𝐶𝑢𝑖
𝑖0
𝑖𝑛
 
 (2.47) 
where 𝐶𝑟 =  reagents costs      
 𝑁𝑢𝑖 =  no units of reagent i  ( volume, mass, 
particles) 
 𝐶𝑢𝑖 = cost per unit  of reagent i  
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The consumables costs were calculated in a similar manner, by multiplying the number 
of each consumable set required by the cost per set. The calculations of the number of 
units of each consumable set required are shown in equations 2.41 and 2.42.  
𝐶𝑐𝑜𝑛 =  ∑ 𝑁𝑢𝑗 × 𝐶𝑢𝑗
𝑗0
𝑗𝑛
 
 (2.48) 
where 𝐶𝑐𝑜𝑛 =  consumable costs      
 𝑁𝑢𝑗  =  No units of consumable j   
 𝐶𝑢𝑗 = cost per unit  of consumable j  
2.4.2.2 Indirect costs  
The equipment costs are also calculated by multiplying the number of units of each type 
of equipment by the cost per equipment unit. Given that equipment units can be used 
across a number of years, the equipment costs per year must also consider the depreciation 
period. The explanation of the calculation of the number of equipment units required can 
be found in equations 2.43 and 2.44. 
𝐶𝑝𝑒 =  
∑ 𝑁𝑢𝑧 × 𝐶𝑢𝑧
𝑧0
𝑧𝑛  
𝑇𝑑𝑒𝑝𝑟𝑒  
  
 (2.49) 
where 𝐶𝑝𝑒 =  main process equipment costs  
 𝑁𝑈𝑧 =  No units of equipment z   
 𝐶𝑈𝑧 = cost per unit  of equipment z  
 𝑇𝑑𝑒𝑝𝑟𝑒 = depreciation period 
In the case study exploring the cost-effectiveness of allogeneic cell therapy products 
(Chapter 4), the facility costs were computed using the adjusted “Lang factor” used in 
Hassan et al (2015). In the case study described in Chapter 5, the facility costs 
characteristic of different CAR T-cell therapy processes were computed using the cost 
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factors described in Section 2.3. The facility depreciation costs per year are calculated by 
dividing the total facility costs by the depreciation period. 
 
𝐶𝐹 =  
𝐶𝑝𝑒 ×  𝐹𝑐
𝑇𝑑𝑒𝑝𝑟𝑒 
− 𝐶𝑝𝑒 
 (2.50) 
where 𝐶𝐹 =  facility costs   
 𝐶𝑝𝑒 =  main process equipment costs 
 𝐹𝑐 = cost factor (CAR T-cell therapy); Lang 
factor (MSC therapy) 
 𝑇𝑑𝑒𝑝𝑟𝑒 = depreciation period 
The equipment and facility maintenance costs per year are calculated as a function of the 
total FCI: 
𝐶𝑚𝑎𝑖𝑛𝑡 = (𝐶𝑝𝑒 +  𝐶𝐹)  × 𝑟𝑚/𝑒  (2.51) 
where 𝐶𝑚𝑎𝑖𝑛𝑡 =  equipment and facility maintenance costs   
 𝐶𝑝𝑒 =  main process equipment costs  
 𝐶𝐹 = facility costs  
 𝑟𝑚/𝑒 = ratio between equipment costs and 
equipment maintenance costs   
 
Labour costs per year are calculated a function of the number of operators required. 
𝐶𝑙𝑎𝑏 =  𝑁𝑜𝑝 × 𝑆𝑜𝑝  ×  𝑟𝑜ℎ/𝑙𝑎𝑏  (2.52) 
where 𝐶𝑙𝑎𝑏 =  labour costs    
 𝑁𝑜𝑝 =  number of operators  
 𝑆𝑜𝑝 = annual operator salary    
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 𝑟𝑜ℎ/𝑙𝑎𝑏 = ratio between operator costs and overheads 
and supervisory costs  
The total costs per batch can then be calculated as: 
𝐶𝑂𝐺𝑏𝑎𝑡𝑐ℎ =  𝐶𝑟 +  𝐶𝑐𝑜𝑛 +
𝐶𝑝𝑒 +  𝐶𝐹 +  𝐶𝑚𝑎𝑖𝑛𝑡 +  𝐶𝑙𝑎𝑏
𝑁𝐵𝑦𝑒𝑎𝑟
   
 
 
 
 
 
 (2.53) 
Where 𝐶𝑟 =  reagent costs    
 𝐶𝑐𝑜𝑛 =  consumable costs   
 𝐶𝑝𝑒 = main process equipment depreciation costs    
 𝐶𝐹 = facility depreciation costs  
 𝐶𝑚𝑎𝑖𝑛𝑡 = equipment and facility maintenance  costs 
 𝐶𝑙𝑎𝑏 = labour costs  
The COG per dose are calculated by dividing the COG per batch by the number of doses 
per batch. In autologous cell therapy bioprocessing one dose is produced per batch; hence, 
the COG per batch equals the COG per dose. 
𝐶𝑂𝐺𝑑𝑜𝑠𝑒 =  
𝐶𝑂𝐺𝑏𝑎𝑡𝑐ℎ 
𝑁𝐷/𝑏𝑎𝑡𝑐ℎ 
 
 (2.54) 
Where 𝐶𝑂𝐺𝑑𝑜𝑠𝑒 =  COG per dose    
 𝐶𝑂𝐺𝑏𝑎𝑡𝑐ℎ  =  COG per batch   
 𝑁𝐷/𝑏𝑎𝑡𝑐ℎ = no doses per batch     
The COG per year can be calculated by multiplying the COG per dose by the number of 
doses per year: 
𝐶𝑂𝐺𝑦𝑒𝑎𝑟 =  𝐶𝑂𝐺𝑑𝑜𝑠𝑒 ×  𝑁𝐷/𝑦𝑒𝑎𝑟  (2.55) 
Where 𝐶𝑂𝐺𝑦𝑒𝑎𝑟 =  COG per year 
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 𝐶𝑂𝐺𝑑𝑜𝑠𝑒 =  COG per dose  
 𝑁𝐷/𝑦𝑒𝑎𝑟 = no doses per year   
2.5 Brute force optimization  
In order to evaluate rapidly multiple commercialisation scenarios the bioprocess 
economics model was coupled with a brute force optimization macro. The brute-force 
optimization macro was developed in Visual Basic Application, VBA (Microsoft 
Corporation, Redmond, WA). During the simulations, brute-force is used to screen 
through all possible demand, dose size, and manufacturing platform solutions in order to 
select the manufacturing platform with the lowest COG that meets the conditions set by 
the user. The only condition set in this model was that only solutions where the percentage 
of the cell culture vessel occupied by cells at the end of the process equals to or exceeds 
the minimum occupation limit established by the user would be considered. The brute 
force optimization macro is summarised in Figure 2.4. 
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Figure 2.4 Schematic representation of brute force optimization. Brute force optimization searches through all 
configurations (X) of the different types of cell culture vessel (i) and checks whether the minimum utilization (Y) 
selected by the user is met. 
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2.6 Multi-attribute decision-making  
A weighted sum method was employed to account for both the operational and economic 
groups of attributes of different manufacturing technologies. The different attributes were 
first ranked according to their importance in the cell therapy field (where a higher rank 
was more beneficial than a lower rank) and normalised weights (Wi) were determined 
relative to the sum of the rankings of all the attributes considered within either the 
operational or economic attribute groups:  
Wi = 𝑟𝑖/ ∑ 𝑟𝑖
𝑖=𝑛
𝑖=1
 
 (2.56) 
where Wi = the normalised weight of attribute i  
  𝑟𝑖 = the importance ranking of category i  
   
For all operational attributes, a high score is desirable whilst for the economic cost 
attributes (COG and FCI) a high value is undesirable. To address this, the attribute values 
were standardised by converting them into a common dimensionless scale from 0 to 1 as 
follows:  
Sij = (sij − siWorst)/ (siBest − siWorst)  (2.57) 
where Sij = the standardised rating for technology j for 
attribute i 
 siMin = the worst outcome for attribute i 
 siMax = the best outcome for attribute i 
The relative importance of the total weighted economic and operational ratings was varied 
using dimensionless contribution ratios, which add up to 1 so as to create scenarios where 
operational attributes were more important than the financial attributes and vice-versa. 
The overall aggregate score of the different technologies was then calculated by using the 
weighted sum method as follows: 
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𝑆𝑎𝑔𝑔𝑟𝑗 = (𝑅𝐶1 × ∑(Sopij 
𝑖=𝑛
𝑖=1
Wi )) + (𝑅𝐶2 × ∑(Seconij 
𝑖=𝑛
𝑖=1
Wi)) 
 (2.58) 
where 𝑆𝑎𝑔𝑔𝑟𝑗  =  the aggregate weighted score of technology 
j 
 𝑅𝐶1 = the operational combination ratio  
 𝑅𝐶2 = the economic combination ratio  
2.7 Monte Carlo simulation model  
Previous sections (2.3 to 2.5) have described deterministic models, which produce useful 
metrics such as FCI and COG without accounting for process variability. Process 
variability is a very important parameter to be considered in cell therapy bioprocessing 
due to differences in donor characteristics and materials used (Heathman et al. 2015; 
Lapinskas 2010; Lopez et al. 2010; Christodoulou et al. 2013). This is even more 
important in autologous processes as  cells are retrieved from sick donors and each dose 
requires a different donor (Mason & Dunnill 2009; Brandenberger et al. 2011). 
Stochastic models have previously been employed in assessing the robustness of different 
manufacturing platforms for cell therapy bioprocessing (Jenkins et al. 2016). This section 
describes a stochastic model which was employed in order evaluate the effect of  possible 
process-related variability as well as patient-to-patient variability on the robustness of 
different manufacturing strategies in autologous and allogeneic cell therapy processing. 
The stochastic model developed uses Monte Carlo simulation as this is able to capture the 
complexity of cell therapy processes by mimicking the variability of multiple independent 
parameters which may affect the robustness of the process. Monte Carlo simulations were 
built using @Risk® (Palisade Corporation, Newfiled, NY), and coupled with the 
bioprocess economics model. During simulations, multiple independent triangular 
distributions of critical process variables such as process yield and patient weight were 
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introduced to the bioprocess economics model. @Risk was then used to perform multiple 
iterations of these variables and measure the probability of different events occurring (e.g. 
probability of achieving target COG). This same model was employed in estimating the 
sensitivity of the desired metrics (e.g. COG) to different process parameters (e.g. process 
yield), by individually changing the value of such parameters by ± a selected percentage 
and measuring the impact that this change has on the desired parameter.  
2.8 Net present value model  
The methods described in all previous sections  provide  useful metrics to distinguish  
between manufacturing platforms. However, these do not account for long-term benefits 
and/or consequences associated with using a particular manufacturing strategy. 
Therefore, an risk-adjusted cash flow model model was developed so as to investigate the 
ramifications of different manufacturing strategies over several years. In order to 
calculate NPV, a risk-adjusted cash flow model linked to the process economics model 
was built using Excel®. The cash flow model captured different elements of the 
development and commercialisation of cell therapy products. These elements include: the 
commercialisation scenario, running costs, product development costs, facility 
preparation costs, capital investment, sales parameters and risks parameters among 
others. 
The commercialisation scenario elements are set by the user and include factors such as 
patient demand, dose size and number of facilities. Manufacturing costs are obtained from 
the process economics model described in Section 2.4 according to the manufacturing 
platform and cell therapy product selected. The running costs include facility oversight 
costs, manufacturing costs, facility insurance costs, facility utilization charge (if product 
manufacture is outsourced), sales and marketing and corporate tax. The manufacturing 
costs are directly retrieved from the process economics tool.  
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The facility insurance costs per year are a percentage of the total FCI: 
𝐶𝐹𝑖 = 𝐹𝐶𝐼 × 𝑟𝐹𝑖/𝐹𝐶𝐼  (2.59) 
where 𝐶𝐹𝑖 =  facility insurance costs   
 𝑟𝐹𝑖/𝐹𝐶𝐼 = ratio between facility insurance costs  
and FCI  
The facility utilization charge is calculated as a function of the total facility costs: 
𝐶𝐹𝑢 = (𝐶𝐹𝐷 +  𝐶𝑢  +  𝐶𝑚𝑜𝑛) × 𝑟𝐹𝑢/𝐹𝑐  (2.60) 
where 𝐶𝐹𝑢 =  facility utilization charge costs  
 𝐶𝐹𝐷  =  facility depreciation costs  
 𝐶𝑢 = utilities costs  
 𝐶𝑚𝑜𝑛 = facility monitoring costs  
 𝑟𝐹𝑢/𝐹𝑐 = ratio between facility utilisation costs 
 and total facility costs   
The sales and marking costs are a function of the total profit before tax  
𝐶𝑆𝑀 = 𝑃𝐵𝑇 × 𝑟𝑆𝑀/𝑃𝐵𝑇  (2.61) 
where 𝐶𝑆𝑀 =  sales and marketing costs   
 𝑃𝐵𝑇 =  profit before tax (revenue – costs )   
 𝑟𝑆𝑀/𝑃𝐵𝑇 = ratio between sales and marketing  
costs and profit before tax   
The corporate tax calculation is also based on the profit after tax 
𝐶𝐶𝑇 = (𝑃𝐵𝑇 −  𝐶𝑆𝑀)  × 𝑟𝑆𝑀/𝑃𝐵𝑇  (2.62) 
where 𝐶𝐶𝑇 =  corporate tax costs  
 𝐶𝑆𝑀 =  sales and marketing costs   
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 𝑟𝑆𝑀/𝑃𝐵𝑇 = ratio between corporate tax costs  
and profit before tax   
The product development costs include the costs for a three-stage clinical trial process, 
process development, technology transfer costs and product stability testing costs. The 
total product development costs are calculated as follows: 
𝐶𝑝𝑑𝑑 = ∑ ( 𝐶𝑂𝐺/𝑏𝑎𝑡𝑐ℎ𝑝 × 𝑟(𝐶𝑂𝐺𝐶𝑜ℎ)𝑝
× 𝑁𝑏𝑎𝑡𝑐ℎ𝑝)
𝑝=3
𝑝=1
+ ∑ 𝐶𝑝𝑐𝑑𝑝
𝑝=3
𝑝=1
+  ∑ 𝐶𝑝𝑠𝑝
𝑝=3
𝑝=1
 +  ∑ 𝐶𝑡𝑡𝑝
𝑝=3
𝑝=1
  
 (2.63) 
where 𝐶𝑝𝑑𝑑  =  product development costs  
 𝐶𝑂𝐺
/𝑏𝑎𝑡𝑐ℎ𝑝 
= COG/batch for clinical trial phase p 
 𝑟
(
𝐶𝑂𝐺
𝐶𝑜ℎ )𝑝
 =  ratio between clinical trials costs and the 
clinical trials overhead costs  
 𝑁𝑏𝑎𝑡𝑐ℎ𝑝 = No of batches produced for phase p 
 𝐶𝑝𝑐𝑑𝑝 
= process development costs for clinical trials 
phase p 
 𝐶𝑝𝑠𝑝 
= product stability testing costs for clinical 
trials phase p 
 𝐶𝑡𝑡𝑝 = technology transfer costs for clinical trials 
phase p 
The facility prep costs vary with the number of facilities used in the selected 
commercialisation scenario.  These costs include technology transfer costs,   facility 
insurance, comparability studies, site license, engineering runs and process performance 
qualification (PPQ) batches. The costs for engineering runs and PPQ batches are directly 
148 
 
attained from the process economics model. All other costs are attained from the database 
incorporated in the integrated bioprocess economics decisional tool. The facility prep 
costs are then calculated as follows:  
𝐶𝐹𝑝 = (𝐶𝑡𝑡𝑐 +  𝐶𝑐𝑠  +  𝐶𝑠𝑙 +  𝐶𝑒𝑟 + 𝐶𝑃𝑃𝑄 ) × 𝑁𝐹  (2.64) 
where 𝐶𝐹𝑠 =  facility prep costs   
 𝐶𝑡𝑡𝑐 = technology transfer costs at commercial 
stage  
 𝐶𝑐𝑠  = comparability studies costs  
 𝐶𝑠𝑙 = site license costs  
 𝐶𝑒𝑟 = engineering runs costs  
 𝐶𝑃𝑃𝑄  = PPQ batches costs  
 𝑁𝐹 = no of facilities  
The annual sales are calculated considering parameters such as the selling price of the 
cell therapy product, the sales ramp up over the years and the batch failure rate. The 
annual sales  are calculated as follows: 
𝑆𝑎 =  𝑁𝐷𝑑𝑒𝑠𝑖𝑟𝑒𝑑 × 𝑆𝑃 × 𝑅𝐵𝐹  × 𝑆𝑟𝑎𝑚𝑝  (2.65) 
Where 𝑆𝑎 =  annual sales    
 𝑁𝐷𝑑𝑒𝑠𝑖𝑟𝑒𝑑 = desired number of doses per year 
 𝑆𝑃 = selling price  
 𝑅𝐵𝐹 = batch failure rate    
 𝑆𝑟𝑎𝑚𝑝 = sales ramp-up  
Risks were also accounted for in this cash flow by  adding a R&D risk factor. The NPV 
is calculated as follows: 
𝑁𝑃𝑉 = −𝐶𝑝𝑑𝑑 − 𝐶𝐹𝑝 − FCI +   ∑
(−𝑐𝑟 + 𝑆𝑎  ) × (𝑅&𝐷𝑟)𝑌
(1 + 𝑟)𝑌
𝑌=𝑛
𝑌=1
 
 (2.66) 
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Where 𝐶𝑝𝑑𝑑 =  product development costs    
 𝐶𝐹𝑝 = facility prep costs   
 𝐶𝑂𝐺
𝑦𝑒𝑎𝑟
 
= COG per year   
 𝑐𝑟 = running costs    
 𝑆𝑎 = sales   
 (𝑅&𝐷𝑟)𝑌
 = yearly R&D risk   
 𝑟 = discount rate  
2.9 Data collection 
Multiple parameters are considered in the process economics tool described in this 
chapter. Some of these parameters are selected by the user, others were set as default 
values derived from the following methods: historical data from the UCL Decisional 
Tools Research Group, extensive literature review and discussions with vendors, industry 
and academic experts. For the fixed capital investment case study described in Chapter 
3, the data collected was obtained from literature review and reinforced through 
discussions with design consultant experts (Andrew Besso and Paul Dempsey from  
eXmoor pharma concepts, Bristol, UK).  Although an extensive database was available 
in the UCL Decisional Tools Research Group for the MSC case study described in 
Chapter 4, additional data was still required as well as updates to  the current data in the 
database as the cell therapy field is under continuous development. This data was attained 
through discussions with industry experts such as Matthieu Egloff (OUAT! Life Sciences, 
Brussels, Belgium), Fabien Moncaubeig BIP-partners (Cugnaux, France), Thierry Bovy 
( Promethera Biosciences, Louvain-la-Neuve),  Greg Rusotti (Celgene, New Jersey, US 
), Reinout Hesselink from eXmoor pharma concepts  (Bristol, UK),  Patrick Stragier  
(Masthercel, Charleroi, Belgium), Philippe Willemsen (Promethera Biosciences, 
Louvain-la-Neuve), Ohad Karneli (ATVIO biotechnology, Nesher, Israel), Claudia 
Lobato da Silva  (IBET, Lisbon, Portugal), Jon A Rowley (Roosterbio,  Frederick, MD , 
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US), Farlan Veraitch (UCL, London, UK), Bruce Levine (University of Pennsylvania, 
PA, USA). Additional to literature review, discussions with industry and academic 
experts were also required to build the set of assumptions used for the CAR T-cell case 
study in Chapter 5. These included Fabien Moncaubeig (BIP-partners, Cugnaux, 
France), Thierry Bovy (Promethera Biosciences, Louvain-la-Neuve),   Bruce Levine 
(University of Pennsylvania, PA, USA),  Reinout Hesselink (eXmoor pharma concepts, 
Bristol, UK),  Tom Breiva  and Greg Rusotti (Celgene, New Jersey, US ), Jim Faulkner 
(Autolus, London, UK) and Clive  Glover (Pall Life Sciences, Brussels, Belgium), 
Romain du Hecquet de Rauville (MaSTherCell, Brussels, Belgium) and Yajin Ni, Ronald 
Fedechko and Mark Leonard (Pfizer, South San Francisco, CA, USA). 
2.10 Conclusions  
This chapter has highlighted the key features of the advanced decisional tool used in 
Chapters 3-5 to provide insights to critical questions facing cell therapy developers. In 
Chapter 3, the FCI model will used provide a short-cut method for the evaluation of FCI 
and facility footprint for bespoke cell therapy facilities considering project-specific 
parameters such as technology selection, commercialisation scenario and facility 
location. Chapter 4 the process economics model is used in combination with the brute-
force optimization macro, the MADM model and the Monte Carlo model, in order to 
provide a holistic approach to assess the operational and economic features of different 
technologies for MSC expansion. The process economics model is also used in Chapter 
5. This time however, this model is coupled with the risk-adjusted cash flow model in 
order to evaluate the long-term economic benefit of different aspects of different 
strategies for CAR T-cell manufacture.  
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Chapter 3: A novel Method for Estimating Facility Footprint and 
FCI 
 
3.1 Introduction  
Chapter 1 described the traditional method for calculating fixed capital investment (FCI) 
for biotech facilities. This is called the “Lang factor” method where a number is 
multiplied by the total equipment purchase costs (TEPC) (including utility costs) to 
provide the total FCI. This number will vary from 3.63 to  4.74 depending on the product 
being manufactured for chemical facilities (Lang 1948) and 4-8 for biopharmaceutical 
protein facilities (Novais et al. 2001). Chapter 1 highlighted also some of the key 
characteristics of cell therapy facilities and how these are likely to differ from traditional 
biotech facilities. Such differences include lower space for clean utilities, as sterilization 
in place (SIP) and cleaning in place (CIP) operations are reduced due to the use of single-
use technologies (Rogge et al. 2015; Barak & Bader 2008; Levine et al. 2012; Rayner 
2010; Haigney 2016; Tiene 2016; Flaherty & Perrone 2012). Moreover, Chapter 1 
underlined the importance of investigating the suitability of the current “Lang factor” 
method for evaluating the FCI of different cell therapy facilities, by highlighting the 
unique features of the different technologies for cell therapy manufacture currently 
available on the market. This chapter uses the fixed capital investment model described 
in Chapter 2 (Section 2.3) to provide detailed factorial methodology for estimating FCI 
and footprint for bespoke cell therapy facilities. This method is employed in evaluating 
FCI in Chapter 5. 
3.2 Case study setup  
The aim of this case study was to first validate the detailed model for FCI and facility 
footprint evaluation described in the Chapter 2 (Section 2.3). The model was used to 
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help understand the trends in FCI and facility footprint for cell therapy manufacturing 
processes using different combinations of technologies referred to as manufacturing 
platforms with the aim of deriving benchmark correlations for project-specific short-cut 
FCI and facility footprint estimation. 
3.2.1 Validation of the detailed factorial methodology for estimating FCI and 
footprint for bespoke cell therapy facilities  
The FCI and facility footprint model was validated in order to increase the confidence in 
the results attained using the short-cut method for FCI and facility footprint evaluation. 
This was done by comparing the FCI and facility footprint results attained with the model 
described in Chapter 2 (Section 2.3) against the values provided by eXmoor Pharma 
concepts Ltd (Bristol, UK) for the same scenario. The scenario selected for this 
comparison was of an allogeneic MSC-based cell therapy process using automated cell 
factories for cell expansion and a fluidised bed centrifuge (FBC) for wash and recovery.  
The equipment list established for this scenario included biosafety cabinets (BSCs), 
multilayer flask incubators (MLINC), 40-layer flask incubators (INC40), automated 
multilayer manipulators (AMLFM) and FBCs. The number of BSCs, MLINCs, INC40s, 
AMLFMs and FBCs modelled in this scenario were 4, 2, 5, 2 and 1 respectively. 
3.2.2 Capital investment and facility footprint for cell therapy facilities 
The model was set to evaluate facility footprint and FCI of hypothetical cell therapy 
facilities using different technologies were first evaluated across annual demands ranging 
from 500 patients per year to 10,000 patients per year. The study was then extended to 
help understand the relationships between technology selection, annual demand, FCI and 
facility footprint. The understanding of these relationships was strengthened by the 
identification of key parameters contributing towards facility footprint and FCI.  
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3.2.3 Estimating project-specific cost factor  
FCI estimates may vary with geographic location. Therefore, the cost factors for FCI 
estimation were adjusted by multiplying these by geographic location factors. The 
geographic location factors were estimated according to the degree of economic 
development of the geographic regions being considered. For example for regions with 
relatively low economic development (e.g. Mexico and India), this factor was assumed to 
be 0.85. For regions with medium economic development such as the Gulf Coast of the 
US, this value was assumed to be 1, and for sites with high economic development such 
as Western Europe and the West Coast of the US this value was assumed to be 1.25 
(Coulson & Richardson 2005). Moreover, project requirements may also vary according 
to the condition of the construction site. Facilities maybe built on a greenfield site, 
brownfield site or an existing facility maybe refurbished to allow for cell therapy 
manufacture. In scenarios where facilities are to be built on a brownfield site, it was 
assumed that no yard improvements were required, hence these costs were removed. In 
scenarios where a facility was to be refurbished (i.e. an existing shell is available), it was 
assumed that the land costs, yard improvements and shell costs were null, so that the 
facility shell was rented and refurbished. 
3.2.4 Process overview  
In order to evaluate the trends in FCI and facility footprint for cell therapy facilities with 
the aim of deriving project-specific cost and area factors, multiple hypothetical facilities 
for autologous and allogeneic cell therapy manufacture were modelled. The unit 
operations carried out within these hypothetical facilities were pre-cell culture steps (e.g. 
cell activation), cell culture, downstream process and formulation and fill.  
The allogeneic process modelled in this case study was based on a 21day-long process 
for the manufacture of mesenchymal stem cells (MSCs). This process is described in 
detail Chapter 4 and the autologous process modelled was based on the manufacturing 
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process of a lentivirus-based chimeric antigen receptor T-cell (CAR T-cell) process 
lasting 13 days (described in detail in Chapter 5). 
For facilities manufacturing autologous CAR T-cells, it was assumed that the number of 
product manufacture rooms was dependent on the manufacturing platform being used and 
proportional to the number of processes being manufactured in parallel.  For facilities 
producing allogeneic MSC-based products on the other hand, it was assumed that the 
starting material was retrieved from a frozen cell bank and therefore an inoculation stage 
using T-flasks in biosafety cabinets surrounded by a Grade B cleanroom was required. 
Moreover, in these facilities it was also assumed that the product manufacture area was 
divided into four main suites:  inoculation room, cell culture room, DSP room and 
formulation and fill room. 
3.2.5 Key assumptions 
The dose size of both autologous and allogeneic cell therapy products manufactured 
within the facilities modelled in this case study was assumed to be 100M cells. It was 
assumed also that these facilities were built on a greenfield site in a medium economically 
developed area and that they were active for 335 days per year.  
The majority of the manufacturing platforms considered in this article allow for 
functionally closed processes, which can be carried out in a Grade C cleanroom. This 
trend excludes multilayer flasks for autologous CAR T-cell therapy manufacture, as these 
require multiple open steps throughout the manufacturing process, and hence must be 
operated in biosafety cabinets surrounded by Grade B processing cleanrooms. The 
characteristics of the technologies combined together to form the different manufacturing 
platforms are summarized on Table 3.1. All other cost and footprint assumptions used in 
this case study are summarised on Table 3.2. 
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Table 3.1 Key characteristics of the manufacturing platforms studied in the FCI and facility footprint case study 
Donor 
type 
Manufacturing platform Abbreviation  Technologies 
requireda 
Max no batches/ 
cleanroom 
Max capacity/unit 
(no doses in 
parallel)b 
Costs/unit ($) Footprint/unit 
(m2)c 
Allogeneic Multilayer flasks MLF BSC; MLINC; 
INC40; AMLFM; 
FBC  
NA 500; 31; 164; 28; 
10,000 
12,800; 13,440; 
198,016; 
482,560; 
261,162 
1; 0.46; 2.9; 
2.3;0.77 
 
Multi-plate bioreactor  MPB BSC; MLINC; 
MPBC; FBC 
NA 500; 9-64 ; 1-32 
;10,000 
12,800; 56,000;  
261,162 
1; 0.46; 0.2; 0.77 
 
Hollow fibre bioreactor  HFB BSC; HFB; FBC NA 500; 5; 10,000 12,800; 150,000;  
261,162 
1; 0.3; 0.77 
 
Stirred tank bioreactor  STR BSC; STR; FBC NA 500; 1-2,898; 10,000 12,800; 35,584-
291,886;  
261,162 
1; 0.87-4.2; 0.77 
Autologous Multilayer flasks with open 
steps 
MLF (open) BSC; MLINC; 
SMF 
1 2; 5; 2 12,800; 13,440; 
79,429 
1; 0.46; 0.35 
 
Static suspension bags  SSB MLINC; SMF 5 5; 2 13,440; 79,429 0.46; 0.35  
Integrated USP/DSP platform INT INT 20 1; 235,500 0.38  
Rocking motion bioreactor RMB MLINC; RMB; 
SMF 
10 5;1;2 13,440; 47,500; 
79,429 
0.46;0.22; 0.35 
a main process equipment required where: BSC = biosafety cabinet; MLINC = multilayer flask incubator; INC40 = 40-layer flask incubator; AMLFM = 
automated multilayer flask manipulator; FBC= fluidised bed centrifuge; MPBC = multi-plate bioreactor controller; HFB = hollow fibre bioreactor; STR = 
stirred tank bioreactor (w microcarriers); SMF = spinning membrane filtration unit; INT = integrated USP/DSP platform; RMB = rocking motion 
bioreactor. For allogenic processes, this capacity is calculated under the assumption that a harvest density of 45,000 cells/cm2 was achieved and that 
microcarier-based processes offer 5,540 cm2/L. 
b number of doses of 100M cells which can be produced using each technology. For MPB multiple bioreactor sizes were considered (with 10 plates. 50 
plates, 100 plates and 200 plates), these bioreactors use the same controller, hence a range in capacity is seen. In STR a range in the capacity of the 
bioreactor is also seen as multiple bioreactor sizes were also considered (1L, 5L, 10L, 20L, 50L, 100L, 500L, 1,000L and 2,000L). 
c For equipment with large volumes ( STR 100L, STR 500L, STR 1,000L and STR 2,000L), footprint includes auxiliary equipment (e.g. holding tanks for 
media and harvest) 
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Table 3.2 Key case study assumptions for FCI and facility footprint evaluation 
Parameter Value  Unit 
Dose size 100M  cells/dose 
No batches per year (allogeneic) 20 batches/year 
Equipment area/ product manufacture 
areaa 
0.163 - 
Material airlock footprintb 6 m2 
Personnel airlock footprintb 6 m2 
No QC labs/ facility 1 - 
Process support equipment costsb  2,389 $/m2 of cleanroom 
Logistics equipment costsb 548 $/m2 of cleanroom 
EMS central unitb 108,800 $/unit 
Probe costsb 1,920 $/sampling point 
Equipment installation costsc  1,920 $/unit 
Building shell costsb 548 $/m2 
Fit-out costs (Grade B)b 8,320 $/m2 
Fit-out costs (Grade C)b 6,106 $/m2 
Fit-out costs (Grade D)b 5,082 $/m2 
Fit-out costs (CNC)b 1,741 $/m2 
Fit-out costs (unclassified)b 64 $/m2 
Contractor feesb 12% of fit-out costs  
Land costsd  6% of shell costs  
Yard improvement costsd  10% of shell costs  
Engineering, management and consultant 
feesb 
20% of direct costs  
Contingency costsb 20% 
of (direct costs + Engineering, 
management and consultants 
fees) 
EMS = environment monitoring systems; CNC = controlled and non-classified 
aDerived from floorplans of different cell therapy facilities 
bDerived from materials provided by and personal contact with Andrew Besso and Paul 
Dempsey (eXmoor pharma concepts, Bristol, UK) 
cDerived from personal contact with Eric Matthieu (MaSTherCell, Gosseles, Belgium) 
d(Peters & Timmerhaus 1991) 
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Table 3.3 Ratio between the footprint of the different sections within a facility and the 
footprint of the product manufacture area 
 
 
Facility section Area/Product manufacture area  
Product manufacture  1.000 
Clean change 1 0.105 
Clean change 2 0.147 
Clean corridors  0.322 
Clean Janitor  0.042 
QC labs 0.650 
Microbiology lab 0.301 
Labs corridor 0.273 
PCR room 0.294 
Janitor  0.042 
Waste corridor  0.804 
Waste change  0.042 
Waste treatment  0.168 
Logistics 1.077 
Offices 3.147 
Meeting rooms  0.105 
Stairs  0.231 
Cold rooms 0.168 
Janitor  0.042 
General corridor  0.399 
Lorry/Van loading docks 0.224 
Reception 0.538 
WC 0.392 
Plant level  4.755 
The ratios between the cleanroom area and the footprint of all other sections within a facility were 
derived  materials provided by and personal contact with Andrew Besso and Paul Dempsey 
(eXmoor pharma concepts, Bristol, UK) 
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Table 3.4 List of equipment required per QC lab and their unit costs 
 
3.3 Results and discussion   
This section provides a summary of the key results attained throughout this case study. 
The case study started with the validation of the FCI model described in Chapter 2 
(Section 2.3). The analysis was extended to investigate the relationship between 
technology selection, FCI, annual demand and facility footprint. This allowed for the 
generation of project-specific factors for FCI and facility footprint calculation. 
3.3.1 Validating the fixed capital investment model 
In order to validate the FCI and facility footprint predictions generated by the FCI and 
facility footprint model, these were compared with values kindly provided by eXmoor 
Equipment  Costs ($/unit) 
Balance (200g)             2,408  
Cell Counter             2,816  
CO2 incubator           13,440  
ELISA/Spectrophotometer           51,200  
Endotoxin Test           12,800  
FACS        128,000  
Filter Integrity Tester           12,800  
FTIR             8,658  
Gel Analysis Instrument             1,920  
HPLC           64,000  
Isolator, Grade A with VHP        153,600  
Microscope           12,160  
MSCII           12,800  
Osmometer           16,698  
PCR           57,600  
PCR Hood – mini LAF for PCR amplification           12,800  
pH Meter             1,039  
Plate Reader             6,221  
Power Packs             1,007  
Peristaltic Pump             1,386  
Sterility Test        153,600  
Turbidity Meter                963  
ELISA =  enzyme-linked immunosorbent assay; FACS =  fluorescence-activated cell sorting; FTIR 
=  Fourier-transform infrared spectroscopy; HPLC = high performance liquid chromatography; VHP 
= vapour hydrogen peroxide;  MSCII = class II microbial safety cabinet; PCR = polymerase chain 
reaction 
 
The list of typical QC equipment in a cell therapy facility was derived through discussions with lab 
scientists and industrial experts. The individual equipment costs were obtained from vendor 
websites.  
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Pharma concepts for the same scenario. This comparison is shown in Figure 3.1. Figure 
3.1 illustrates a good agreement in the estimates of facility footprint (-3%) and FCI costs 
(+3%) when comparing the results provided by eXmoor Pharma concepts and those 
generated by the FCI and facility footprint model. The small difference in facility 
footprint can be explained by differences in ratios used to compute the total facility 
footprint (shown in Table 3.3).  
Figure 3.1 Comparison between results attained using the FCI model and those provided 
by eXmoor Pharma Concepts for a) facility footprint and b) FCI. 
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The key factors causing differences in the FCI predictions are the QC equipment costs 
(+455%) and EMS costs (-23%). The difference in QC equipment costs is attributed to 
the fact that the list of QC equipment included in the FCI model (Table 3.4) comprises 
additional equipment that was not included in the analysis carried out by eXmoor Pharma 
concepts. Moreover, in the FCI model, it was assumed that a single environmental 
monitoring probe per measurement (humidity, pressure and temperature) is required in 
each manufacturing suite. This may not ways be the case. Hence, the difference in EMS 
costs can be attributed to differences in the number of environment monitoring probes 
used.  
3.3.2 Trends in facility footprint and capital investment for different manufacturing 
platforms  
As previously highlighted Chapter 1 (Section 1.5) and in Table 3.1, there are a number 
of different technologies available on the market for the commercial scale manufacture 
of cell therapy products. These technologies have different features therefore, when 
selecting a platform for cell therapy manufacture, it is important to understand the effect 
that this may have on the FCI and facility footprint. The effect of manufacturing platform 
selection on the relationship between FCI and facility footprint of cell therapy facilities 
with increasing demand was investigated in Figure 3.2. Figure 3.2 a shows that 
autologous processes require higher footprints than allogeneic processes. This is an 
expected trend since autologous products require a scale-out manufacturing model as 
samples from different patients cannot be mixed. Allogeneic processes on the other hand 
benefit from the use of a scale-up approach to product manufacture, thus rapidly 
decreasing the facility footprint. 
Figure 3.2 a also indicates that for allogenic cell therapies, the manufacturing platform 
with the highest footprint is the multilayer flasks followed by the hollow fibre bioreactor. 
The manufacturing platform with the lowest facility footprint alternates between the 
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multi-plate bioreactor and the stirred tank bioreactor depending on the commercialisation 
scenario. 
Multilayer flasks have the highest footprint across all manufacturing platforms. This is 
due to the fact that specific incubators (INC40) and automation (AMLFM) are employed 
for incubation and manipulation of larger multilayer flasks. These technologies have 
relatively high footprints (INC40: 2.3m2; AMLFM: 2.9 m2), thus, increasing the facility 
footprint for processes employing multilayer flasks.  
Hollow fibre bioreactors have the second highest footprint across all platforms for 
allogeneic cell therapy manufacture featured in this article. Given the dose size selected 
for this study (100M cells), a single hollow fibre bioreactor is capable of producing 5 
doses per batch. As the annual demand moves from 500 to 10,000 doses per year, the 
batch size increases from 25 to 500 doses. Therefore, as the number annual demand 
increases so does the number of hollow fibre bioreactors in parallel, increasing the facility 
footprint. 
The manufacturing platform with the lowest footprint alternates between the multi-plate 
bioreactor and the stirred tank bioreactor. A single multi-plate bioreactor has a lower 
footprint than a stirred tank bioreactor (Table 3.1) and is able to process up to 64 doses 
of 100M cells. Therefore, at smaller annual demands, where a single multi-plate 
bioreactor is required per batch, this platform offers a lower facility footprint than stirred 
tank bioreactors. As the annual demand increases to 10,000 doses, multiple multi-plate 
bioreactors are required in parallel to meet the batch size of 500 doses. As a single stirred 
tank bioreactor can manufacture up to 2,898 doses per batch (Table 3.1), these become 
the platform with the lowest facility footprint. 
Figure 3.2 a also demonstrates that for autologous manufacturing platforms, multilayer 
flasks are again the manufacturing platform with the highest facility footprint, followed 
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by the rocking motion bioreactor, the static suspension bags and the integrated USP/DSP 
platform. As autologous processes operate at a relatively small scale, automated 
manipulator and large incubators are not used in combination with multilayer flasks. The 
relatively high facility footprint seen for these cell culture vessels in autologous 
processing is attributed to the use of biosafety cabinets (BSCs) required for open 
processing.  
The rocking motion bioreactor has the second highest footprint. This is caused by two 
factors: 1) a rocking motion platform is required per batch and 2) incubators are used 
during the pre-cell culture steps as these are carried out in static suspension bags (SSBs) 
as described in Chapter 4.  In the static suspension bags manufacturing platform, no 
dedicated equipment is required as all equipment used is shared across different batches 
manufactured in parallel, reducing the facility footprint. When using the integrated 
USP/DSP platform, a dedicated platform is also required per batch. However, this is an 
“all-in-one” platform, with relatively low footprint (Table 3.1).  
Figure 3.2 b highlights that similarly to the trends seen for facility footprint, FCI is higher 
for autologous processes versus allogeneic processes. However, the manufacturing 
platforms rank differently in FCI and facility footprint. Figure 3.2 b shows that the 
allogeneic manufacturing platform with the highest FCI is the hollow fibre bioreactor 
followed by multilayer flasks, and that the platform with the lowest FCI alternates 
between multi-plate bioreactor and the stirred tank bioreactor. 
The hollow fibre bioreactor has the highest FCI due to a combination of poor scalability 
and relatively high equipment costs ($150,000/unit) (Table 3.1). Multilayer flasks have 
the second highest FCI due to the requirement of INC40s and AMLFMs. These 
technologies not only have high equipment costs (INC40 = $198,016; AMLFM = 
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$482,560), but also increase the facility footprint (as seen in Figure 3.2 a), increasing the 
building shell and fit-out costs as well as land and yard improvements costs.  
Similar trends are seen in the ranking for FCI and facility footprint for stirred tank 
bioreactors and multi-plate bioreactors, where at lower annual demands multi-plate 
bioreactors have the lowest FCI. As the annual demand increases, increasing the number 
of multi-plate bioreactors per batch, stirred-tank bioreactors become the manufacturing 
platform with the lowest FCI. 
As for autologous platforms, Figure 3.2 b shows that multilayer flasks have the highest 
FCI followed by the integrated USP/DSP platform, rocking motion bioreactor and static 
suspension bags. Multilayer flasks have the highest FCI due the use of BSCs in  Grade B 
cleanrooms which causes all  cleanroom-dependent costs (e.g. building shell costs, fit-out 
costs etc.) to increase. The integrated USP/DSP platform has relatively high FCI due to 
fact that a dedicated platform with relatively high equipment costs ($235,500/unit) is 
required per batch.  
Despite the fact that the rocking motion bioreactor was shown to be the platform for 
autologous cell therapy manufacture with the second highest facility footprint (Figure 
3.2 a), the equipment costs associated with the platform are relatively low, allowing this 
platform to have the second lowest FCI. Moreover, static suspension bags have the lowest 
FCI due to the fact that these only required shared equipment with relatively low costs. 
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Figure 3.2 a) Facility footprint b) FCI with increasing annual demand for different manufacturing platforms. The unit operations 
included in the allogenic platforms were inoculation, cell culture and wash and volume reduction while the unit operations included 
in the autologous platforms were cell wash, cell activation, viral transduction, cell culture and wash and volume reduction. For 
allogenic processes a harvest density of 45,000 cells/m2 for all platforms and surface area/L for microcarier-based platforms of 
5,540cm2/L were assumed . For autologous processes a maximum cell density for cell culture was 7 × 106 cells/ml was assumed. 
The abbreviations indicate the name of the different manufacturing platforms: MLF = multilayer flask; MPB = multi-plate 
bioreactor; HFB = hollow fibre bioreactor; STR = stirred tank bioreactor; MLF (open) = multilayer flask with open steps; SSB = 
static suspension bag; INT = integrated USP/DSP platform; RMB = rocking motion bioreactor. 
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3.3.3 Relationship between capital investment and facility footprint  
Figure 3.2 has revealed that cell therapy facilities using different manufacturing 
platforms have different facility footprints and FCI. This section will establish the 
relationship between facility footprint and FCI across multiple manufacturing platforms 
in order to draw general relationships between  FCI, facility footprint and technology 
selection. 
Figure 3.3 a shows a linear relationship between FCI and facility footprint across all 
manufacturing platforms. However, the slope of this relationship changes significantly 
across manufacturing platforms, indicating that some manufacturing platforms have 
higher FCI per m2 of facility footprint than others. In allogeneic facilities, this slope 
ranges between 7,000 $/m2 (multilayer flasks) to 13,000 $/m2 (hollow fibre bioreactor). 
Similarly, in autologous facilities, FCI per m2 ranges between 8,200 $/m2 (multilayer 
flasks) to 16,000 $/m2 (integrated USP/DSP platforms). For the allogeneic processes, the 
manufacturing platform with the highest FCI per m2 is the hollow fibre bioreactor 
platform (13,000 $/m2) followed by the multi-plate bioreactor platform (9,500 $/m2), the 
stirred tank bioreactor platform (8,000 $/m2) and finally the multilayer flasks platform 
(7,500 $/m2).  
Hollow fibre bioreactors have a relatively high FCI per m2 due the combination of low 
capacity and high equipment costs as previously explained. Although both multi-plate 
bioreactors and stirred tank bioreactors have relatively low FCI (Figure 3.2 b), these 
platforms also have low facility footprints increasing the FCI: facility footprint ratio. 
Moreover, even though the multilayer flasks have the second highest FCI across all 
platforms for allogeneic cell therapy manufacture (Figure 3.2 b), this platform has 
significantly high facility footprint (Figure 3.2 a), decreasing the FCI: facility footprint 
ratio. 
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For autologous processes, Figure 3.3 a shows that the manufacturing platform with the 
highest FCI per m2 is the integrated USP/DSP platform (15,000 $/m2) followed by the 
rocking motion bioreactor (8,500 $/m2), the static suspension bag (8,400 $/m2) and finally 
the multilayer flasks platform (8,300 $/m2). The relatively high FCI per m2 seen when 
Figure 3.3 a) Relationship between FCI and facility footprint across multiple 
manufacturing platforms. b) Relationship between FCI per m2 of facility and facility 
footprint across multiple manufacturing platforms. The unit operations included in the 
allogenic platforms were inoculation, cell culture and wash and volume reduction while 
the unit operations included in the autologous platforms were cell wash, cell activation, 
viral transduction, cell culture and wash and volume reduction. For allogenic processes a 
harvest density of 45,000 cells/cm2 for all platforms and surface area/L for microcarier-
based platforms of 5,540 cm2/L were assumed . For autologous processes a maximum 
cell density for cell culture was 7 × 106 cells/ml was assumed. The abbreviations indicate 
the name of the different manufacturing platforms: MLF = multilayer flask; MPB = multi-
plate bioreactor; HFB = hollow fibre bioreactor; STR = stirred tank bioreactor; MLF 
(open) = multilayer flask with open steps; SSB = static suspension bag; INT = integrated 
USP/DSP platform; RMB = rocking motion bioreactor. 
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using the integrated USP/DSP platform is attributed to high equipment costs previously 
highlighted. Rocking motion bioreactor and static suspension bags offer lower FCI per 
m2 due relatively low FCI associated with this platforms. Similar to the trends seen for 
allogeneic processes, even though multilayer flasks have the highest FCI (Figure 3.3 b), 
they also have the highest facility footprint across all manufacturing platforms for 
autologous cell therapy manufacture considered in this case study, which reduced the FCI 
per m2. 
Figure 3.3 b shows the relationship between FCI per m2 of facility and facility footprint. 
This figure shows that for allogeneic processes, FCI per m2 decreases with increasing 
facility footprint across all manufacturing platforms but for autologous processes, this 
ratio remains constant. This is due to the economies of scale achieved in allogeneic 
processes as a result of a scale-up approach to cell therapy manufacture which allows for 
fixed overhead costs (e.g. EMS and QC costs) to be spread over a higher number of doses. 
3.3.4 Key factors influencing the fixed capital investment and footprint of cell 
therapy facilities  
As previously mentioned Chapter 1 (Section 1.7), the layout of cell therapy facilities is 
likely to differ from traditional biotechnology. This section highlights the key features of 
the facility layout of cell therapy facilities and identify the major factors contributing to 
FCI.  Figure 3.4 illustrates the relationship between the different sections within the 
product manufacture floor of a cell therapy facility, by showing the detailed facility 
floorplan used as the basis to evaluate the ratios provided in Table 3.3. Even though the 
plat area is not shown in Figure 3.4 since it was assumed to be in a different floor, this is 
the section within the facility with the highest footprint. The section with the second 
highest footprint is the office space, this is also not clear from Figure 3.4, as this space 
was split across two different levels. 
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Figure 3.5 shows that the cost drivers affecting the FCI vary across the different 
manufacturing platforms. For allogeneic processes, when the annual demand is of 500 
doses per year, the key direct cost drivers across most manufacturing platforms are 
building fit-out costs followed by process equipment costs and QC equipment costs. The 
effect of the core equipment costs on the hollow fibre bioreactor is higher than for other 
manufacturing platforms due to a combination of high equipment costs and low capacity 
as previously discussed. As the annual demand increases to 10,000 doses, economies of 
scale allow for overhead costs (EMS and QC costs) to be spread over a higher number of 
batches, reducing the relative contribution of these costs. 
In autologous processes at 500 doses per year, for most manufacturing platforms, the 
building fit-out costs are the key direct cost driver followed by process equipment costs 
and the facility shell costs. This trend excludes the integrated USP/DSP platform due to 
the significantly higher core equipment costs associated with this platform. Increasing the 
annual demand to 10,000 has no significant effect on these trends due to the scale-out 
approach applied in autologous cell therapy manufacture. 
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Figure 3.4 General facility layout used in this analysis to determine the relative footprint of the different 
areas within a cell therapy facility. Yellow regions = Grade C area classification; Green regions = Grade D 
area classification; white regions = Grade U area classifications. 
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3.3.5 Evaluating costs and area factors  
Figure 3.2 and Figure 3.3 have shown that different manufacturing platforms require 
very different facility footprints and FCI and that the relationship between FCI and facility 
footprint may vary with annual demand. Therefore, costs and area factors were derived 
in order to provide short-cut methods to evaluate footprint and FCI for bespoke cell 
therapy facilities. This is shown in Figure 3.6. A detailed breakdown of the different 
factors contributing to the overall cost factor across the different manufacturing platforms 
can be found in Table 3.5.  
Figure 3.6 a shows  an inverse relationship between the cost factors and the area factors 
where manufacturing platforms with the highest area factors (i.e. highest core equipment 
costs per m2) (e.g. hollow fibre bioreactors and integrated USP/DSP platforms) have the 
lowest cost factors (i.e lowest ratio between FCI and core equipment costs) and vice versa. 
Figure 3.5 Contribution of the different factors towards the FCI for a dose size of 100M 
cells and annual demands of 500 and 10,000 doses per year. The abbreviations indicate 
the name of the different manufacturing platforms: MLF = multilayer flask; MPB = 
multi-plate bioreactor; HFB = hollow fibre bioreactor; STR = stirred tank bioreactor; 
MLF (open) = multilayer flask with open steps; SSB = static suspension bag; INT = 
integrated USP/DSP platform; RMB = rocking motion bioreactor. 
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This figure also shows that annual demand has an impact on FCI and facility footprint of 
allogeneic processes but not on autologous processes due to the economies of scale 
achieved with allogeneic processes as previously discussed. Moreover, Figure 3.6 a 
shows that for allogenic processes, area factors range between 950 (stirred tank 
bioreactor) and 5,400 (hollow fibre bioreactor) and cost factors range from 2.3 (hollow 
fibre bioreactor) and 8.3 (stirred tank bioreactor). Similar trends are seen for autologous 
processes as area factors range between 980 (multilayer flasks) and 6,500 (integrated 
USP/DSP platform) and cost factors vary from 2.3 (integrated USP/DSP platform) and 
8.5 (multilayer flasks). 
As Figure 3.6 a highlighted that the cost and area factors are sensitive to annual demand 
in allogeneic processes, Figure 3.6 b was generated to illustrate the process of selecting 
the adequate cost and area factor from Figure 3.6 a taking into account the manufacturing 
platform used and the target annual demand. 
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Table 3.5 Cost factor breakdown for different hypothetical cell therapy facilities producing 5,000 doses per year 
 Items   Allogeneic Autologous  
   MLF MPB HFB STR MLF (open) SSB INT RMB 
𝑓1 Main process equipment  
 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
𝑓2 Process support equipment 
 0.10 0.11 0.03 0.15 0.23 0.09 0.02 0.08 
𝑓3 QC equipment 
 0.12 0.56 0.05 0.79 0.07 0.09 0.02 0.04 
𝑓4 Logistics equipment 
 0.02 0.03 0.01 0.04 0.05 0.02 0.01 0.02 
𝑓5 EMS 
 0.03 0.16 0.01 0.22 0.02 0.02 0.00 0.01 
𝑓6 Equipment installation 
 0.01 0.04 0.01 0.02 0.05 0.03 0.01 0.04 
𝑓7 Shell costs  
 0.34 0.39 0.11 0.55 0.79 0.32 0.08 0.27 
𝑓8 Fit-out costs  
 1.23 1.50 0.39 2.10 2.97 1.16 0.28 0.96 
𝑓9 Contractor fees 
 0.15 0.18 0.05 0.25 0.36 0.14 0.03 0.12 
𝑓10 Land costs  Greenfield & Brownfield 0.02 0.02 0.01 0.03 0.05 0.02 0.00 0.02 
𝑓11 Yard improvements  Greenfield 0.03 0.04 0.01 0.05 0.08 0.03 0.01 0.03 
𝑓12 Engineering, management and consultant fees 
Greenfield  0.61 0.81 0.34 1.04 1.13 0.58 0.29 0.52 
Brownfield  0.61 0.80 0.33 1.03 1.12 0.58 0.29 0.51 
Refurbishment  0.60 0.79 0.33 1.03 1.11 0.57 0.29 0.51 
𝑓13 Contingency 
Greenfield  0.73 0.97 0.40 1.25 1.36 0.70 0.35 0.62 
Brownfield  0.73 0.96 0.40 1.24 1.34 0.69 0.35 0.61 
Refurbishment  0.72 0.95 0.40 1.23 1.33 0.69 0.35 0.61 
𝐹𝐶 Total 
Greenfield  4.41 5.80 2.42 7.51 8.16 4.21 2.11 3.71 
Brownfield  4.36 5.75 2.41 7.43 8.04 4.16 2.10 3.67 
Refurbishment  4.33 5.71 2.40 7.38 7.98 4.14 2.10 3.65 
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Figure 3.6 a) Trends in area factor and cost factor across multiple manufacturing platforms and commercialisation scenarios for 
a products with dose size of 100M cells. The unit operations included in the allogenic platforms were inoculation, cell culture and 
wash and volume reduction while the unit operations included in the autologous platforms were cell wash, cell activation, viral 
transduction, cell culture and wash and volume reduction. For allogenic processes a harvest density of 45,000 cells/m2 for all 
platforms and surface area/l for microcarier-based platforms of 5,540 were assumed . For autologous processes a maximum cell 
density for cell culture was 7 × 106 cells/ml was assumed. The abbreviations indicate the name of the different manufacturing 
platforms: MLF = multilayer flask; MPB = multi-plate bioreactor; HFB = hollow fibre bioreactor; STR = stirred tank bioreactor; 
MLF (open) = multilayer flask with open steps; SSB = static suspension bag; INT = integrated USP/DSP platform; RMB = rocking 
motion bioreactor b) Method for evaluating facility footprint and FCI. 
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3.3.6 Selecting a project specific cost factor   
The hypothetical facilities considered in this case study so far were assumed to be built 
on a greenfield site. However, the starting condition of the site chosen to build the facility 
may vary from project to project. Some projects may be built on a brownfield site and 
others in an existing building shell. Moreover, the geographical location of the facility 
will also have an effect on the FCI. Furthermore, different manufacturing platforms 
require the use of different cost factors for relevant evaluating of FCI as previously 
observed (Figure 3.2 and Figure 3.3).  Hence, it is important to provide cost factors that 
capture project-specific features in order to increase the accuracy of estimated. The 
differences in cost factor across the manufacturing platforms were captured by grouping 
them together into three categories according to the core equipment costs per m2 
characteristic of the different platforms. These categories were: high equipment costs per 
m2 of facility, medium equipment costs per m2 of facility and low equipment costs per m2 
of facility. 
The different platforms were grouped together according to the trends seen for area factor 
on Figure 3.6 a. The hollow fibre bioreactor and integrated USP/DSP platforms were 
considered to have relatively high equipment costs per m2. Platforms with medium 
equipment costs per m2 of facility were assumed to be the multilayer flasks (allogeneic), 
multi-plate bioreactor, static suspension bags and rocking motion bioreactor. 
Manufacturing platforms with low equipment costs per m2 of facility were assumed to be 
stirred tank bioreactor and the multilayer flask with open steps (autologous). The effect 
of manufacturing platform selection, the starting condition of the construction site and its 
geographical location and manufacturing platform selection are captured in Figure 3.7. 
For each site condition-geographic region combination, each group of manufacturing 
platforms seen Figure 3.7 offers a range of cost factors in order to account for the effect 
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of annual demand on the cost factor; such that at smaller annual demands, users may 
choose higher cost factors and vice-versa. 
Figure 3.7 shows that manufacturing platforms with high equipment costs per m2 have 
cost factors between 2.1 and 3.5 depending on the annual demand, geographic region and 
initial condition of the construction site. This factor increases to 3.5-7.5 for platforms 
with medium equipment costs per m2 and 6.1-8.4 for platforms with high equipment costs 
per m2. Moreover, Figure 3.7 shows also that in low economically developed areas such 
as India and Mexico, the cost factors are lower as building materials, land and labour 
costs are lower. As the degree of economic development increases to geographic areas 
such as the US west coast or Eastern Europe, these costs increase, increasing the overall 
cost factor.  Furthermore, when building a facility in the Brownfield site as opposed to a 
Green filed site, it was assumed that no yard improvements were required such that these 
costs would be null, decreasing the overall project costs and hence the cost factor. This 
assumption may not always apply as in some cases land remediation maybe required due 
to possible soil contamination, which will incur some yard improvement costs. Moreover, 
when considering building the facility in an existing (rented) shell, although the land 
costs, yard improvement costs and shell costs maybe null, resulting in lower FCI, and 
hence a lower cost factor, the facility running costs would be higher as the company now 
must pay to rent the facility. Furthermore, when using an existing shell possible design 
restrictions must also be considered. 
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3.4 Conclusion  
This chapter aimed at proposing a detailed project-specific factorial methodology and 
using it to provide benchmark short-cut ratios for FCI and facility footprint evaluation for 
cell therapy facilities using the core equipment costs.  The results clearly highlight that 
allogenic facilities have significantly lower FCI and facility footprint than autologous 
facilities. Moreover, when evaluating FCI and facility trends for different cell therapy 
facilities, the results showed that multiple factors will have an effect on the FCI and 
footprint of cell therapy facilities including annual demand, manufacturing technology, 
initial condition of the construction site and geographic location of the facility. These 
parameters caused the cost factors to range between 2.15 and 8.6 and the area factors to 
range between 950 and 6,500.  
Figure 3.7 Change in cost factor with initial condition of the facility site, 
manufacturing platform and geographic location of the facility. The manufacturing 
platforms with high costs/m2are the hollow fibre bioreactor and the integrated 
USP/DSP. The manufacturing platforms with medium costs/m2 are the multilayer 
flasks, multi-plate bioreactor, static suspension bags and rocking motion bioreactor and 
the manufacturing platform with low  costs/m2 are the stirred tank bioreactor and 
multilayer flasks with open steps. 
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FCI and facility footprint are important factors to consider when selecting a 
manufacturing strategy for a novel cell therapy product. This method can be used for 
manufacturing platform selection based on crude FCI and facility footprint estimates 
during the early stages of process development of novel cell therapy products. 
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Chapter 4: Impact of Allogeneic Stem Cell Manufacturing 
Decisions on Cost of Goods, Process Robustness and 
Reimbursement 
4.1 Introduction  
Chapter 1 has underlined the therapeutic potential of mesenchymal stem-based cell 
therapies across a number of different indications as well as the challenges associated 
with the manufacture of these therapies. These challenges include high cost of goods 
(COG), high process variability and scale-up restrictions (Heathman et al. 2015; 
Lapinskas 2010; Lopez et al. 2010; Christodoulou et al. 2013; Mount et al. 2015a; 
Ratcliffe et al. 2011). As COG decreases with increasing manufacturing scale (Simaria et 
al. 2014b), there is an increased interest in the development and evaluation of scalable 
technologies for cell therapy manufacture. Methods for the evaluation of novel 
technologies are based often on COG and process yield. However, there are a number of 
less tangible issues that must be considered also when designing a manufacturing process 
for cell therapy products such as robustness, biological limitations, technology scalability, 
and ease of development. This chapter aims at utilizing the advanced decisional tool 
described in Chapter 2 to provide a holistic approach to select the optimal manufacturing 
technology for the manufacture of adherent cells (MSC-products) that captures economic 
aspects (e.g. COG, fixed capital investment, reimbursement potential) as well as 
operational aspects (e.g. robustness, resource requirement, ease of validation, ease of 
operation, ease of development). 
The remainder of this chapter is structured as follows. Section 4.2 presents the case study 
setup. In Section 4.3 the results are presented and discussed. Section 4.3.1 focuses on the 
deterministic analysis. In Section 4.3.2 multi-attribute decision-making and Monte Carlo 
simulations are used to evaluate the operational features of different technologies for the 
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expansion of MSC.   In Section 4.3.3 multiple reimbursement strategies are applied to 
hypothetical cell therapy products with industrially relevant dose sizes, and the analysis 
identifies scenarios where commercial feasibility will be challenging due to economic 
and/or operational bottlenecks. Section 4.3.3 also provides insights on areas within the 
manufacturing process, for which additional development would allow for commercial 
feasibility of MSC-based cell therapy products. 
4.2 Case study setup  
The decisional tool described in Chapter 2 was used in this case study in order to assess 
the economic and operational benefits of different manufacturing platforms for the 
production of allogeneic MSC-based cell therapy products. The bioprocess economics 
model simulates each day of a single product facility operating 335 days a year with two 
annual maintenance shutdowns, one in the summer and one in the winter. The 
manufacturing process modelled in this case study is based on  a 21 day long cell culture 
process with 3 expansion stages and with the final cell harvest, wash, concentration and 
formulation occurring on day 21 (Table 4.1). 
The annual demand for MSC-based products is likely to vary according to the indication 
being targeted, for example, indications such as chronic low back pain have lower dose 
sizes (~107 cells) (Pang et al. 2014; GlobeNewswire 2016b), whilst other indications such 
as GvHD the dose requirement is much higher (~108-109 cells per patient) (Hare et al. 
2009; Bell Potter 2011; Introna et al. 2014; Lin & Hogan 2011; Lazarus et al. 2005; 
ClinicalTrials.gov 2016).  
Given the differences in annual demands of different MSC-based cell therapy products, 
the tool was used to analyse the behaviour of different manufacturing technologies across 
manufacturing  scales varying from 1 to 100 billion cells per batch and demands ranging 
from 10 billion to 10,000 billion cells per year. This scale limit was established in Hassan 
et al (2015) as the maximum number of cells which the current technologies for cell wash 
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and concentration can process.  A minimum and maximum number of batches per year 
that can be processed in a single facility was established through discussions with industry 
experts to be 10 and 100 respectively. 
Table 4.1 Key assumptions for MSC process economics case study  
Category Parameter Value Unit 
Scenario set up Max no  batches 100 - 
Min no batches 10 - 
Lang factor 23.67 - 
Max No FBCs/batch 1 - 
Depreciation period 7 years 
    
Mass balance Seeding density 4,000 cells/cm2 
Harvest density 45,000 cells/cm2 
    
Costs Trypsin 30 $/L 
QC materials 10,000 $/batch 
Media 450 $/L 
Microcarrier costs 5 $/g 
Biosafety cabinet 17,000 $/unit 
Operator cost 120,000 $/y 
    
Time constraints Shift time 8 hours 
Gowning, documentation  
and cleaning time 
20% of shift time 
Maximum time allowed for  
expansion process setup (day 
1) 
6 hours 
Passage (days 7 & 14) 3 hours 
Media exchange (days 4, 10 
&17) 
6 hours 
Harvest (day 21) 3 hours 
Microcarrier removal, wash 
and concentration (day 21) 
4 hours 
Vialling (day 21) 2 hours 
FBC = fluidised bed centrifuge; QC = quality control 
 
In Simaria et al (2014) a condition was applied where microcarrier-based cell culture was 
only considered in scenarios where planar platforms were infeasible due to capacity 
constraints, so as to accommodate the fact that planar systems are well-established 
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technologies, and therefore preference would be given to them when possible. In the case 
study described in this case study, however, this assumption has been lifted in order to 
explore the cost-benefit of microcarrier-based cell culture at smaller manufacturing 
scales. 
The planar technologies considered in this case study were multi-layer flasks (MLF) (e.g. 
Cell Factories®, CellSTACKs®), multi-plate bioreactors (MPB) (e.g. Xpansion®), 
hollow fibre bioreactors (HFB) (e.g. Quantum®) and the 3D technology considered was 
single-use bioreactors with microcarriers in suspension in stirred tank reactors (STR). The 
key characteristics of the different technologies are outlined in Table 4.2.  
The resource requirement, COG and major cost drivers of these manufacturing platforms 
were identified across different scales through a detailed process economics analysis. The 
cost-effectiveness of microcarrier-based cell culture was further investigated by 
evaluating the critical process parameters which make 3D cell culture more attractive than 
planar technologies. The results from the process economics analysis were used in the 
multi-attribute decision analysis where both operational and economic attributes of 
different manufacturing platforms were quantified. The robustness of the different 
technologies was also assessed at different manufacturing scales through a Monte Carlo 
analysis.  The process economics analysis was placed in context by evaluating the 
commercial feasibility of products manufactured using different technologies when 
current reimbursement strategies are applied.  This analysis identified scenarios where 
successful commercialisation is unfeasible due to high COG or capacity constraints 
resulting in failure to meet the annual demand. These scenarios were further investigated 
through an optimization analysis. 
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Table 4.2 Manufacturing platform-specific assumptions for the MSC case study 
Category Parameter Multi-layer Multi - plate Hollow 
fibre 
Single-use 
bioreactors with 
microcarrierb 
Resource 
capacities and 
requirements 
Technology name MLF 1 MLF 2 MLF 5 MLF 10 MLF 40 MLF10 MPB 
50 
MLB 
100 
MPB 
200 
HFB STR: 1L – 2,000L 
Surface area (cm2) 636 1,272 3,180 6,320 25,280 6,120 30,600 61,200 122,400 21,000 5,540-11,080 ,000c 
Media volume (ml/ 
cm2) 
0.25 0.25 0.25 0.16 0.16 0.27 0.18 0.18 0.18 0.37 0.09 
Incubator capacity 60 60 24 12 16 2 2 2 2 - - 
Equipment 
capacitya 
- - - - 16 1 1 1 1 1 1 
Executing: 
Documentation 
operator ratio 
1:1 1:1 1:1 1:1 1:1 2:1 2:1 2:1 2:1 2:1 2:1 
Costs Consumable costs 
($/unit) 
60 73 241 507 1,265 2,310 4,412 6,778 9,820 12,000 680-10,500 
Incubator costs 
($/unit)) 
17,835 17,835 17,835 17,835 30,000 10,000 10,000 10,000 10,000 - - 
Equipment costs 
($/ unit) 
- - - - 425,000 59,800 59,800 59,800 59,800 150,000 88,470-575,000 
Time Start culture 
duration (h) 
0.14 0.14 0.14 0.14 1.3 1 1 1 1 0.17 2 (for volume 
 ≤ 200 L), 3 (for 
volume > 200L) 
Media exchange 
duration (h) 
0.07 0.07 0.07 0.07 0.67 0.5 0.5 0.5 0.5 0 1 (for volume ≤ 
200L), 1.5 (for 
volume >200L) 
Passage time (h) 0.21 0.21 0.21 0.21 1.97 1.5 1.5 1.5 1.5 0.37 3 (for volume ≤ 
200L), 4.5 (for 
volume >200L) 
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Harvest duration 
(h) 
0.07 0.07 0.07 0.07 0.67 0.5 0.5 0.5 0.5 0.2 1 (for volume ≤ 
200L), 1.5 (for 
volume >200L) 
Biosafety cabinet 
requirement 
Y Y Y Y N N N N N N N 
arefers to any equipment required in order to use the technology excluding incubators and biosafety cabinets (eg. Controllers and manipulators). 
bin the interest of clarity, only the maximum and minimum sizes used were listed. Other sizes considered were: 5L, 10L, 20L, 50L, 100L, 500L and 1,000L. 
cfor the estimation of the surface area per cell cultures vessel, the following assumptions were made: bioreactor space efficiency = 50%, microcarrier seeding density = 4 g/L 
and microcarrier surface area = 2,770 cm2/g. The media volume required for microcarrier-based cell culture was optimized such that these processes have lower media 
consumption. 
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4.2.1 Process overview 
The manufacturing process starts with cell culture assuming that master cell banks are in 
place. Three cell culture stages were modelled each lasting 7 days, making a total of 21 
days of cell culture. During each cell culture stage a media exchange step was performed 
such as to maintain nutrient concentration and hence promote cell viability. The cells 
were seeded at 4,000 cells per cm2 and harvested at density of 45,000 cells per cm2 with 
a doubling time of around 48 h.  
The cell culture stage was followed by cell wash and concentration. Given that fluidised 
bed centrifuge (FBCs) are expensive (between £180,000-£500,000 (Hassan et al. 2015)), 
and that it is impossible to manufacture 100 batches of 21 days in series within a year, the 
utilization of FBCs was maximised by staggering batches in parallel such that cell wash 
and concertation took place on different days for different batches being manufactured in 
parallel.  The final concentration of the manufacturing process was assumed to be 
10million cells per ml. These cells were then diluted in DMSO containing solution, placed 
in 6 ml cryovials and cryopreserved using a controlled rate freezer.  
The labour requirement was evaluated by using the number of operators per team of 
operators. The number of operators per team varies according to the manufacturing 
platform used, as these require different numbers of manipulations. For example, in open 
processing using multi-layer flasks, a higher number of manipulations is required with 
respect to the use of automated bioreactors and therefore the number of operators per 
team is higher for these technologies. 
The shift time applied here was 8 h, however, an assumption was made that only 80% of 
the shift time was spent in the cleanroom and the remaining 20% was used in gowning 
and de-gowning and documentation.  
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4.2.2 Key assumptions 
Robustness analysis was performed using the Monte Carlo simulation model described 
in Chapter 2 (Section 2.7). During this analysis, the manufacturing process was fixed 
and different critical process parameters were varied such that the absolute COG 
remained constant whilst the throughput varied. Moreover an assumption was made that 
in scenarios where the number of cells produced exceeded the expected number of cells, 
these additional cells would still be commercialised and not wasted resulting in lower 
COG/million cells in such scenarios. 
The values used for the critical process variables were attained through a series of 
discussions with industry experts. The rationale behind these assumptions is based on the 
fact that multi-layer flasks are manual systems and therefore prone to variability. This 
was assumed to have an impact on the cell doubling time and batch failure rate due to the 
limited control over the process parameters. Moreover, given that microcarrier-based cell 
culture is a more nascent technique in the cell therapy field, it was also assumed that the 
variability in the proliferation rate of cells would also be higher in these systems. The 
additional degree of difficulty in dissociating cells from microcarriers with respect to 2D 
technologies was also accounted for by allowing extra variability in cell detachment 
efficiency in 3D cell culturing. Table 4.3 summarises the minimum, maximum and most 
likely values of the parameters evaluated.  
Multi-attribute analysis was performed in order to quantify both operational and 
economic parameters. The scores for operational attributes were attained by distributing 
a survey questionnaire across multiple industry experts on their experience in designing 
a process for commercial scale manufacture of cell therapy products. In total, seven 
interviews were carried out with experts spanning roles such as senior pilot plant 
manager, business development manager, global product manager, vice president of 
technology and manufacturing, and head of cell culture services across innovator 
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companies, contract manufacturers and vendors. The survey asked them to rank 
operational categories according to their importance and to rank different cell culture 
technologies on those categories. The operational categories considered were ease of 
development, ease of validation, ease of setup, ease of operation and ease of scale-up. 
The actual development costs were not considered at this stage but have been explored in 
parallel work by Hassan et al 2015. The scores used in this section were the average of 
the responses and are summarised in Table 4.3. The scores from both economical 
categories (FCI and COG/million cells) were gathered from the process economics 
model. Here, an assumption was made that the COG/million cells was twice as important 
as the FCI costs, such that the long term benefits of using a particular technology would 
outweigh the initial capital investment. 
In this analysis, the capacity of the different manufacturing technologies for producing 
enough cells for different commercialisation scenarios was assessed. An assessment of 
the commercial feasibility of MSC-based cell products under the UK’s National Institute 
of Health and Care Excellence (NICE) maximum reimbursement limit (approximately 
$40,000 per quality adjusted life) (Bubela et al. 2015) was also carried out. This allowed 
for the identification of scenarios where commercial failure would occur due to capacity 
or economic constraints.  
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Table 4.3 Assumptions for multi-attribute decision-making and stochastic cost analysis 
 Attribute Ranka MLF MPB HFB STR 
 Multi-attribute decision-making analysis 
O
p
er
at
io
n
al
 
p
ar
am
et
er
s 
Ease development Tr(1,2.2,3) Tr(1,4,5) Tr(2,3.4,5) Tr(2,3.2,5) Tr(1,2.4,4) 
Ease of validation Tr(2,3.6,4) Tr(2,3.2,5) Tr(3,3.4,5) Tr(1,2.8,5) Tr(2,3,4) 
Ease of setup Tr(1,2.8,5) Tr(1,3.6,5) Tr(2,3,4) Tr(3,3.8,5) Tr(2,3,4) 
Ease of operation Tr(2,3.4,5) Tr(1,2.2,4) Tr(2,3.6,4) Tr(1,3.6,5) Tr(3,3.6,4) 
Ease of scale-up Tr(1,3.8,5) Tr(1,2.4,4) Tr(3,3.6,5) Tr(1,1.6,2) Tr(1,3.2,5) 
E
co
n
o
m
ic
 
p
ar
am
et
er
s COG/millionb ($) 2 Tr(25,78,435) Tr(21,46,99) Tr(85,163,351) Tr(10,37,10) 
FCIb ($M) 1 55.7 19.8 81 21 
 Robustness  analysis 
 Cell detachment 
yield 
- Tr(0.85,0.9,0.95) Tr(0.85,0.9,0.95) Tr(0.85,0.9,0.95) Tr(0.6,0.75,0.9) 
 DSP yield - Tr(0.58,0.68,0.78) Tr(0.58,0.68,0.78) Tr(0.58,0.68,0.78) Tr(0.512,0.612,0.712) 
 Batch success rate - Tr(0.9,0.95,0.97) Tr(0.93,0.95,0.98) Tr(0.93,0.95,0.98) Tr(0.93,0.95,0.98) 
 Doubling time (h) - Tr(32,34,37) Tr(33,34,35) Tr(33,34,35) Tr(32,34,37) 
 For the operational criteria, a higher score of 5 indicated the best technology in that particular criteria and a lower score of 1 indicated the worst technology. 
Tr(a,b,c) refers to the triangular probability distribution where a, b, c are the minimum, most likely, and maximum values, respectively. 
aThe ranks and scores were attained from a survey distributed across industry experts in positions such as: Senior pilot plant manager, business development 
manager, global product manager, vice president of technology and manufacturing, head of cell culture services of Eufets GmbH, Promethera, Pluristem and Pall 
Life Sciences. The higher the rank the better the technology. A higher value of the rank indicated a criterion of greater importance/weighting. 
bCOG and FCI are taken from a scenario with a batch size of 10 B cells per batch and a demand of 100 B cells per year. 
MLF = multilayer flask; MPB = multi-pate bioreactor; HFB = hollow fibre bioreactor; STR = stirred tank bioreactor 
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In order to recommend possible process improvements to overcome these challenges, a 
sensitivity analysis was performed. This analysis aimed at identifying the key factors 
contributing to both economic and operational bottlenecks. During the sensitivity analysis 
cost parameters were varied by ±25% and operational parameters varied according to the 
minimum and maximum values used in the robustness analysis (Table 4.3). The effect of 
varying these factors on COG and throughput was measured and the factors with the 
highest impact on the economic and operational performance of MSC-based 
manufacturing processes were then used during the optimization analysis, where target 
values for these factors were recommended. 
4.3 Results and discussion  
This section summarises the key insights from the techno-economic analysis of 
alternative cell culture technologies for allogeneic MSC therapies across different dose-
demand scenarios. The analysis identifies key COG drivers, weighs up the financial and 
operational benefits, and determines the robustness and reimbursement potential of each 
technology.  For scenarios where product commercialisation was deemed infeasible, the 
key parameters which influence both cost-effectiveness and capacity were identified and 
optimised. 
4.3.1 Process economics analysis  
4.3.1.1 Deterministic cost comparison 
The relative cost-effectiveness of different manufacturing platforms is highly dependent 
on the scale and demand being explored (Simaria et al. 2014b). This is illustrated in 
Figure 4.1 a, which shows the COG per million cells profile of the different 
manufacturing platforms featured in this case study across different annual demands and 
scales. At a smaller scale of 1 billion cells per batch, planar platforms are more cost-
effective than 3D cell culture. When such small batch sizes are manufactured in low 
frequency (10 times per year) such that indirect costs dominate the overall COG, multi-
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plate bioreactors become the most cost-effective option due to the low equipment costs 
and relatively low labour requirement. When the number of batches is increased to 100, 
direct costs become the major cost driver, which causes the optimal technology to shift 
to multi-layer flasks; this is due to the fact that these have considerably lower consumable 
costs with respect to all other manufacturing platforms (Table 4.2). These scenarios can 
be translated into a process manufacturing 100 to 1,000 doses per year of an MSC based 
treatment for heart disease with a dose size of 100 million cells (Bell Potter 2011; Introna 
et al. 2014; Lin & Hogan 2011; Lazarus et al. 2005; ClinicalTrials.gov 2016; Hare et al. 
2009). 
When increasing the scale to 10 billion cells per batch, reaching demands of 1 trillion 
cells per year (10,000 doses per year of a treatment for heart disease), the scalability of 
the different manufacturing platforms determines their cost-effectiveness. High 
scalability decreases the number of cell culture vessels used per batch, and therefore 
decreases the requirement for equipment and personnel. Hence, microcarrier-based cell 
culture becomes the most cost-effective technology at both demands, 100 billion and 1 
trillion cells per year, with a very small economic advantage with respect to multi-plate 
bioreactors ($21/million cells vs $27/million cells). Increasing the scale further to 100 
billion cells per batch reaching high demands of up to 100,000 doses of 100 million cells 
per year, increases the importance of scalability, making microcarrier-based cell culture 
significantly more cost-effective than all other technologies. Furthermore, in scenarios 
where the market penetration increases over time, such that the production of MSCs 
increases  from low demands up to “blockbuster-like” quantities being manufactured 
annually, microcarriers offer relatively low COG across the different scales of production. 
Figure 4.1 a portrays hollow fibre bioreactors as the least cost-effective technology 
across most scales and demands. These bioreactors, offer superior operational features 
(Table 4.3), however, the high consumable and equipment costs associated with this 
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technology (Table 4.2) do not allow this bioreactor  to be financially competitive at 
commercial scale. 
 
4.3.1.2 Factors affecting the cost-effectiveness of different manufacturing 
technologies  
Understanding of the key factors affecting the COG (e.g. media, cell culture vessel, 
equipment etc.), is critical for effective process optimization. Since the impact of different 
process components on COG/million cells varies with the scale and demand selected, 
Figure 4.1 b illustrates the change in cost drivers across different scenarios. 
Figure 4.1 a) COG per million cells across multiple demands and scales. The optimal 
manufacturing platform in each batch size-demand scenario is represented by a black 
bar b) Impact of different cost categories on COG with increasing demand and batch 
size. Where MLF= Multilayer flasks,  MPB =Multi-plate bioreactors, HFB =hollow 
fibre bioreactors and STR=single use bioreactors with microcarriers. 
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The effect on COG/million was explored when: (1) increasing the scale of production 
(from, 10 billion cells/batch to 100 billion cells/batch) while keeping the same annual 
demand (1 trillion cells/year); (2) increasing the scale and annual demand (from 10 billion 
cells/batch and 1 trillion cells/year to 100billion cells/batch and 10 trillion cells/year) 
while maintaining the same number of batches per year (100); (3) increasing the annual 
production (from 1 trillion cells/year to 10 trillion cells/year) while keeping the same 
batch size (100 billion cells/batch) and increasing the number of batches per year (from 
10 batches/year to 100 batches/year). 
1) Scaling up from 10 billion cells per batch to 100 billion cells per batch while 
keeping the same annual demand has a negative effect on the COG of all planar 
technologies. This is attributed to capacity constraints in planar technologies; 
scaling up means adding more cell culture vessels in parallel requiring more 
equipment and personnel, and therefore, increasing the depreciation and labour 
costs. Microcarrier-based cell culture on the other hand benefits from high 
capacity, therefore no increase in number of manipulations was seen. 
Furthermore, these bioreactors can handle larger numbers of cells with no 
additional depreciation costs and using the same number of operators reducing 
changes in COG with increasing scale. 
2) Increasing the annual demand by keeping the same number of batches and 
increasing the scale of manufacture increases the number of aseptic 
manipulations, however, it has cost benefits across all technologies. Although the 
increase in scale was previously shown to increase the labour and depreciation 
costs in planar technologies, these costs are now spread over a higher number of 
cells resulting in an overall positive effect in the COG/million cells. This positive 
impact is clearly seen in microcarriers where there is a dramatic drop in 
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COG/million cells of 42% with the increase in scale causing cell culture media to 
be the main cost driver.  
3)  Increasing the annual production by increasing the number of batches per year 
and keeping the same batch size decreases the COG/million further for all 
technologies as the indirect costs are spread over more cells as seen in the previous 
point. 
4.3.1.3 Critical parameters contributing to the cost effectiveness of microcarrier-
based cell culture 
Microcarriers in single-use bioreactors are the most cost-effective technology for the 
manufacture of adherent cell therapy products with high annual demands (Figure 4.1 a). 
Since different microcarriers have different surface areas and will result in different cell 
detachment yields (Chen et al. 2011b),  Figure 4.2 illustrates the critical process 
parameters which allow for microcarrier-based cell processing to be more cost-effective 
than planar technologies across different scales and demands. In Figure 4.2, the 
efficiency in separating the cells from the microcarriers (cell detachment yield) is varied, 
and the critical cell detachment yield for which microcarriers are more cost-effective than 
planar technologies is calculated. Figure 4.2 shows that at small scales of 1 billion cells 
per batch, where planar technologies are more cost-effective (Figure 4.1 a), the yield of 
the microcarrier-cell detachment step must be increased from 75% to up to 85% in order 
for these to be more cost-effective than planar technologies. Losses in detachment yield 
can be minimised by using thermosensitive microcarriers or even avoided with injectable 
or dissolvable microcarriers. When using thermosensitive mircrocarriers, the cells can be 
detached from the microcarriers by changing the temperature instead of using enzymes 
and thus this enhances the detachment yield (Yang et al. 2010). When using injectable 
microcarriers, no microcarrier separation step is required (Confalonieri et al. 2017). The 
use of injectable microcarriers will pose some regulatory implications as it will change 
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the properties of the product. Moreover, the use of injectable microcarriers may also affect 
the cryopreservation process. Additional strategies to enhance the detachment yield 
include optimizing the conditions for cell detachment (e.g. enzyme used, washing 
protocol, incubation time and temperature). As the scale increases, scalability plays its 
part and microcarriers become more cost-effective than planar platforms, hence this 
critical cell detachment yield drops significantly to as low as 30%. Figure 4.2 also shows 
that the manufacturing scale has a higher effect on the relative cost-effectiveness of 
microcarrier-based cell culture than annual demand. 
 
Figure 4.2 Critical surface area per litre for which single use bioreactors with 
microcarriers are more cost effective than planar platforms across multiple scales and 
demands for a recovery efficiency of 75% and critical detachment efficiency for which 
single use bioreactors with microcarriers are more cost-effective than planar 
technologies across multiple scales and demands, for non-porous microcarriers with a 
surface area per litre of 11,080cm2. Min and max number of batches per year = 10 and 
100 respectively. 
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Figure 4.2 explores the critical surface area per litre for which microcarriers are more 
cost-effective than planar technologies. Typical values for surface area per litre can vary 
from the 100’s cm2/L to the 10,000’s cm2/L (Chapter 1 Table 1.4) depending on the 
microcarrier of choice and its seeding density. This figure shows that at low scales of 1 
billion cells per batch, the surface area per litre must be increased in order for 
microcarriers to be more cost-effective than planar technologies. Different strategies can 
be applied in order to increase the surface area per litre of cell culture. These include 
increasing the concentration of microcarriers in cell culture and switching from a non-
porous to a porous microcarrier. If decantation is used to separate the cells from the 
microcarriers, adding more microcarriers to the bioreactor may increase the overall 
process time if the cells settled around the beads are to be recovered through consecutive 
dilution. Moreover, if fluidised bed centrifugation is used for the separation of 
microcarriers from the solution as was assumed in this chapter, a higher seeding 
concentration of microcarriers would fill the chambers of the FBC more rapidly requiring 
a higher number of cycles, which also has a negative impact on the processing time. 
Furthermore, switching to a porous microcarrier may alter the performance of the process 
as cells may grow differently depending on the microcarrier surface and structure. As the 
scale increases, Figure 4.2 shows that the flexibility in surface area per litre also increases 
for the reasons previously mentioned. 
4.3.2 Operational characteristics of manufacturing platforms for mesenchymal stem 
cell culture   
4.3.2.1 Labour requirement 
One of the key differences across the alternative technologies used is the labour 
requirement. This parameter is related to the number of manual operations required in the 
manufacturing process. Figure 4.3 shows the number of manhours required to 
manufacture 100 batches of 50 billion cells for each different manufacturing platform 
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featured in this chapter. For greater resolution, the figure only shows the first 50 days of 
the year. The different batches are staggered one day apart such that harvest occurs on 
different days for each batch as previously described in Section 4.2.2. The manufacturing 
process from cell culture to formulation occurs in 21 days. In Figure 4.3, seven batches 
are being manufactured in parallel in staggered mode, and, the highest labour utilization 
occurs from day 14 to 24.  On the 14th day the passage to the last expansion stage (the 
stage with the highest number of cell culture vessels per batch) is carried out. The media 
exchange at the last expansion stage is carried out on day 17 and harvest on day 21 (Table 
4.1). As 7 batches are being staggered, labour utilization is increased from day 14 to day 
16 as the final passage is being carried out on 3 batches, from day 17 to 20 the other 4 
batches are passaged, however, media exchange of the first batch occurs on day 17 
explaining the dramatic increase in labour utilization. On day 21, all batches have been 
passaged but the first batch is being harvested and the last media exchange of batch 5 is 
initiated, explaining the slight drop in labour utilisation. Finally on day 24, media 
exchange in the last expansion stage was concluded for all 7 batches, and the only 
operation taking place is the harvest of batch 4 and therefore the number of manhours 
required drops further and the cycle is repeated for the next set of 7 batches. 
Figure 4.3 shows clearly that multilayer flasks have relatively high labour requirement. 
A similar trend in labour requirement would be expected when using hollow fibre 
bioreactors due to the fact that these also have limited capacity  in comparison with multi-
plate bioreactors and single-use bioreactors with microcarriers (Table 4.2); however, the 
fact that hollow fibre bioreactors are automated systems causes its labour requirement to 
be reduced. Microcarriers in stirred tank bioreactors have high capacity and therefore only 
a single bioreactor is used per batch reducing the number of manipulations required and 
hence reducing the number of operators needed.  
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Figure 4.3 Labour utilization per day for cell culture, wash and formulation throughout the first 50 days of the year, for a single product facility 
manufacturing 100 batches of 50 B cells and across multiple manufacturing platforms. The number of FTEs required for each manufacturing 
platform is represented on the top right corner of each figure. Where MLF= Multilayer flasks, MPB =Multi-plate bioreactors, HFB =hollow 
fibre bioreactors and STR=single use bioreactors with microcarriers. 
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4.3.2.2 Multi-attribute decision-making  
Additional to resource requirement, operational benefits of technologies for adherent cell 
expansion also include: ease of development, ease of validation, ease of setup and ease 
of operation. The relative scores of the different manufacturing technologies in each of 
these categories are summarised in Table 4.3. The category which was voted to have the 
highest importance when selecting a manufacturing technology was ease of scale-up. 
Table 4.3 also shows that processes using multi-layer flasks are relatively easy to validate 
and develop but difficult to operate and scale-up. Multi-plate bioreactor-based processes 
are relatively easy to validate, are automated and easy to scale-up. These systems are 
however considered relatively difficult to setup with respect to hollow fibre bioreactors 
and multilayer flasks. Hollow fibre bioreactors are relatively easy to setup and provide a 
high degree of automation, however, these bioreactors pose challenges during scale-up. 
Microcarrier-based cell culture is relatively easy to scale-up and it is a highly automated 
platform; the challenges associated with this platform include setting-up the bioreactor 
and developing the microcarrier-based process. 
Figure 4.4 a shows the weighted sum of the operational and economic attributes of the 
technologies featured in this chapter across different commercialisation scenarios. This 
figure highlights that at small scale-small demand combinations, for all values of the 
economic combination ratio, multi-plate bioreactors have the highest rank with the 
highest aggregate score. This is due to the fact that these bioreactors have the highest 
overall operational score, and that these are also the most cost-effective technology at 1 
billion cells per batch and 10 billion cells per year as seen in Figure 4.1. 
In the same scenario, the second optimal technology for all combination ratios of 
economic features versus operational features are single use bioreactors with 
microcarriers, and, although these have a slightly lower operational score with respect to 
multi-layer flasks, they are far more cost-effective than these. This trend becomes more 
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evident as the combination ratio of the economic attribute increases, resulting in a greater 
difference between the aggregate scores of single use bioreactors with microcariers and 
multi-layer flasks.  Figure 4.1 illustrated that in small scale-small demand scenarios, the 
decision between microcarriers and multi-plate bioreactors is challenging as there is only 
a 10% difference in COG between the two systems. Figure 4.4 a helps discriminate 
further between these manufacturing platforms by reconciling economic and operational 
benefits characteristic of each platform. In this scenario, the multi-plate bioreactors have 
the highest overall aggregate score and can hence be considered the optimal technology. 
On the other hand, when the annual demand is increased to 10,000 billion cells in Figure 
4.4 a, the technology rankings change. At this higher scale, there are now only two 
manufacturing platforms competing against each other, as the others lack the capacity to 
fulfil such high scales. As previously mentioned, multi-plate bioreactors have superior 
operational features with respect to microcarrier-based cell culture, however, when 
considering the financial attributes, the COG per million for these manufacturing 
platforms is now $17.4 and $13.3 respectively resulting in a 30% difference.  This causes 
the trends seen in Figure 4.4 a where, on the left hand side, where operational features 
are prioritized, multi-plate bioreactors rank first. This ranking slowly changes, and, in the 
middle, when both economic and operational characteristics have the same importance, 
microcarrier systems take over as the optimal manufacturing technology remaining in 
first place as the priority is shifted towards the economic benefits. Figure 4.4 a shows 
that despite the superior operational features of multi-plate bioreactors, scalability is the 
most important parameter in large scale manufacture of adherent cell therapy products (as 
shown in Table 4.3) and therefore microcarrier systems are the best technology to be used 
in such scenarios. 
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Figure 4.4 a) Sensitivity plots showing the economic attribute versus the operational attribute across different commercialisation 
scenarios. The y-axis represents the aggregate score between both attributes, where the optimal technology has the highest score. The 
x-axis, represents the weight of the economic attribute with respect to the operational attribute, where towards the left-hand-side the 
operational attribute is more important, at the centre, where the weight of the economic attribute is 0.5, both attributes have the same 
importance and on the right-hand-side the economic attribute has the highest importance. b) COG per million cells distribution across 
two different commercialisation scenarios. Where MLF= Multilayer flasks, MPB =Multi-plate bioreactors, HFB =hollow fibre 
bioreactors and STR=single use bioreactors with microcarriers. 
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4.3.2.3 Robustness analysis  
Process variability is another key operational parameter which may affect the potential 
for commercial success of cell therapy processes, as failure to meet the demand will 
increase the COG/million cells. Figure 4.4 a shows clearly the effect of the higher 
variability of processes employing microcarriers and multi-layer flasks through wider 
COG distributions. Despite this fact, and although the deterministic analysis portrays 
multi-plate bioreactors as the most cost-effective technology in small scale scenarios, 
microcarriers still have a similar probability of achieving the optimal COG/million cells 
(lowest COG/million cells). This is due to the fact that the variability of the different 
parameters is both positive and negative and the difference in COG between multi-plate 
bioreactors and stirred tank bioreactors with microcarriers is small. Increasing the scale 
and demand decreases the probability of multi-plate bioreactors achieving the minimal 
(optimal) COG/million cells and emphasises that, despite the uncertainties surrounding 
microcarrier systems, these are the optimal platform to be used for large scale production 
of MSC-based cell therapy products.  
Table 4.4 confirms that although microcarriers have higher variability they still have the 
highest probability of achieving the optimal COG/million cells at higher scales. The table 
also indicates that at smaller manufacturing scales multi-plate bioreactors have a slightly 
higher probability of being the technology with the highest economic and operational 
aggregate score with respect to microcarrier-based platforms, and as the scale increases, 
this trend is altered as microcarriers have the highest aggregate score. All distributions 
were found to be significantly different from one another as indicated by all p-values 
being smaller than 0.05; an illustration of these p-values is highlighted in Table 4.4 
compared to the baseline planar technology at low and high demands. 
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Table 4.4 Statistical data on COG/million cells and multi-attribute decision making 
analysis for the competing technologies for low and high demand scenarios 
 
Batch size: 1B cells per batch 
Demand: 10 B cells per year 
 Batch size: 100 B cells per 
batch 
Demand: 10,000 B cells per 
year 
 MLF MPB HFB STR 
 
MPB STR 
 
COG/million cells ($) 
 
p(COG ≤ COGoptimal) (%) 
20 50 5 45 
 
15 45 
Mean 
347 224 342 238 
 
17 13 
Standard deviation 
162 63 97 111 
 
5 6 
p-value 
N/A 2E-23 7E-19 4E-39 
 
N/A 9E-119 
 
Aggregate score  
p(Aggregate score ≥ 0.5) 
(%) 
25 80 50 70 
 
25 80 
Mean 
0.26 0.89 0.32 0.68 
 
0.59 0.69 
Standard deviation 
0.16 0.13 0.12 0.13 
 
0.15 0.15 
p-value 
N/A 1E-155 2E-58 4E-63 
 
N/A 2E-85 
Note: The p-values were attained using a 2-tailed homoscedastic t-test with an alpha value of 0.05.  A 
p-value below 0.05 indicates a significant difference between distributions. p-values were derived 
using each of the technologies as the baseline for statistical significance testing; in all cases p-values 
below 0.05 were obtained and this table shows the p-values using one of the planar technologies as 
the baseline case as an illustration. MLF = multilayer flask; MPB = multi-pate bioreactor; HFB = 
hollow fibre bioreactor; STR = stirred tank bioreactor 
4.3.3 Performance targets for successful commercialisation analysis 
4.3.3.1 Reimbursement analysis  
The reimbursement strategy to be applied to a product is a useful parameter to establish 
manufacturing COG targets and may vary according to the indication, efficacy of the 
treatment and country of commercialisation. Figure 4.5 a shows the minimum selling 
price for which the manufacturing COG is 40% or 15% of sales across multiple 
commercialisation scenarios. COG as 40% sales has been established to be the higher end 
of COG as % sales in allogeneic cell therapy products, and 15% is a typical COG as % 
sales of small molecules (Smith 2012b).  Figure 4.5 a shows that for a drug with low 
patient demand (100 patients per year), achieving COG as 40% sales with a selling price 
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of $40,000/dose will be challenging. Figure 4.5 a also shows that even at high annual 
demands (10,000 patients/year) products with high sizes (1 billion cells) will struggle to 
achieve COG as 15% sales as the minimum COG as % sales achievable in such scenarios 
is 33%. Moreover, Figure 4.5 a also identifies annual demands that are unachievable due 
to the lack of capacity of current manufacturing technologies; this is seen in high-dose 
high-demand scenarios. For example, with the specifications applied to this case study 
for a size of 1 billion cells it is challenging to achieve 100,000 doses/year as the maximum 
number of doses achievable is 60,000. 
Figure 4.5 b shows the effect of process variability in the reimbursement strategy of cell 
therapy products for industry relevant indications by evaluating the range in selling price 
required for COG to be 15% sales. The indications considered were chronic discogenic 
lumbar back pain, congestive heart and (GvHD) with dose sizes of 10 million, 100 million 
and 1 billion cells per dose respectively. The reimbursement assumed for each different 
indication were $1,200 (costs of caudal epidural injections, (Manchikanti et al. 2015)), 
$40,000 (average myocardial regeneration reimbursement, (McAllister et al. 2008)) and 
$107,000 (extracorporal photopherisis for GvHD, (de Waure et al. 2015)) respectively.  
Figure 4.5 b shows that for an MSC-based cell therapy product with a dose size of 10 
million cells per patient, COG as 15% sales could be achieved under the current NICE 
reimbursement per QALY with any technology. However, when the reimbursement 
applied to chronic discogenic lumbar back pain is used in this scenario, an MSC-based 
cell therapy product would struggle to be competitive with current treatments, as these 
are more cost-effective. For an indication requiring a higher dose size of  100 million cells 
such as congestive heart failure, most manufacturing platforms would satisfy the COG as 
% sales target under the current reimbursement for congestive heart failure which 
coincides with the current NICE reimbursement.  
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Figure 4.5 a) Minimum selling price across multiple dose size and demands for which COG is 40% and 15% of sales when the minimum  
COG/dose across the different manufacturing platforms is applied. The dashed line represents the current reimbursement from the NICE. 
b) Minimum selling price distribution for which COG is 15% of sales. For an annual demand of 10,000 patients per year and for indications 
with different dose sizes and reimbursement strategies. The dashed line on each graph represents the typical reimbursement applied to 
these indications. Where MLF= Multilayer flasks, MPB =Multi-plate bioreactors, HFB =hollow fibre bioreactors and STR=single use 
bioreactors with microcarriers. 
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Higher reimbursements may be considered as some of these treatments may replace the 
requirement for a heart transplant which are priced up to $500,000 (Touchot & Flume 
2015). Furthermore, comparing the NICE reimbursement with the reimbursement applied 
in Heartcelligram-AMI® (Pharmicell, South Korea) an autologous MSC-based cell 
therapy product for post-myocardial infraction which is priced at $19,000 per dose 
(Bravery n.d.), it is clear that current processes for the manufacture of MSC-based 
products shown in Figure 4.5 b will struggle even more to reach commercial success. 
A further increase in dose size to 1,000 million cells will narrow down the choices in 
technology availability for MSC cell culture, as only multi-plate bioreactors and 
microcarrier systems are able to satisfy such high scales of production. Moreover, none 
of these platforms would be able to achieve satisfactory COG as % sales under current 
NICE reimbursement. Furthermore, even when the typical reimbursement with similar 
dose size is applied (GvHD), multi-plate bioreactors are not able to meet the target COG 
as %  sales and microcarrier systems would struggle to do the same. When applying the 
reimbursement applied to Temcel® (Mesoblast, Australia) an allogeneic MSC-based 
product targeted at GvHD with a dose size of 1.2 – 1.7 billion cells resulting in a selling 
price of $117,983 – $167,143 per dose ($7,079 per 72 million cells) (GlobeNewswire 
2016a), it is clear that even at this higher selling price, both manufacturing platforms will 
struggle to meet the target COG as % of sales. 
4.3.3.2 Sensitivity analysis 
In order to understand the direction in which the development effort should be focused, 
so as to address both the gross margin limitations, and the capacity constraints mentioned 
in Figure 4.5, a sensitivity analysis was performed. The manufacturing platform used in 
this analysis is the single-use bioreactor with microcarriers, as this is the most cost-
effective technology to be used in a high demand scenario such as this (Figure 4.1). 
Figure 4.6 indicates that the factors that have the greatest impact on COG at high dose 
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size-high annual demand scenarios are mostly operational since these will ultimately 
influence the cell quantities which are produced per batch. The factor with the highest 
effect on the COG is the cell doubling time, this is attributed to the fact that this is a 
crucial factor in determining the number of cells required from the beginning of the 
process to meet a particular batch size due to the model set up. A higher cell doubling 
time would mean a slower process, and hence more cells would be required at the 
beginning of the cell culture. This would increase the size of the cell culture vessels 
required during the initial cell culture stages since more cells are being loaded into them, 
increasing the resource requirement and hence the COG. 
The nature of this scenario explains the asymmetry seen in the impact of operational 
parameters on COG in Figure 4.6. During the last expansion stage of the chosen scenario, 
a single use bioreactor of 1,000L is being utilised at 60% capacity. Given that the full 
capacity of this bioreactor is not being utilised, when the DSP or cell detachment yield  
are decreased to 75% of their initial value, there is no significant change in COG since 
the same bioreactor can accommodate the additional cells required to make up for the 
lower yields. When the opposite occurs, and the DSP yield and cell detachment yield are 
adjusted to 125% of their original value, the number of cells required to meet the batch 
size decreases such that a 500L bioreactor becomes optimal. Figure 4.6 confirms the 
conclusion drawn from Figure 4.1 b, where the cost parameter with the greatest effect on 
the total COG in large scale scenarios is the media costs. 
Figure 4.6 also highlights the considerable impact that the cell doubling time has on the 
productivity of a cell therapy processes. In this figure, the capacity of the single-use 
bioreactor (surface area per litre) was not varied, as this parameter has no bearing on the 
number of cells produced. The number of cells initially loaded into the process, the DSP 
yield and the cell detachment efficiency were varied by ±25% of the base case instead. 
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As expected, increasing any of these parameters by 25% increases the number of 
maximum doses produced by 25%. 
4.3.3.3 Optimization case study  
Having identified the key parameters affecting the profitability and capacity of 
technologies for adherent cell culture, this section will determine the development effort 
required to overcome current process and economic challenges. 
Figure 4.7 shows how varying the different parameters highlighted by the sensitivity 
analysis affects the COG as % sales for a selling price of $40,000. The base case scenario 
presented in this figure shows that in order to achieve COG as 15% sales, the surface area 
per litre inside the bioreactor must be at least 20,000cm2. If the cell doubling time is 
decreased (Scenario 2), the COG as 15% sales target can be reached by almost doubling 
the current bioreactor capacity (5,540 cm2 per litre) to 10,000cm2 per litre in combination 
with increasing the detachment yield from 75% to 100%. Solutions for increasing the 
detachment yield have previously been discussed in Section 3.1. The same COG target 
can be achieved without changing the proliferation rate of the cells if the DSP yield can 
Figure 4.6 Sensitivity analysis showing the impact of varying both process parameters 
and cost parameters by ±25% with the exception of the batch success rate (varied by±5% 
since the base case is 95%). This figure shows the effect of process and economic 
parameters on the COG and throughput of an MSC product with dose size of 1 B cells 
and a demand of 10,000 cells per patient. 
207 
 
be enhanced from 61 to 81% (Scenario 4). The DSP yield is a combination of microcarrier 
removal, cell wash, concentration  and cryopreservation yields, with the values of 90%, 
85% and 80% (Hassan et al. 2015; Smith 2010) respectively. In this analysis, an 
assumption was made that the FBC would be used to remove the microcarriers from the 
cell containing solution. An alternative way to increase the yield of this step is the 
employment of the harvestainerTM (Thermoscientific, Waltham, MA, USA) technology 
instead of the FBC system for microcarrier removal. Another alternative to increase the 
overall DSP yield is to use a different cryoprotectant to DMSO in order to decrease cell 
loss during cryopreservation (Ostrowska et al. 2009) . Moreover, additional strategies to 
increase the DSP yield include decreasing the concentration of the cryoprotectant used 
and optimizing freezing process. 
Figure 4.8 shows how varying the key parameters which influence the productivity of a 
manufacturing process for MSCs affects its ability to achieve 100,000 doses per year of 
1billion cells.  Figure 4.8 shows that the process throughput is dependent on the DSP 
yield, and, that the maximum number of doses achievable across all scenarios is 75,600. 
This target is only achievable if the DSP yield is increased to 81% (Scenario 3 & 5). 
Figure 4.8 also shows that excessively increasing the number of cells initially added to 
the process under the base case detachment yield would not increase productivity; 
although this would result in a higher number of cells achieved during the expansion 
process, the maximum capacity of a single FBC system under 4 h is ~1 trillion cells, 
which translates into 1.8 billion cells initially added to the process.  Furthermore, Figure 
4.8 shows that the capacity of current DSP technologies is the key obstacle to commercial 
scale manufacture of MSC-based cell therapy products. Moreover, improving the 
performance of these technologies will result in lower COG as COG decreases with 
increasing scale, hence the development effort should be shifted towards the downstream 
process. 
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Figure 4.7 Measurement of the impact of different parameters on the ability of reaching COG as 15% sales for a selling price 
of $40,000 per dose, an annual demand of 10,000 doses and a dose size of 1 billion cells. The shaded are represents scenarios 
where COG as 15% sales is reached. A = discount on media costs, B= cell doubling time and C= DSP yield. 
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Figure 4.8 Measurement of the impact of different parameters on the ability of reaching 100,000 doses per year of 1 billion 
cells. A = Cell doubling time. B =DSP yield; C= Batch success rate. 
 
Scenario 5: A = 34h B = 81.2% C = 100% 
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4.4 Conclusion  
This study has explored the economic and operational performance of four candidate 
technologies for the commercial scale expansion of MSCs in order to evaluate the 
probability of each of these technologies leading to a feasible business model. The results 
show that from an economic perspective, planar manufacturing platforms are most cost-
effective at smaller scales (≤ 1B cells/batch) whilst microcarrier systems are more cost-
effective at medium to large scales (10-100B cells/batch). The results have revealed that 
for applications with low dose sizes (10 million cells), the COG/dose varies between 
$485-$1750 and for applications with high dose sizes (1 billion cells), the COG/dose 
varies between $13k-$111k depending on the technology and manufacturing scale 
selected. The results also show that the superior operational characteristics of multi-plate 
bioreactors allows them to closely compete with microcarrier systems even at larger 
scales. However, ultimately, microcarriers are the optimal technology for large-scale 
expansion of allogeneic MSC-based cell therapy products. Furthermore, this study 
highlights that in order to achieve commercial success under current reimbursement 
strategies significant improvement is required in the sector for treatments with large dose 
sizes and that the market penetration of certain indications is limited by the capacity of 
the current technologies. This study has also shown that future resources for the 
development of technologies for commercial scale manufacture of cell therapy products 
should be focused on DSP technologies. These findings can be used to understand and 
quantify the current limitations and characteristics of the different technologies for 
mesenchymal cell expansion and can be extended to explore further options such as the 
use of cultures based on aggregates or spheroids. Such analyses help predict the minimum 
reimbursement levels for different MSC-based cell therapy products that allow for 
feasible business models. The next chapter will illustrate how this holistic approach can 
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be adapted and applied to tackle some of the critical challenges facing autologous CAR 
T-cell developers. 
.  
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Chapter 5: Addressing the Challenges to Successful 
Commercialization of CAR T-cell Therapies: Technology, Costs, 
Reimbursement and Supply Chain 
 
5.1 Introduction 
The previous chapter explored the economic and operational features of multiple 
platforms for the manufacture of allogeneic mesenchymal stem cell (MSC) -based cell 
therapy products. In this chapter, extra model features were developed to apply the 
decisional tool to a case study focused on highlighting and addressing some of the 
inherently different challenges associated with autologous therapies, using the complex 
example of chimeric antigen receptor (CAR) T-cell products. These features included 
additional unit operations, manufacturing platforms and facility configurations.  
Chapter 1 underlined some of the key characteristics, benefits and challenges related to 
CAR T-cell therapies as well as the technologies currently available in the market for the 
manufacture of these products. At the top of the list of issues surrounding CAR T-cell 
therapies is the high cost of goods (COG) associated with these products which are 
currently estimated to be  between $45,000-$150,000 (Reuters 2015). Furthermore, there 
are challenges related to single-site manufacture of patient-specific products, which 
include limited market access, poor response to market fluctuations, risk of supply chain 
interruption and complex logistics (Medcalf 2016; Davie 2013; Rafiq 2013; Trainor et al. 
2014; Coopman & Medcalf 2008). Moreover, debate exists on the key implications and 
advantages of using an allogeneic approach to CAR T-cell manufacture in an effort to 
solve some of the issues characteristic of autologous processes. 
Hence, this chapter explores the following questions related to CAR T-cell manufacture: 
technology selection considering operational and economic parameters, COG versus 
213 
 
reimbursement of CAR T-cell therapy products, long-term benefits of multi-site 
manufacture for patient-specific products and economic benefits of allogeneic cell 
therapy manufacture.  To address these questions, the decisional tool was extended to 
incorporate the more rigorous factorial FCI methodology outlined in Chapter 2 (Section 
2.3), a revised COG model with additional unit operations and more detail on quality 
costs since they are more significant with autologous processes, and a database of default 
values for CAR T-cell processes. In addition, a risk-adjusted lifecycle cash flow model 
were built to evaluate holistically the impact of different degrees of multi-site 
manufacture compared to centralised manufacture. This accounted for impact of the 
different facility configurations not only on FCI and COG but also on activities such as 
technology transfer, comparability studies and transportation.  The CAR T-cell case study 
provides the first in-depth process economic analysis for these therapies with a set of 
insights at both the technology level and an enterprise’s facility configuration level. 
 The remainder of this chapter is organised as follows. In Section 5.3 an overview of the 
case study is described, which addresses multiple questions related to the process 
economics of CAR T-cell therapies. In Section 5.3.1 provides an understanding of how 
the COG, technology availability, ranking and cost drivers vary with dose size and annual 
demand. Section 5.3.2 explores the operational features and resource requirement of 
different technologies for autologous CAR T-cell manufacture. Section 5.3.3 assesses the 
economic feasibility of autologous CAR T-cell products under current reimbursement 
strategies. Section 5.3.4 investigates the capital investment requirement, risk and 
potential long-term economic benefits of different facility configurations for multi-site 
manufacture of patient-specific therapies. Finally, Section 5.3.5 provides insights on the 
cost-effectiveness of allogeneic CAR T-cell therapies with respect to autologous CAR T-
cell therapies. 
5.2 Case study setup  
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The case study described in this chapter aims at using the decisional tool described in 
Chapter 2 (Section 2.4) to evaluate different strategies for the manufacture of CAR T-
cell products in Europe. In order to do so, significant modifications were made to the  
bioprocess economics model described in Chapter 2 (Section 2.4 ) so as to include more 
detailed calculations of costs which are higher in autologous cell therapy manufacture 
such as facility-related costs, labour and material costs associated with pre-cell culture 
steps and  quality activities. Table 5.1 summarises the methods used to compute the cost 
categories used to compute the COG/dose in this case study. 
The case study starts with an appraisal of the economic and operational benefits of 
multiple platforms for the manufacture of autologous CAR T-cell products. This analysis 
was then extended to capture the long-term effect of adopting different facility 
configurations for patient-specific CAR T-cell manufacture. In order to do so, a risk-
adjusted cash flow model was incorporated into the advanced decisional tool described 
in Chapter 2. The final section of this case study assesses the cost benefit of adopting an 
allogeneic approach to CAR T-cell therapy manufacture. 
When evaluating the advantages of different strategies for the manufacture of CAR T-
cell products, multiple commercialisation scenarios were considered which included 
annual demands varying between 100-10,000 patients per year and dose sizes (transduced 
cells / patient) ranging between 5M-500M cells. The metrics used to quantify these 
benefits were COG, fixed capital investment (FCI), facility footprint, personnel 
requirement, rNPV and financial risk expressed as the minimum selling price for which 
rNPV = 0.  
In contrast with the case study described in Chapter 4, in addition to the manufacturing 
process (core process & release testing), the scope of the case study was also extended to 
capture tissue acquisition via leukapheresis and inbound and outbound transportation 
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(Figure 5.1), as these costs are higher in patient-specific therapies. The administration of 
the therapy and any pre-conditioning treatment required was excluded from this analysis. 
Table 5.1 Summary of the equations used to compute the different cost categories 
included in the COG 
Cost category Value 
Direct Direct raw materials f (utilization per batch)  
QC materials  f (utilization per batch)  
Transportation  f (utilization per batch)  
 Leukapheresis f f (utilization per batch) 
   
Indirect Depreciation Capital investment / depreciation period / no batches 
per year  
Facility maintenance  0.1 x FCI / no batches per year  
Energy costs  Energy costs per m2 x Cleanroom footprint / no 
batches per year  
Gowning No of operators x no gowns per day x no operating 
days x cost per gown / no batches per year 
  Labour: 
   Process operator No operators per team  x no batches in parallel x 
Annual salary / (no batches in parallel per team  x no 
batches per year)   
   Supervisors 0.7 x Total no operators x annual salary / no batches 
per year  
 QCmonitoring  No cleanrooms x QC salary / no batches per year 
 
 QCtesting  No batches in parallel x QC salary / (no batches per 
year x no batches per QC operator)  
 QA  0.5 x No (QCmonitoring + QCtesting ) x QA salary / no 
batches per year  
 QP No batches in parallel x QP salary / (no batches per 
year x no batches per QP) 
 
Cost of goods per batch 
 
Direct costs + indirect costs 
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Figure 5.1 Schematic representation of the CAR T-cell therapy supply chain activities captured in this case study. These include 
leaukapheresis, inbound transportation, manufacturing process (core process & release testing) and outbound transportation. The y-axis in 
the bar chart represents the different steps within the manufacturing process and the x-axis represents the manufacturing platforms 
considered in this case study where MLF = multilayer flasks, SSB = static suspension bags, GPV = gas permeable vessel, HFB = hollow 
fibre bioreactor, INT = integrated USP/DSP platform and RMB = rocking motion bioreactor. The colour of the bar in each process step-
manufacturing platform combination represents the technology used, which is listed in the bottom legend. 
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5.2.2 Key assumptions for autologous and allogeneic CAR T-cell process flowsheets 
In this chapter, manufacturing processes for both autologous and allogeneic cell therapy 
products were modelled. In autologous processes, it was assumed that the initial cells 
loaded into the process were retrieved from the patient according to the dose size of the 
CAR T-cell treatment, with no limit on the max number of cells that each patient can 
provide. In allogeneic processes on the other hand, cells were retrieved from a healthy 
donor to produce a single batch and the number of doses produced per batch varied 
according to the dose size. The maximum number of cells that could be retrieved from an 
allogeneic donor was assumed to be 1.67 × 1010 cells.   
In this case study, gene editing of T-cells was achieved by viral transduction and process 
flows with two different viral vectors were considered, namely lentivirus and γ-retrovirus. 
The process steps modelled were the same for both viral vectors. However, the length of 
these process steps differed across viral vectors (Figure 5.1).  
In both lentivirus-based and γ-retrovirus-based processes, it was assumed that cell 
enrichment, cell wash and magnetic T-cell selection were carried out on the first day of 
the manufacturing process. In lentivirus-based processes, T-cell activation was also 
carried out on day 1 followed by gene editing on day 2 and cell culture on the 3rd day of 
the manufacturing process. In γ-retrovirus-based processes, 2 days were allowed for cell 
activation (day 1 and 2) and a further 2 days were allowed for gene editing (days 3 and 
4) such that cell culture started on the 5th day of the manufacturing process. This was done 
to account for the fact that γ-retrovirus cannot infect non-dividing cells as it requires 
nuclear deconstruction of the target cell for integration of the cDNA into the chromosome 
(Cooray et al. 2012; Luigi Naldini et al. 1996; Liechtenstein et al. 2013).  
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Gene editing using γ-retrovirus requires the use of retronectin for co-localization of T-
cells and the viral vector (Cooray et al. 2012; Tumaini et al. 2013; Dodo et al. 2014; Rees 
2014; Ascierto et al. 2015). The costs of retronectin were computed differently across 
manufacturing platforms. For the flask-based platforms such as multilayer flasks and gas 
permeable vessels, these costs were calculated using a retronectin concentration of 
25µg/cm2 of the base of the flask. For all other manufacturing platforms, the 
concentration of retronectin used was 25µg/ml of the cell containing fluid inside the cell 
culture vessels. 
Moreover, the fact that transduction efficiencies of γ-retrovirus-based processes are 
typically lower than for lentivirus-based processes was also accounted for. This was done 
by assuming that the viral transduction for γ-retrovirus and lentivirus processes were 20% 
and 30% respectively. 
 The quantities of viral vector required for T-cell transduction are often given in 
multiplicity of infection (MOI). The values reported for this metric in CAR T-cell therapy 
manufacture vary between 0.2-18 (Valton et al. 2015; Zhou et al. 2003; Milone et al. 
2009; Barry et al. 2000). In this study, it was assumed that an MOI of 5 was applied in 
both lentivirus and γ-retrovirus-based processes. Furthermore, the difficulty of producing 
lentivirus vectors with respect to γ-retrovirus vectors due to the lack of stable packaging 
cell lines (Cooray et al. 2012; Qasim & Thrasher 2014) was also highlighted in this study 
by attributing significantly higher viral vector costs to lentivirus-based processes (Table 
5.2). 
In both the lentivirus-based and γ-retrovirus-based processes, it was assumed that the cell 
culture step lasted for 10 days. Published articles show that the proliferation rate achieved 
with CAR T-cells vary significantly across sources as shown in Chapter 1. Table 1.3 
shows that the reported cell doubling times for CAR T-cells range from 31h to 257h. In 
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this study, it was assumed that the cell doubling time was 65h such that a 10-fold increase 
in cell number was achieved in 10 days of cell culture.  In both lentivirus and γ-retrovirus-
based processes, the final wash and concentration as well as cryopreservation were 
assumed to be carried out on the last day of the processes. This resulted in a total process 
length of 13 days and 15 days for lentivirus and γ-retrovirus-based processes respectively. 
The allogeneic process modelled in this chapter resembles the autologous process using 
lentivirus for gene editing previously described. In order to minimize the risk of GvHD, 
two additional steps were incorporated into the allogenic process. The first step is an 
additional gene editing stage prior to cell culture. This additional gene editing step targets 
the constant region of alpha chain of the T-cell receptor (TRAC) and is typically carried 
out using transcription activator-like effector nuclease (TALEN) via electroporation 
(Qasim et al. 2017). The second step is a magnetic cell enrichment step and it is carried 
out after the wash and concentration step. These two extra process steps result in a lower 
overall process yield for allogenic processes (16%) with respect to autologous processes 
(28%) as the electroporation efficiency and the yield of the final magnetic purification 
step were assumed to be of  70% and 80% respectively. The key differences between the 
schedules used for autologous and allogeneic process are summarised in Figure 5.2.  
CAR T-cell products are prone to variability at the point of care due to differences in 
thawing technique across physicians (Davie 2013; Trainor et al. 2014). Furthermore, the 
transportation of fresh or frozen CAR T-cell products requires complex supply chain 
models. In order to ensure that the adequate dose (transduced cells/patient) was delivered 
to all patients, a redundancy multiplier was added to this analysis such that the number of 
cells produced were double the cells stipulated in the dose size. These additional cells 
would be stored in the facility in case of failure during transportation or point of care 
delivery. Since allogeneic CAR T-cell therapies were considered to be “off-the-shelf” 
products, this redundancy ratio was not applied for these therapies, since another dose 
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would be readily available in case of transportation or administration failure. Additional 
differences between allogeneic and autologous processes modelled in this chapter include 
the fact that in autologous processes 50% of cells produced per batch are retained for QC 
testing while for allogeneic processes this number was reduced to 25% as the batch size 
is usually higher in allogeneic processes.  
Table 5.2 General assumptions used for computing the direct costs of CAR T-cell 
products   
Parameter Value  Unit 
Mass 
balance 
Process yield (Elutriation; cell wash; magnetic cell 
selection; cell wash and concentration; cryopreservation) 
65; 92; 80; 
85; 70 
% 
 Transduction efficiency (lentivirus; γ-retrovirus) 30; 20 % 
 Electroporation yield  70 % 
 Losses due to QC (autologous; allogeneic) 50;25 % 
 Max no cells retrieved per allogeneic donor 1.67 × 1010 - 
  Min cell culture vessel utilization 10 % 
 
Redundancy multiplier for failures (autologous) 2 - 
 
Volume of separation beads  20 µl/10 M cells 
 No activation beads per cell  4 - 
 
Activation bead concentration 200 Mcells/ml 
 
MOI  5 - 
 
Retronectin concentration 25 µg/cm2 or µg/ml  
 DMSO concentration 7 % 
 
TALEN concentration 0.025 g/L 
 
Cells concentration in electroporation buffer  7×10
6
 cells/ml 
Costs  Leukapheresis  10,000a $/batch 
 Buffer costs (HesPan, PBS, NaCl, magnetic separation 
buffer, magnetic separation rinsing buffer) 
0.14; 0.04; 
0.36; 2.1; 
2.1 
$/ml 
 Separation beads  245 $/ml 
 
Activation bead  298 $/ml 
 
Viral vector (lentivirus; retrovirus) 3; 0.3 $/ 1M IFU 
 
Retronectin  518 $/mg 
 
Elutriation consumables 1,964 $/set 
 
Cell wash consumables 480 $/set 
 
Cell magnetic separation set 2,218 $/set 
 DMSO  1.8 $/ml 
 Cryopreservation bags (20ml – 270ml) 17.8 - 25 $/bag 
 
QC materials  10,000 $/dose 
 
Transportation  3,000 $/dose 
 TALEN costs  6,500,000 $/g 
 Electroporation buffer  0.78 $/ml 
 Electroporation unit  32,350 $/unit 
a(Meehan et al. 2000)  
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5.2.3 Key assumptions for different platforms for autologous CAR T-cell 
manufacture  
The metrics used to evaluate different platforms for autologous CAR T-cell manufacture 
were COG/dose, personnel requirement and facility footprint. The annual demands 
considered in this analysis range between 100 and 10,000 doses per year of 5M to 500M 
cells. 
Figure 5.2 Schematic representation of the differences between the autologous and 
allogeneic processes modelled in this chapter. 
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The manufacturing platforms evaluated in this chapter are composed of a combination of 
technologies currently available on the market, which were previously described in 
Chapter 1 (Section 1.5). The sequence in which these technologies are employed within 
each manufacturing platform can be found in Figure 5.1 and a summary of the 
characteristics of the different manufacturing platforms considered in this chapter is 
shown in Table 5.3. The fundamental difference between these manufacturing platforms 
is the cell culture vessel used during the cell culture stage. Moreover, the manufacturing 
platforms also require different facility designs and labour efforts. In order to compute 
the labour costs for the different manufacturing platforms, six different labour categories 
were considered (Table 5.1). These categories were: process operator, supervisors & 
managers, QCtesting scientists, QCmonitoring scientists, QA scientists and QP.  
Process operators correspond to the operators that carry out the day-to-day tasks of the 
core process. The number of process operators required was calculated taking into 
account the degree of automation incorporated in each manufacturing platform. In this 
case study, the manufacturing platforms were divided into three categories: manual 
(multilayer flasks, gas permeable flasks and suspension bags), semi-automated (rocking 
motion bioreactor and hollow fibre bioreactor) and fully automated (integrated USP/DSP 
platform). A ratio between the number of process operators per team and the maximum 
number of batches in parallel that a single team can process was applied. This ratio was 
assumed to be 3:2, 2:2 and 2:6 for the manual, semi-automated and fully automated 
platforms respectively. The number of managers and supervisors were computed as a 
function of the number of process operators.  
The QCtesting scientists are responsible for batch release testing. The number of QCtesting 
personnel was calculated under the assumption that each QCtesting can process up to 2 
batches in parallel. The QCmonitoring scientists are responsible for analysing samples for 
environment monitoring. The number of QCmonitoring scientists are calculated according to 
223 
 
the number of cleanrooms within the facility. In this case study, it was assumed that each 
QCmonitoring scientist was capable of looking after 2 cleanrooms simultaneously. The 
number of cleanrooms within the facility is dependent on the number of batches that can 
be manufactured per cleanroom. As a risk-mitigation strategy against cross-
contamination, the number of cleanrooms varied according to the manufacturing platform 
used. For manual platforms that require open processing (multilayer flasks), the 
maximum number of batches per cleanroom was assumed to be 1. Manual platforms that 
do not require open processing (static suspension bags and gas permeable vessels) would 
allow for up to 5 batches to be manufactured in parallel per cleanroom. This number was 
doubled for semi-automated and closed manufacturing platforms (rocking motion 
bioreactor and hollow fibre bioreactor) and increased by 4-fold in processes employing 
fully automated closed platforms (integrated USP/DSP platform). QA engineers are 
responsible for reviewing the documents generated by the QC team. In this case study, it 
was a assumed that the ratio between QA engineers and QC scientists was 1:2.  In Europe, 
a QP is required for batch  certification prior to final release and sale. In this analysis, the 
number of QPs within a facility was calculated assuming that each QP could certify 2 
batches manufactured in parallel.  
As seen in Chapter 3, most manufacturing platforms do not require open processing and 
therefore can be operated in a “Grade C” environment. The manufacturing platform using 
multilayer flasks is the only platform evaluated in this case study that requires open 
processing. Therefore, biosafety cabinets surrounded by  “Grade B” rooms were assumed 
to be in place when using this platform.  
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Table 5.3 Manufacturing platform-specific assumptions for the CAR T-cell case study 
Manufacturing 
platform 
Abbreviation Type 
Vessel 
volume 
(L) 
Vessel 
Capacity 
(cells/ 
cell 
culture 
vessel) 
No of 
operators 
per team: 
lots in 
parallel 
ratio 
Max no 
of 
batches 
per 
room 
Vessel 
costs 
Incubator 
requirement 
Biosafety 
cabinet 
requirement 
Dedicated 
equipment 
costs 
Multilayer flask MLF Manual 
0.025-
3.14 
175M - 
22B 
3:2 
1 
$2 - 
$241 
Y Y - 
Static 
suspension bag 
SSB Manual 0.05-3 
350M - 
21B 
3:2 
5 
$57 - 
$198 
Y N - 
Gas permeable 
vessel 
GPV Manual 
0.07-
3.6 
500M - 
25B 
3:2 
5 
$50 - 
$950 
Y N $15,000 
Hollow fibre   
bioreactor 
HFB 
Semi - 
automated 
0.2 1.4B 2:2 
10 
$1,200 Y N $150,000 
Integrated 
USP/DSP 
platform 
INT Automated 0.4 2.8B 2:6 
10 
$2512 N N $235,500 
Rocking motion 
bioreactor 
RMB 
Semi - 
automated 
3.14-20 
22B – 
140B 
2:2 
20 
$326 - 
$713 
Y N $47,500/$70,000 
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FCI costs were estimated using the detailed factorial methodology for estimating FCI and 
footprint for bespoke cell therapy facilities described on Chapter 2 Section 2.3 and 
applied in Chapter 3. It was assumed that incubators with the capacity to hold 5 batches 
(1 batch her shelf)  were in place when multilayer flasks, gas permeable vessels and static 
suspension bags were in use. The summary of the assumptions used to compute the labour 
and facility-related costs is shown in Table 5.4. 
Table 5.4 General assumptions used to compute the indirect costs of CAR T-cell products 
 
Parameter Value  Unit 
Scenario  No of active days 330 Days/year  
Process length (lentivirus, retrovirus) 13; 15  Days  
Time spent in cleanroom per shift 6.4 Hours  
Depreciation period 7 Years 
Mass balance & 
sizing 
No batches per QC operator  2 - 
 No cleanrooms per QCmonitoring 
scientist 
  
 No QA scientist: QC scientist 0.5 - 
 No batches per QP 2 -  
No supervisors & managers: no of 
process operators  
0.7 - 
 
No gowns used per operator per day 4 - 
 Max no cells per final purification 
cycle 
5 × 1010 - 
 Max no purification cycles per 
magnetic purification unit per shift 
2 - 
 Max no batches per QC lab 10 - 
 
Costs Annual salary 120,000 $/operator  
Gowning costs (Grade B ; Grade C) 60; 45 $/gown  
Facility energy costs  637 $/m2 /year 
 Capacity of shared equipment  (A; B, 
C, D, E, F) 
2; 5; 4; 2; 2;4 Batches/ unit 
 Cost of shared equipment (A; B, C, 
D, E, F) 
12.8; 13.4; 62.4; 79.5; 
55; 32.4 
$‘000s/ unit 
 Cryofreezer capacity 1.8 L 
 Cryofreezer costs  30 $’000s/ unit 
A= Biosafety cabinet; B= 5-shelve incubator; C= Elutriation system; D= Spinning membrane 
filtration; E= Magnetic selection system; F = Electroporation system 
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5.2.4 Key assumptions for commercial feasibility scenario of autologous CAR T-cell 
products under current reimbursement constraints 
Following the identification of COG/dose, the commercial feasibility of CAR T-cell 
products manufactured using different manufacturing platforms was investigated under 
current reimbursement strategies. In this analysis, autologous CAR T-cell products with 
an annual demand of 10,000 doses of 50M and 5000M cells were considered.  
As estimating a suitable reimbursement for CAR T-cell products is a challenge at present, 
the commercial feasibility of the different manufacturing platforms was evaluated by 
calculating the selling price required to reach COG as % sales of 15% and 40% and 
comparing these to the selling prices of current autologous CAR T-cell therapy products 
on the market. COG as 15% of sales has been established as the standard for traditional 
biopharmaceutical products and COG as 40% of sales has been proposed as a benchmark 
for autologous cell therapy products (Smith 2012b).  
5.2.5 Key assumptions for multi-site manufacture scenario for patient-specific cell 
therapy products  
Chapter 1 (Section 1.7.6) highlighted some of the challenges associated with centralised 
manufacture of patient-specific products, which included complex supply chain and poor 
response to market demand. This section will explore the economic benefit to the inventor 
company of multiple alternative facility configurations for the manufacture of an 
autologous CAR T-cell product with an annual demand of 10,000 doses of 500M cells.  
This analysis was carried out using the cash flow model described in Chapter 2 (Section 
2.8). This model was set to assess the long term benefits of different facility 
configurations by assessing important trade-offs in FCI, financial risk and rNPV caused 
by a number of factors including facility start-up costs (tech transfer, comparability 
studies, facility validation and site license etc.), transportation costs, potential fees paid 
to the administration and/or manufacturing site.  The FCI was attained from the detailed 
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factorial methodology for estimating FCI and footprint for bespoke cell therapy facilities 
described in Chapter 2 Section (2.3) which was adapted to account for multi-site 
configurations. Financial risk was evaluated by computing the minimum selling price for 
which NPV = 0 where a high selling price was associated with high risk; and the rNPV 
was computed by discounting future cash flows by a discount rate that relates to the risk 
associated the project and the company’s cost of capital. 
In this case study, a sales ramp-up was assumed of 40% in years 1 and 2, 70% in years 3 
and 5 and 100% from year 6 after market release of the CAR T-cell product. It was also 
assumed that in multi-site facility configuration the facilities were built in response to 
annual demand whilst in the centralised manufacture facility configuration it was 
assumed that a single facility with adequate capacity for product manufacture at 100% 
market penetration would be in place as soon as the product was released into the market. 
The selling price used in this analysis was the selling price that resulted in a COG as % 
sales of 40% when using the integrated USP/DSP platform to manufacture 10,000 doses 
per year of 50M cells. The integrated USP/DSP platform was selected for this analysis as 
it was the platform with the lowest COG/dose in the selected commercialisation scenario 
and it was the only manufacturing platform that resembled a fully integrated and 
automated platform for end-to-end CAR T-cell therapy manufacture.  
In order to provide a complete cash flow analysis the development costs were included in 
the cash flow model and assumed to be absorbed by the inventor company, even though 
these costs did not differ across facility configurations. The development costs included 
in this analysis were clinical trials costs (Phase I to Phase III), technology transfer costs, 
comparability studies, product stability studies and process development. The clinical 
trials costs were estimated according to the number of patients treated at each stage, the 
overheads costs per patient and the COG/dose of the CAR T-cell product generated by 
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the bioprocess economics model for scenarios with annual demands of 10 (Phase I), 50 
(Phase II) and 100 (Phase III) patents. In this case study, it was assumed that the stability 
studies and comparability studies were carried out using the materials generated during 
clinical trials, process performance qualification batches (PPQ) and engineering runs. 
Moreover, additional assay costs for these studies were also considered. The technology 
transfer costs, and process development costs were computed based on the number of 
fulltime equivalent (FTE) personnel required to carry out these tasks.  
Furthermore, this case study also considers facility preparation costs. These costs were 
also assumed absorbed by the inventor company. The facility preparation costs included 
in this analysis were site license, engineering runs and PPQ batches and additional 
technology transfer and comparability studies.  The site license costs included comprised 
all the costs related to acquiring a license for cell therapy manufacture, which included 
validation activities. The costs associated with engineering runs and PPQ batches were 
attained from the process economics model. In this case study it was assumed that 5 
engineering runs and 3 PPQ batches were carried out per manufacturing site. 
The facility configurations investigated in this case study were: centralised, decentralised, 
hospital site and “GMP-in-a-box” manufacture. The key characteristics of these facility 
configurations are summarised in Table 5.5. In the centralised facility configuration, it 
was assumed that a single facility would cater for the whole market and that the inventor 
company would be responsible for all costs related to providing the product, from tissue 
acquisition to transportation to the administration site. In return, the inventor company 
would retain the full revenue from product sales. A similar model was applied in the 
decentralised manufacture configuration; this time however, a single facility was replaced 
by multiple identical sites resulting in a higher proximity between the manufacturing site 
and the administration site, which decreases the transportation costs. 
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Table 5.5 Key characteristics of the centralised and different multi-site facility configurations  
Parameter Centralised  Decentralised  Hospital site “GMP-in-a-box” 
Batch failure rate  5% 5% 5% 5% 
Revenue  100% Sales 100% Sales 100% Sales 95% Sales 
FCI  Equipment + Facility Equipment + Facility Equipment  Equipment  
Development costs  
Clinical trials  
Development stage tech transfer  
Process development  
Product stability tests  
Clinical trials  
Development stage tech transfer  
Process development  
Product stability tests  
Clinical trials  
Development stage tech transfer  
Process development  
Product stability tests 
Clinical trials  
Development stage tech transfer  
Process development  
Product stability tests 
Facility prep costs 
Facility insurance  
Commercial stage tech transfer  
Comparability studies  
Site license  
Engineering runs  
PPQ batches  
Facility insurance  
Commercial stage tech transfer  
Comparability studies  
Site license  
Engineering runs  
PPQ batches 
Commercial stage tech transfer  
Comparability studies  
Site license  
Engineering runs  
PPQ batches  
Commercial stage tech transfer  
Comparability studies  
Site license  
Engineering runs  
PPQ batches 
Running costs  Materials  
Labour  
Facility & equipment overheads 
QC 
Materials  
Labour  
Facility & equipment overheads 
QC 
Materials  
Facility charge 
Labour  
Equipment overheads 
QC 
Materials  
Equipment overheads 
QC 
Hospital charge  
Transportation costs  $3,000/dose $1,500/dose - - 
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In the hospital site configuration, the product manufacture activities were moved to 
existing cleanrooms within the administration site rented by the inventor company for a 
fixed annual fee (referred to as facility charge). For this facility configuration, it was 
assumed that the inventor company would be responsible for providing the adequate 
personnel, equipment and materials for product manufacture and that it would retain full 
revenue from product sales. As the product manufacture and administration were 
collocated, the transportation costs were nullified.  
In the “GMP-in-a-box” facility configuration, it was assumed  that a single fully 
integrated and automated equipment that requires minimal manipulation for “end-to-end” 
manufacture of CAR T-cell products was provided to the administration sites by the 
inventor company along with all the materials required for the manufacturing process. 
Given the degree of automation of this hypothetical platform, it was assumed that the 
hospital staff would be able to operate this fully automated equipment for a fee of 5% of 
the revenue from each dose (referred to as hospital charge).  
For all multi-site manufacture scenarios, two different QC strategies were modelled- 
centralised and decentralised QC testing. In the decentralised QC scenario, QC labs were 
present in each manufacturing site whilst in the centralised QC scenario a single QC lab 
was shared across the different manufacturing sites with the aim of increasing the 
utilization of the lab facilities and personnel such as to reduce costs. The key assumptions 
used in the case study are summarised in Table 5.6. 
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Table 5.6 General NPV assumptions for facility configuration case study  
 
Parameter  Value  Unit 
 
Market penetration  40% (years 1-2); 70% (years 3-5); 100% (years 6-10) - 
Running costs Facility charge (hospital site only) 1.20 × (Facility depreciation + Facility maintenance costs + Facility monitoring costs) $/y 
 
Hospital charge (“GMP-in-a-box” only) 0.05 × sales  
 
Facility insurance  0.01 × FCI - 
 
Sales and marketing (S&M) 10% of sales/y 
 
Corporate tax  24% 
of taxable 
income  
Development 
costs  
Process development  500,000 (Phase I); 500,000 (Phase II); 1,500,000 (Phase III) $ 
 
Technology transfer  500,000 (Phase I); 500,000 (Phase II); 1,500,000 (Phase III) $ 
 
Product stability  50,000 (Phase I); 40,000 (Phase II)  $ 
 
Number of patients for clinical trials  10 (Phase I); 50 (Phase II); 100 (Phase III) - 
 
Autologous clinical trials (centralised, 
decentralised and hospital site)    87,584 (Phase I); 41,116 (Phase II); 39,281 (Phase III) 
$ 
 
Autologous clinical trials (“GMP-in-a-
box”) 
168,399 (Phase I); 95,283 (Phase II); 94,141 (Phase III) $ 
 
Allogeneic clinical trials  159,377 (Phase I); 42,105 (Phase II); 27,163(Phase III) $ 
Facility prep 
costs  
PPQ batches  
    3 × 39,281 ( autologous: centralised, decentralised and hospital site); 3 × 94,141    
(autologous: “GMP-in-a-box”); 3 × 27,163 (allogeneic: centralised and decentralised ) 
$/site 
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Engineering runs  
5 × 39,281 ( autologous: centralised, decentralised and hospital site); 5 × 94,141 
(autologous: “GMP-in-a-box”); 5 × 27,163 (allogeneic: centralised and decentralised ) 
$/site 
 
Technology transfer  1,500,000 $/site 
 
Comparability studies  350,000 $/site 
 
Site license  3,000,000 $/site 
Risk  Clinical failure risk 0% (Phase I); 13% (Phase II); 45% (Phase III); 64% (Commercial stage) - 
Other Discount rate 10% - 
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5.2.6 Key assumptions for allogeneic versus autologous CAR T-cell therapy products 
scenario  
The final scenario investigated the cost-effectiveness of allogeneic CAR T-cell products 
with respect to autologous CAR T-cell products under the assumption that both 
autologous and allogeneic CAR T-cell therapy products would achieve comparable safety 
and efficacy profiles. The annual demands considered in this comparison ranged between 
100-10,000 doses of 5M-500M cells. In this analysis, process flows with lentivirus for 
genetic editing were considered for both autologous and allogeneic processes. For  
autologous processes, the optimal manufacturing platform (with the lowest COG/dose) 
for each commercialisation scenario was compared against allogeneic processes using the 
rocking motion bioreactor. This platform was selected with the aim of maximising 
economics of scale given that this is the manufacturing platform with the highest capacity 
(Table 5.3)  
As previously mentioned, a final magnetic purification step is required in allogenic 
processes such as to minimise the risks of GvHD.  Current technologies for magnetic 
purification have limited capacity (5 × 1010 cells/cycle) and in situations where the 
number of cells produced during cell culture exceeded the maximum number of cells that 
the DSP could handle, it was assumed that the excess cells would be discarded. 
As previously mentioned, this case study assumed that the maximum number of cells that 
can be retrieved from a donor is 1.67 × 1010  which results in a total cell number of 5.26 × 
1011 after the cell culture step. Given the current capacity contains of technologies for 
magnetic separation of T-cells, it is clear that the cells produced during cell culture will 
overwhelm the DSP process. Hence the effect of using multiple magnetic purification 
units in parallel was explored. Moreover, the benefits of re-sizing the manufacturing 
process according to the constraints of the DSP process such as to minimize the number 
of magnetic purification units used while avoiding discarding cells was also investigated. 
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5.3 Results and discussion  
This section analyses and discusses the results from the case studies highlighted in the 
previous section. The case studies provide useful insights to some of the critical questions 
faced by cell therapy developers when designing a manufacturing strategy for CAR T-
cell therapy products. The questions addressed in these case studies included operational 
and economic benefits of manufacturing platforms, commercial feasibility under current 
reimbursement limits, long term benefits of multi-site manufacture of patient-specific 
products and  cost benefits of allogeneic CAR T-cell therapy products. 
5.3.1 Identifying and understanding current COG of autologous CAR T-cell therapy 
products 
Understanding the trends in COG and how these change across commercialisation 
scenarios and manufacturing strategies is key to making informed decisions during early 
stages of the process development. Figure 5.3 shows how the COG/dose of processes 
using different manufacturing platforms and viral vectors varies with increasing dose size 
and annual demand. Figure 5.3 shows that for autologous CAR T-cell therapy products, 
COG/dose varies between $60,000 and $160,000 and that both the availability of 
manufacturing platforms for autologous CAR T-cell manufacture and the COG/dose 
increase with dose size. The COG/dose shown in Figure 5.3 seem to be well in line with 
the costs reported for autologous CAR T-cell therapy products which range between 
$45,000 and $150,000 (Reuters 2015). 
For lower doses sizes (5M cells), Figure 5.3 indicates that the static suspension bag is the 
manufacturing platform that offers the lowest COG. As the dose size increases to 50M 
cells, the integrated USP/DSP platform becomes the most cost-effective manufacturing 
platform and at larger dose sizes of 500M cells, the rocking motion bioreactor provides 
the lowest COG/dose. This trend remains unchanged irrespectively of the annual demand 
and viral vector selected for gene editing.  
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Figure 5.3 COG/dose for CAR T-cell products manufactured using different manufacturing platforms across different 
commercialisation scenarios for lentivirus-based processes and γ-retrovirus-based processes. MLF = multilayer flasks. 
SSB = static suspension bags¸ GPV = gas permeable vessel, HFB = hollow fibre bioreactor, INT = integrated USP/DSP 
platform and RMB = rocking motion bioreactor. 
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The number of candidate manufacturing platforms increases with increasing dose size 
due to a constraint placed in this case study which states that the utilization of the cell 
culture vessel used during cell culture must be 10% or higher for that manufacturing 
platform to be considered.  Figure 5.3 indicates that for a dose size of 5M cells, which 
translates into a ~20ml and ~30ml cell culture for lentivirus-based and γ-retrovirus-based 
processes respectively, the only manufacturing platforms that are suited for such small 
cell culture volumes are the multilayer flasks, static suspension bags and gas permeable 
vessels. Higher cell culture volumes are required with γ-retrovirus-based processes as 
these have lower transduction efficiencies and hence additional cells must be processed 
in order to achieve the same number of transduced T-cell per dose (Table 5.2). In this 
scenario, static suspension bags is the platform with the lowest COG/dose with a marginal 
advantage with respect to gas permeable vessels (~1%). The higher cost-effectiveness of 
these platforms with respect to the multilayer flasks is attributed to the fact that indirect 
costs (labour, gowning and facility-related costs) dominate the COG/dose of autologous 
CAR T-cell therapy products with small dose sizes. Given that multilayer flasks require 
the use of biosafety cabinets in a “Grade B” environment the indirect costs associated 
with this platforms are higher than for the other candidate platforms. 
For lentivirus-based processes, increasing the dose size further to 50M cells (~190ml and 
~280ml of cell culture volume for lentivirus and γ-retrovirus-based processes 
respectively) allows the integrated USP/DSP platforms and the rocking motion bioreactor 
to appear in the list of candidate technologies. In these medium dose size scenarios, the 
integrated USP/DSP platform becomes the most cost-effective option, due to the lower 
labour costs associated with the platform.  
At the highest dose size scenario of 500M cells (which translated into cell culture volumes 
of 1.9L and 2.8L for lentivirus and γ-retrovirus processes respectively), multiple cell 
culture vessels were required in order to meet the batch size with the hollow fibre 
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bioreactor and the integrated USP/DSP platform due to capacity constraints, making these 
the least cost-effective platforms. The number of hollow fibre bioreactors required per 
batch was as high as 10 (lentivirus process) – 14 ( γ-retrovirus). The integrated USP/DSP 
platform has a higher capacity than hollow fibre bioreactors, hence a lower number of 
cell culture vessels per batch was required (5 and 7 for lentivirus and γ-retrovirus 
respectively). 
A single rocking motion bioreactor is capable of coping with large dose sizes of 500M 
cells for both lentivirus and γ-retrovirus-based processes. This combined with the fact 
that the rocking motion bioreactor has lower labour costs than manual platforms makes 
the rocking motion bioreactor the optimal manufacturing platform for CAR T-cell therapy 
products with this high dose size. 
Increasing the annual demand to 10,000 doses per year has no effect on the trends seen 
in both lentivirus and γ-retrovirus processes as the dose size has a higher effect on the 
COG/dose than the annual demand. This is due to the poor economies of scale 
characteristic of the scale-out model applied to autologous processes. 
The relative contribution of the different factors which influence the COG changes 
significantly with dose size; understanding the effect of these different factors will help 
identify where to focus development efforts. Figure 5.4 shows the cost breakdown by 
major supply chain activity, manufacturing process step and cost category with increasing 
dose size when the annual demand is 10,000 patients.   
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Figure 5.4 COG breakdown at medium and high doses across different 
manufacturing platforms for an annual demand of 10,000 doses per year. a) COG 
breakdown by activity, b) COG breakdown by process step and c) COG breakdown 
by cost category (for the manufacturing process only). MLF = multilayer flasks, SSB 
= static suspension bags¸ GPV = gas permeable vessel, HFB = hollow fibre 
bioreactor, INT = integrated USP/DSP platform and RMB = rocking motion 
bioreactor. Medium dose = 50M cells, high dose = 500M cells. 
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 Figure 5.4 a) shows that at a medium dose (50Mcells), for all viral vector-manufacturing 
platform combinations, the major supply chain activities with the highest COG are the 
core process activities (38%-54% of COG), product release testing (28%-38% of COG) 
and the collection and testing of the leukapheresis sample (13%-19% of COG). As the 
dose size increases, so does the materials costs required during the manufacturing process, 
which causes for the manufacturing process to have a higher effect on COG (47%- 71%). 
When taking a closer look into the manufacturing process, Figure 5.4 b) shows that the 
process step with the highest labour and materials costs is the product release testing step 
(32% - 58% of COGMFG) followed by the cell culture step (20% -51%) and the gene 
editing step ( 3% - 17%). This is due to the fact that product release testing requires 
dedicated labour and the cell culture is the longest step and therefore has the highest core 
process-related labour costs. 
 As the dose size increases from 50M cells to 500M cells, the relative contribution of the 
gene editing step towards the COGMFG increases for all viral vector-manufacturing 
platform combinations (from 3% - 5% of COGMFG to 3% - 17% of COGMFG). In 
lentivirus-based processes this is attributed to the higher quantities of viral vector used 
and in γ-retrovirus-based processes the increase in gene editing costs is caused by the 
higher use of retronectin.  
These trends are confirmed by Figure 5.4 c), which shows the manufacturing cost 
breakdown by cost category with increasing dose size. Figure 5.4 c) shows that the 
relative contribution of  viral vector costs towards the COGMFG increases in lentivirus-
based processes from 1% - 2% of COGMFG to 8% - 14% of COGMFG. In γ-retrovirus-
based processes the increase in the relative contribution of the retronectin costs towards 
the COGMFG is seen by the increase of the reagent cost as a proportion of COGMFG from 
2%-4% to 5% - 12% of COGMFG. 
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Figure 5.4 c) also shows that the cost category with the highest effect on the COG for all 
manufacturing platforms at lower dose sizes of 50M cells is the labour costs (33% - 55% 
of COG). This is due to the manual nature of current processes for autologous CAR T-
cell manufacture combined with the scale-out approach used for patient-specific 
therapies. The relative contribution of this cost category is magnified in medium dose size 
scenarios where the material costs are lower.  
As previously mentioned, at high dose sizes of 500M cells multiple hollow fibre 
bioreactors and integrated USP/DSP platforms are required per batch during cell culture. 
Figure 5.4 c) shows clearly the effect of capacity constraints of manufacturing platforms 
through the dramatic increase in facility overheads costs as a proportion of the total COG 
seen for these manufacturing platforms with increasing dose size. The relative cost 
contribution of the facility-related costs increases from 14% to 36% for hollow fibre 
bioreactors and 21% to 46% for integrated USP/DSP platform. 
5.3.2 Operational features of manufacturing platforms for autologous CAR T-cell 
manufacture 
While COG/dose is an excellent parameter to base manufacturing process decisions on, 
in autologous CAR T- cell process there are many other parameters that must be 
considered when selecting a platform for product manufacture. Moreover, when working 
with autologous products for high annual demand applications, the number of batches 
manufactured in parallel rapidly increases increasing the personnel number and the 
facility footprint. This section investigates the personnel and facility footprint when 
different manufacturing platforms are used to manufacture a CAR T-cell therapy with a 
dose size of 50M cells across annual demands of 100 patients and 10,000 patients.  
Figure 5.5 a) shows that the facility footprint required for autologous CAR T-cell 
manufacture changes with annual demand, viral vector and manufacturing platform. For 
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lentivirus-based processes the facility footprint changes from 200m2 (multilayer flasks) - 
400m2(integrated USP/DSP platform) to 13,500m2 – 33,300m2 when moving from an 
annual demand of 100 patients per year to 10,000 patients per year.  The values for facility 
footprint achieved in γ-retrovirus-based processes are higher. This is due to the fact that 
γ-retrovirus-based processes were assumed to be longer (Figure 5.1) and hence a higher 
number of batches in parallel would be required to satisfy the same annual demand. The 
facility footprint for γ-retrovirus-based processes ranged between 350m2 (static 
suspension bags) – 550 m2 (multilayer flasks) and 18,200m2 – 38,000m2 for annual 
demands of 100 and 10,000 patients respectively. 
For both lentivirus-based and γ-retrovirus-based processes, Figure 5.5 a) shows that the 
manufacturing platform with the highest facility footprint is the multilayer flaks. The 
higher facility footprint achieved with multilayer flasks is caused by the use of biosafety 
cabinets and the higher number of cleanrooms. The platform with the lowest facility 
footprint is the integrated USP/DSP (lentivirus –based process) and the static suspension 
bags (γ-retrovirus-based processes). 
The integrated USP/DSP platform is an “all-in-one” platform which can carry out most 
process steps within the manufacturing process and hence does not require most of the 
additional shared equipment that are necessary in other manufacturing platforms (e.g. 
incubators, spinning membrane filtration units and biosafety cabinets) resulting in a lower 
facility footprint. When the integrated USP/DSP platform is used in γ-retrovirus 
processes, the additional cells manufactured to compensate for the lower viral 
transduction efficiency assumed for γ-retrovirus causes for multiple units of the integrated 
242 
 
USP/DSP platform to be required during cell culture which increases the facility 
footprint. 
Figure 5.5 a) Facility footprint across different manufacturing platforms and viral vectors 
with increasing annual demand and a dose size of 50M cells. b) Breakdown of personnel 
requirement with increasing annual demand. The numbers in the embedded table 
correspond to working volume of the cell culture vessels in ml used during cell culture for 
dose sizes of 50M and 500M cells. The number on top of each bar represents the ratio 
between the number of process operators and the total personnel number within a facility. 
MLF = multilayer flasks, SSB = static suspension bags¸ GPV = gas permeable vessel, HFB 
= hollow fibre bioreactor, INT = integrated USP/DSP platform and RMB = rocking motion 
bioreactor. 
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Figure 5.5 b) shows the breakdown of the different personnel categories modelled in the 
chapter with increasing annual demand. This figure shows that the personnel number 
increases from 11(integrated USP/DSP platform) – 30 (multilayer flask) and 750 – 2,500 
as we move from 100 patients per year to 10,000 patients per year. This figure also shows 
that the personnel number required is higher for γ-retrovirus-based processes and that the 
ra tio between the different types of personnel changes with manufacturing platform.  
For both lentivirus-based and γ-retrovirus-based processes, the integrated USP/DSP 
platform has the lowest personnel requirement. This is due to the degree of automation 
incorporated into this manufacturing platform, which results in lower process operator 
numbers and a high ratio of total personnel number to operator number (5.5 – 7). For all 
other manufacturing platforms, core process staff are the highest contributors toward the 
total staff number.  
 The multilayer flask is the platform with the highest staff number. This is due to a 
combination of poor automation (which increases the number of process operators) and 
high number of processing rooms (which increases the number of QCmonitoring scientists). 
The ratio between total personnel number and process operator number ranges between 
3.5 and 3.8 for this platform.  
Static suspension bags and gas permeable vessels have the second highest personnel 
number. This is due to the fact that these platforms are manual and hence require a 
relatively high number of process operators. The ratio between total personnel number 
and process operators are lower for these platforms than for multilayer flasks due to the 
lower number of facility monitoring staff (2.7 and 3). 
Rocking motion and hollow fibre bioreactors are semi-automated platforms and therefore 
have the second lowest number of process operators. This combined with a lower number 
244 
 
of facility monitoring staff results in similar rations between total personnel number and 
process operators to multilayer flasks (3.1 and 3.8). 
5.3.3 Assessing the commercial feasibility of autologous CAR T-cell products  
This section aims at investigating the commercial feasibility of CAR T-cell products 
manufactured using the platforms considered in this thesis by measuring the selling price 
for which COG is 15% and 40% of sales and comparing this selling price with the price 
of current autologous CAR T-cell therapy products in the market. 
To date only two autologous CAR T-cell products that have received approval for market 
release. These products are Yescarta® (Kite Pharma, Los Angeles, CA, USA) and 
Kymriah® (Novartis, Basel, Switzerland). Yescarta® is a CAR T-cell product targeted at 
adult large B-cell lymphoma and is priced at $373,000 per treatment (Clarke & Berkrot 
2017; Herper 2017; Ramsey 2017). Kymriah® is a CAR T-cell therapy targeted at B-cell 
Figure 5.6 Minimum selling price for which COG is 15% (grey bar) and 40% (black bar) 
sales across different manufacturing platforms and viral vectors. The dashed lines 
represent the reimbursement for current autologous CAR T-cell products in the market – 
Kymriah (red) and Yescarta (yellow). The commercialisation scenario selected is of an 
annual demand of 10,000 patients and dose sizes of 50M and 500M cells. MLF = 
multilayer flasks, SSB = static suspension bags¸ GPV = gas permeable vessel, HFB = 
hollow fibre bioreactor, INT = integrated USP/DSP platform and RMB = rocking motion 
bioreactor. 
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acute lymphoblastic leukaemia in children and young adults and is priced at $475,000 per 
treatment (Sagonowsky 2017b; Mukherjee 2017; Lauerman & Paton 2017).  
Figure 5.6 shows that for a medium dose size of 50M cells, in order for COG as 40% 
sales to be achieved, the selling prices applied must be $130,000 - $185,000. If lower 
COG as % sales of 15% are to be achieved, then the selling prices must increase to 
$350,000 - $495,000. These selling prices are well in line with the reimbursement values 
applied to current autologous CAR T-cell therapy products.  
For autologous CAR T-cell products with higher dose sizes of 500M cells, the selling 
prices required to achieve COG as 40% of sales are again in line with current products in 
the market ($165,000 - $370,000). However, if the target COG as % sales is reduced to 
15%, Figure 5.6 shows that the chances of achieving this cost target with the current 
reimbursement applied to autologous CAR T-cell products will be highly dependent on 
the manufacturing platform employed. The  selling prices required to reach COG as 15% 
of sales for a CAR T-cell product with a dose size of 500M cells are between $370,000 
and $980,000. The platforms that fail to meet this cost target under current reimbursement 
strategies applied to autologous CAR T-cell products are the multilayer flasks, hollow 
fibre bioreactor and integrated USP/DSP platform. This trend is attributed to the high 
facility-related costs associated with these platforms. For multilayer flasks, this is caused 
by the use of biosafety cabinets in “Grade B” environment and for hollow fibre bioreactor 
and integrated USP/DSP platforms, this trend is caused by the requirement of multiple 
units per batch due to capacity constraints. This underlines the importance of selecting 
the correct platform for autologous CAR T-cell manufacture.  
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5.3.4 Assessing the risk, reward and investment of different strategies for multi-site 
manufacture of CAR T-cells 
Multi-site manufacture can be presented in different configurations such as decentralised 
facility manufacture, hospital site manufacture and bedside “GMP-in-a-box” 
manufacture. The economic benefit of each of these strategies with respect to a single 
centralised facility will be evaluated in this section under different QC strategies when 
the number of manufacturing sites is varied between 5 and 50. The scenario selected for 
this analysis was of an annual demand 10,000 patients per year and a dose size of 50M 
cells. The manufacturing platform selected for this scenario was the integrated USP/DSP 
platform and the selling price selected was $150,000, as this is the selling price which 
results in a COG of ~ 40% of sales ( COG/dose = $53,000). 
Figure 5.7 shows the relationship between rNPV, capital investment and financial risk of 
different facility configurations for autologous CAR T-cell manufacture. Given that the 
same selling price was applied across all facility configurations, the differences in NPV 
are caused by the net present costs associated with the different strategies. The detailed 
breakdown of these costs is shown in Figure 5.8. This figure shows that the economic 
benefit of multi-site facility configurations decreases with increasing number of sites and 
it is maximised when QC testing for all sites is carried out in a single facility. Moreover, 
in the scenario presented in this case study, the “GMP-in-a-box” and the hospital site 
manufacture configuration provide very similar economic benefits. 
In multi-site facility configurations, when the number of manufacturing is set to 5, Figure 
5.7 shows that the decentralised manufacture is the only facility configuration which has 
a higher capital investment than the centralised facility configuration. Figure 5.7 also 
shows that with a low number of sites, all multi-site facility configurations offer a higher 
rNPV and lower risk than a centralised facility.  
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When looking at the effect of the capital investment on the net present costs, Figure 5.8 
shows that although a higher capital investment is required for decentralised manufacture 
as previously seen in Figure 5.7, the net present investment costs are lower for the 
decentralised facility configuration than for the centralised facility configuration. This is 
due to the fact that in the decentralised configuration capacity is built over the years which 
means that higher discount rates are applied to the capital invested in later years, 
decreasing the overall impact of these costs on the rNPV. This, along with the lower 
transportation costs causes the decentralised manufacture with 5 manufacturing sites to 
have a higher rNPV than the centralised manufacture. 
Further reductions in capital investment are achieved with both the hospital site 
configuration and “GMP-in-a-box” configuration, as in the hospital site facility 
configuration, the only capital investment absorbed by the inventor company is 
Figure 5.7 NPV (x-axis) versus FCI (y-axis) versus minimum selling price for which 
NPV=0 (bubble size) across different facility configurations, QC strategies and number of 
manufacturing sites. The green bubbles represent multi-site manufacture scenarios where 
the number of sites is 5 and the green bubbles represent multi-site manufacture scenarios 
where the number of sites is 50. The commercialisation scenario here presented is of an 
autologous CAR T-cell therapy product with an annual demand of 10,000 patients per year 
and a dose size of 50M cells. 
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equipment and in the “GMP-on-a-box” scenario the inventor company is responsible for 
the equipment costs and the local QC facilities. Moreover, in the hospital site 
configuration and in the “GMP-in-a-box” configuration product manufacture takes place 
at the administration site, which nullifies the product transportation costs resulting in 
overall lower net present costs with respect to the centralised and decentralised facility 
configurations. Furthermore, as product manufacture is carried out by the hospital staff 
in the “GMP-in-a-box” configuration, the only personnel costs absorbed by the inventor 
company are the costs related to testing and releasing the product, which reduces the net 
present labour costs. 
 Even though the facility-related costs and the labour costs are lower when adopting a 
“GMP-in-a-box” configuration to autologous CAR T-cell manufacture than for a hospital 
site facility configuration, a hospital charge of 5% is applied to any revenues attained 
from product sales in the “GMP-in-a-box” configuration. This causes the net present costs 
of the “GMP-in-a-box” configuration to become similar to the hospital site configuration, 
which include an additional facility charge as product manufacture takes place in rented 
cleanrooms within the hospital. 
Increasing the number of manufacturing sites to 50, increases the capital investment and 
facility prep costs in multi-site facility configurations, increasing the risk associated with 
these strategies and causing the economic benefit of these strategies to decrease. When 
adopting a centralised QC strategy, both labour and facility-related costs are reduced in 
multi-site facility configurations. This is due to the fact that the number of QC laboratories 
and QC personnel are reduced as the production in different facilities is staggered in order 
to maximise the utilization of the QC facility. 
 It should be noted that the “GMP-in-a-box” facility configuration is more sensitive to the 
selling price selected than other facility configurations due to the hospital charge applied 
to this facility configuration. As the hospital charge is a function of the selling price, there 
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are scenarios where the benefits of the “GMP-in-a-box” configuration are outweighed by 
the higher hospital charge caused by higher selling price. 
 
5.3.5 Assessing the cost-benefit of allogeneic versus autologous CAR T-cell 
manufacture 
Allogeneic CAR T-cell products have been proposed as a possible solution to the 
challenges associated to autologous CAR T-cell products. These challenges include 
complex logistics, high batch-to-batch variability and high COG (Levine et al. 2017; 
Sharpe & Mount 2015b; Mount et al. 2015b; Webster 2016). As previously highlighted 
in Section 5.2.3, for allogenic CAR T-cell manufacturing processes, the number of cells 
attained per batch is limited by the capacity of current technologies for magnetic 
purification of CAR+ T-cells. Figure 5.9 explores the effect of increasing the number of 
DSP units in parallel for final purification of allogeneic CAR T-cells on the overall 
process throughput for commercialisation scenarios with dose sizes varying between 5M-
500M cells and an annual demand of 10,000 patients. 
Figure 5.8 Breakdown of the net present costs included in the NPV analysis across 
different facility configurations, QC strategies and number of manufacturing sites. The 
commercialisation scenario here presented is of an autologous CAR T-cell therapy product 
with an annual demand of 10,000 patients per year and a dose size of 50M cells. 
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As the cells attained per donor is fixed (1.67 × 1010 cells), the number cells produced at 
the end of the cell culture process is also constant (7.20 × 1011 cells). Therefore, as the 
dose size increases the number of doses produced per batch decreases and the number of 
batches per year required to reach a particular annual demand (doses/year) increases.  
 
 
Figure 5.9 shows that increasing the number of DSP units used in parallel per batch 
increases the number of doses produced per batch as less cells are being discarded after 
cell culture and hence decreases the number of batches required per year. Figure 5.10 
and 5.11 illustrate the effect of dose size, annual demand and number of DSP purification 
units on the cost-effectiveness of allogeneic CAR T-cell products as the ratio of 
COG/dose of autologous to COG/dose of allogeneic products vary between 0.73 and 118. 
These figures show that the cost-effectiveness of allogeneic CAR T-cell products 
increases with annual demand and decreases with dose size.  
Figure 5.10 shows that when comparing the COG/dose of an autologous CAR T-cell 
product against an allogeneic product with a dose size of 5M cells/dose and an annual 
demand of 100 patients per year, the indirect costs (labour & facility and equipment 
Figure 5.9  Number of doses produced per batch and number of batches required per year 
in order to fulfil an annual demand of 10,000 patients across different DSP strategies for 
allogeneic CAR T-cell products with different dose sizes. Allo = allogeneic, 1_DSP = 1 
magnetic purification unit/batch, 3_DSP = 3 magnetic purification units/batch and 6_DSP 
= 6 magnetic purification units/batch. 
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overheads) dominate the COG. Moreover, if in the same commercialisation scenario the 
maximum number of DSP units available per batch is set to 1, the costs of producing the 
allogeneic product are 43% lower than the costs of the autologous product. If the 
allogeneic process is re-sized to fit a single DSP unit, allogenic processes become even 
more cost-effective,  as the costs of allogeneic products become 54% lower than for 
autologous products. This trend is explained by the fact that autologous products have 
higher labour, materials, QC and transportation costs as only one dose is produced per 
batch.  
Increasing the number of DSP units available for the allogeneic process to 3, increases 
the facility-related costs and the labour costs as extra personnel would be required to 
operate the additional DSP units. At a low annual demand, these additional costs are 
spread over a limited number of doses, reducing the making allogeneic products only  6% 
cheaper than autologous products. Further increasing the number of DSP units in parallel 
for allogeneic CAR T-cell manufacture to 6, increases the indirect costs even further, 
making allogeneic cell therapy products 45% more expensive than autologous products. 
When the annual demand is increased to 10,000 doses, allogenic CAR T-cell products 
become more cost-effective than autologous products even in scenarios where the number 
of DSP units in parallel is 6. This is explained by the fact that at higher annual demands, 
the additional indirect costs caused by the higher number of DSP units are spread over a 
higher number doses. When allowing 6 DSP units in parallel resulting in a maximum of 
12 cycles/batch (two cycles/ unit/ shift), the COG/dose of allogeneic CAR T-cell products 
remains unchanged whether the process is resized or not. This is due to the fact that  the 
number of cycles required to process one batch (5.26 × 1011 cells) is 11 and hence no cells 
are discarded in both scenarios. For autologous products, little change in COG/dose is 
achieved with increasing annual demand as previously seen in Figure 5.3.  
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Figure 5.10 COG breakdown across two different annual demands dose sizes. Auto = autologous, Allo = allogeneic, 
_DSP = 1 magnetic purification unit/batch, 3_DSP = 3 magnetic purification units/batch, 6_DSP = 6 magnetic purification 
units/batch and Resized = cell culture process resized accroding to DSP limitations. 
. 
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The COG/batch of allogeneic CAR T-cell processes is always higher than COG/batch of 
autologous processes given that the batch size of allogeneic processes is typically larger 
than for autologous processes and that allogeneic processes require two additional process 
steps (Figure 5.2). However, in allogeneic cell therapy processes, these costs are spread 
over a higher number of doses typically resulting in an overall lower COG/dose. As the 
dose size increases the number of doses produced per batch decreases (Figure 5.9) and 
hence, the benefits of allogeneic CAR T-cell therapy manufacture are reduced. 
As the previously seen, as the dose size increases to 500M cells, the relative contribution 
of the direct COG/dose towards the total COG/dose increases. Figure 5.10 shows that for 
allogeneic products a balance must be achieved between reducing the direct COG/dose 
by adding DSP units in parallel (and therefore reducing the number of discarded cells) 
Figure 5.11 Relative cost-effectiveness of allogeneic CAR T-cell products with respect 
to autologous CAR T-cell products across multiple dose size and annual demand 
scenarios. Auto = autologous, Allo = allogeneic, Non- Resized = cell culture process not 
resized accroding to DSP limitations and  Resized = cell culture process resized according 
to DSP limitations. 
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and reducing the indirect COG/dose by reducing equipment and personnel numbers. 
Hence, at smaller annual demands of 100 patients per year, it is optimal to reduce the 
number of DSP units in parallel for the reasons mentioned. However, as the annual 
demand increases and the direct COG dominate the COG/dose, it is optimal to increase 
the number of DSP units and resize the process according to the DSP limitations so as to 
reduce the number of batches in parallel and reduce the number of cells discarded after 
the cell culture process. 
 5.4 Conclusions  
This chapter aimed at assessing the economic and operational benefit of different 
strategies for CAR T-cell manufacture and at providing useful benchmarks for decision 
making during early development stages of CAR T-cell therapy products such as to 
enhance the commercial feasibility of these therapies. The case studies discussed in this 
chapter tackled some of the critical questions facing CAR T-cell therapies developers. 
These questions were related to the selection of the optimal manufacturing platform, 
optimal facility configuration and optimal donor source (autologous v allogeneic). 
The results show that the COG/dose for autologous CAR T-cell products vary between 
$60,000 and $160,000 and that the dose and the manufacturing platform used have a 
greater effect on the COG/dose than the annual demand. Moreover, the analysis also 
revealed that given the current reimbursement strategies for CAR T-cell cell therapy 
products, technology selection is a crucial factor to be taken into account when designing 
a manufacturing strategy for these products.  The need to selected adequate manufacturing 
platforms for autologous CAR T-cell products is magnified if there is pressure to reduce 
the current selling price; in such cases  additional development would be required in order 
to achieve successful commercialisation of autologous CAR T-cell products.  
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The economic benefits of multi-site manufacture were clearly underlined in this chapter. 
This benefit changes significantly with the number of manufacturing sites and the facility 
configuration selected. Hence, it is very important to identify the optimal combination of 
these factors when selecting a facility configuration. 
The results have also revealed that the cost-effectiveness of allogenic CAR T-cell 
products increases with increasing annual demand and decreases with increasing dose 
size. Therefore, it is important to consider the commercialisation scenario when selecting 
the donor source for CAR T-cell products. Moreover, the results also highlighted the 
current limitations of technologies for magnetic purification of allogeneic CAR T-cell 
products and that addressing these constraints will yield significant cost reductions.  
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Chapter 6: Conclusions and Future Work 
 
6.1 Introduction  
This thesis has discussed the creation and  application of advanced decisional tools for 
tackling some of the critical challenges facing cell therapy companies with the aim of 
providing useful insights on how different aspects of the manufacturing strategy can be 
optimized to enhance the commercial feasibility of these products. A series of case studies 
were carried out  addressing multiple factors to be considered when designing a 
manufacturing strategy for cell therapy products including technology selection, 
reimbursement constraints, fixed capital investment (FCI) and facility configuration with 
the specific example of mesenchymal stem cell (MSC) and chimeric antigen receptor 
(CAR) T-cell products. This chapter summarises the key contributions from the thesis 
and suggests further steps to extend this research. 
6.2 A technology-specific detailed factorial method for estimating facility footprint 
and FCI with benchmark cost and area factors for cell therapy facilities 
6.2.1 Key contributions 
Chapter 3 provided short-cut methods for facility footprint and FCI estimates. These 
methods are highly tailored to cell therapy facilities as they consider their unique features 
including technology considerations, manufacturing mode (scale-up versus scale-out), 
facility layout and cleanroom classification. The method proposed for FCI calculation 
(the cost factor method) resembles the “Lang factor” approach used for biotech/pharma 
facilities, while the method proposed for estimating facility footprint (the area factor 
method) is based on a novel factorial approach where the user can compute the facility 
footprint of bespoke cell therapy facilities using the costs of the core process equipment. 
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In the method described in Chapter 3 two different ratios were provided for FCI and 
facility footprint estimation – the cost factor and the area factor. The cost factor is the 
ratio between the FCI and the core process equipment costs (e.g. incubators and skids). 
The area factor is the ratio between the core process equipment costs and the facility 
footprint. As the different technologies for cell therapy manufacture have significantly 
different characteristics, the detailed factorial methodology for estimating FCI and 
footprint for bespoke cell therapy facilities described in Chapter 2 Section 2.3 was used 
to compute technology-specific cost and area factors so as to increase the accuracy of the 
estimates. The estimates attained using the detailed factorial methodology for estimating 
FCI and footprint for bespoke cell therapy facilities were successfully validated against 
values provided by an engineering company for the same scenario. Moreover, the case 
study was extended to capture additional project-specific features of cell therapy facilities 
such as the geographic location of the facility and the initial condition of the building site 
(e.g. greenfield v refurbishment). 
The results revealed that the cost factors varied between 2-12 and the area factors varied 
between 800$/m2-7,000$/m2 depending on the project specifications (e.g. annual 
throughput, technology selected, geographic location). The results showed also that the 
parameter that has the greatest effect on both cost factor and area factor is the combination 
of technologies (manufacturing platform) selected for cell therapy manufacture.  
Platforms with high equipment costs per unit footprint have higher area factors and lower 
cost factors and vice versa. These results clearly illustrate the need for bespoke methods 
such as this for estimating footprint and capital investment for cell therapy facilities. 
6.2.2 Future work 
Even though, multiple manufacturing platforms were included in the case study described 
in Chapter 3, a number of manufacturing steps were excluded from the analysis as 
emphasis was put in the cell culture step. Further research could explore the change in the 
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costs and area factors when technologies for magnetic purification, electroporation, filling 
and cryopreservation are considered. Moreover, the fact that the emphasis of this case 
study was placed on the cell culture technologies meant that the technologies for pre and 
post cell culture steps remained constant across manufacturing platforms. Future work 
could explore also the effect on the FCI and facility footprint when, for example, the 
fluidised bed centrifuge for cell wash and concentration is replaced with tangential flow 
filtration systems. Moreover, the mass balance and sizing of equipment for the chapter 
was carried out for a fixed process schedule. The number of equipment units required 
may vary significantly with the process schedule employed. For example, if multiple 
batches are to be harvested simultaneously, the number of DSP units required would be 
higher than if the batches were staggered. Future research could capture also the effect of 
different process schedules on resource requirement.  Finally, in this chapter, it was 
assumed that manufacturing facilities modelled would not include provisions for buffer 
and media preparation and that these reagents would come pre-formulated into the facility 
as this is common practice in the cell therapy industry. In the future, companies may opt 
to produce these reagents in-house and hence further research could explore the trade-
offs of in-house buffer and media preparation.  
6.3 Impact of allogeneic stem cell manufacturing decisions on cost of goods, 
process robustness and reimbursement 
6.3.1 Key contributions 
Chapter 4 aimed at providing a novel holistic approach to evaluate the operational and 
economic benefits of different candidate technologies for the manufacture of MSCs with 
emphasis on the cell culture process. This chapter also aimed at identifying performance 
targets to be reached in order to overcome economic challenges and/or operational 
constraints which may affect the commercial feasibility of these products. This was 
achieved by using different components of the decisional tool described in Chapter 2 to 
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compute operational and economic metrics such as COG, FCI and probability of reaching 
optimal COG. These components were the process economics model, the Monte Carlo 
model and the multi-attribute decisional-making model. The candidate technologies 
included in this study were the multilayer flasks, multi-plate bioreactors, hollow fibre 
bioreactors and microcarriers in stirred tanks. 
The results showed that the COG/dose of allogeneic cell therapies decreases with annual 
demand and planar manufacturing platforms are most cost-effective at smaller scales (≤ 
1B cells/batch) whilst microcarrier systems are more cost-effective at medium to large 
scales (10-100B cells/batch). The results highlighted also that when considering both 
economic and operational features, multi-plate and microcarriers in stirred tanks compete 
closely even at higher manufacturing scales but ultimately microcarriers in stirred tanks 
are the optimal technology for large-scale expansion of MSCs. 
Moreover, this study shows that the market penetration for MSC-based products with 
high dose sizes is constrained by the capacity limitations of current DSP technologies and 
that significant process optimization is required in order for commercial success of these 
therapies to be achieved under current reimbursement limits. This work has clearly shown 
that, in order for cell therapy products to be commercially successful, manufacturing 
platform selection must be carried out with the commercialisation scenario (annual 
demand & dose size) in mind. Moreover, this study has also illustrated the use of 
decisional tools for identifying process bottlenecks and ways to overcome these.  
6.3.2 Future work 
As the emphasis of this case study was also placed on the technologies for expansion of 
MSCs, the potential cost-benefits of alternative DSP technologies was not captured. 
Future work could focus on evaluating the operational and economic trade-offs of using 
TFF systems for cell wash and concentration and of using Harvestainer® for microcarrier 
removal. In this chapter, the issues related to the use of microcarriers for MSC cell culture 
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were highlighted as well as how some of these issues may be addressed with the use of 
alternative methods for suspension cell culture of MSCs such as spheroids and aggregate 
cell culture and injectable/ thermosensitive microcarriers. Future work could aim to assess 
the operational and economic implications of the use of these alternative methods for 
suspension cell culture of MSC products.  
Furthermore, this case study assumed that adequate cell banks were in place for MSC cell 
culture without considering costs of cell bank development and the typical size of MSC 
cell banks. Future work could aim to capture the costs of developing MSC cell banks as 
well as any potential constraints in cell number that may affect the maximum scale of the 
cell culture step. 
6.4 Addressing the challenges to the successful commercialization of CAR T-cell 
products 
6.4.1 Key contributions 
Chapter 5 employs the bioprocess economics tool described in Chapter 2 to provide the 
first in-depth economics analysis for CAR T-cell product at an technology level and an 
enterprise’s facility configuration level. This chapter addresses some of the key 
challenges faced by companies aiming to designing strategies for autologous CAR T-cell 
therapy manufacture. The topics addressed in this chapter included technology selection, 
resource requirement, reimbursement, facility configuration and cell source selection 
(autologous v allogeneic). This also provides a visualisation of the personnel numbers 
and facility footprint required for commercial scale manufacture of patient-specific cell 
therapy products with high annual demands.  
The results have shown that the COG/dose of autologous CAR T-cell products range 
between $60,000-$160,000 depending on the manufacturing platform selection, viral 
vector used for gene editing and the commercialisation scenario and that the parameters 
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with the highest effect on the COG/dose are the dose size and manufacturing platform. 
This chapter also shows that under the reimbursement applied to the autologous CAR T-
cell therapy products currently available in the market (~$400,000), low COG as % sales 
levels of 15% are achievable with current manufacturing processes. However, if the 
reimbursement limits are to be lowered to $150,000, then products with high dose sizes 
would struggle to be commercially successful highlighting the need to develop cell 
therapy products with lower dose sizes. 
The results also revealed the effect of manufacturing platform selection on the personnel 
number and facility footprint for a given commercialisation scenario; personnel number 
estimates varied by 3-fold and facility footprint estimates varied by 2.5-fold depending 
on the manufacturing platform selected. 
This chapter shows also that the economic benefit of different strategies for multi-site 
manufacture of autologous CAR T-cell products is highly dependent on the number of 
sites built. Moreover, the results have also shown that the cost-effectiveness of allogeneic 
CAR T-cell products with respect to autologous CAR T-cell products varies significantly 
with the commercialisation scenario selected. This chapter has also highlighted the batch 
size of allogeneic CAR T-cell products is limited  by current capacity constraints of DSP 
technologies for magnetic purification.  
This study is another example of how commercial success of cell therapy products is 
contingent on the selection of the correct manufacturing platform and that the 
commercialisation scenario is a crucial factor to be considered when designing a 
manufacturing strategy for cell therapy products. These findings can help guide CAR T-
cell therapy developers in selecting the optimal manufacturing strategy according to their 
product specifications.  
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6.4.2 Future work 
The case study in Chapter 5 focused on evaluating the trade-offs of different platforms 
for autologous CAR T-cell manufacture with emphasis on the technology used during the 
cell culture step and hence, the technologies used for pre and post cell culture steps were 
kept constant across different manufacturing platforms. Future work could explore the 
benefits of different technologies for pre and post cell culture steps (e.g. replacing the 
spinning membrane filtration system for cell wash and concentration with a centrifuge).  
This case study has revealed that the labour costs are one of the major cost drivers in 
autologous CAR T-cell processes. A number of different personnel categories were 
included in this case study such as process operators, QA & QC scientists and QP. 
However, a number of additional personnel categories were excluded from the case study 
such as facility managers, supply chain managers and engineers. Future work could aim 
to capture all the different personnel categories within a cell therapy facility in order to 
evaluate the full effect of the labour costs on the total COG. Moreover, multiple 
companies are currently looking to automation in order to reduce labour costs and 
promote process robustness. Future research could also capture the economic and 
operational trade-offs of implementing automation in autologous CAR T-cell 
manufacture.  
Operator-handling is not the only cause of batch-to-batch variability in autologous cell 
therapy processes. The patient cells can also be a source of variability. Moreover, in CAR 
T-cell therapy, doses are typically given as a function of the patient weight; hence, future 
work could investigate the effect of these variables on the suitability of different 
technologies for autologous CAR T-cell manufacture. 
One of the key benefits of adopting a decentralised approach to the manufacture of 
biopharmaceutical products is the potentially higher market penetration as different 
263 
 
facilities can be designed to comply with the regulatory bodies in different geographic 
regions. This advantage was not captured in this case study, as it was assumed that all 
facilities were situated in Europe. Future work could aim to capture the implications of 
the geographic location of the facilities for autologous CAR T-cell manufacture such as 
reimbursement levels, market penetration and the requirement for QP for batch release. 
When comparing the relative cost-effectiveness of allogeneic CAR T-cell products with 
respect to autologous products, an assumption was made that these products were equally 
safe and efficacious. Future research could investigate if this assumption is accurate once 
more information on the clinical performance of allogeneic products is available. If this 
data shows that allogeneic CAR T-cell products do not perform as well as autologous 
products, then additional research is required in order to evaluate how the dose size and 
reimbursement of allogeneic products would compare to autologous products. 
The series of case studies described in this thesis have highlighted the role of decisional 
tools in enabling commercial success of cell therapy products as they have illustrated the 
key factors to be considered when designing different aspects of the manufacturing 
strategy for cell therapy products. This research has provided also benchmark values and 
short-cut methods for estimating parameters such as FCI, facility footprint, COG/dose 
and personnel numbers. These findings can be implemented early on within process 
development of cell therapy products enabling companies to save time and money. 
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Chapter 7: Process Validation in Cell Therapy  
 
7.1 Introduction  
Like in traditional biopharmaceutical products, process validation in cell therapy is a 
complex task, which involves the validation of different aspects of the cell therapy facility 
and manufacturing process that may affect the quality of the product. These aspects 
include equipment, materials and cleanrooms. Process validation often takes place at the 
same time as the Phase III of clinical trials. In order to achieve successful validation of a 
cell therapy product, it is crucial to understand the features of the product. Cell therapy 
products are significantly more complex than traditional biopharmaceutical products and 
parameters such as dose size, potency, impurities and formulation must be considered 
early on in the process development (Shanley 2015). Moreover, considering technology 
selection early on within the process development so as to identify the most cost-effective 
platform for cell therapy manufacture can result in significant cost and time savings by 
avoiding the need for major process change applications (Hassan et al. 2016). This thesis 
has demonstrated how decisional tools can provide a fast and cost-effective framework 
for evaluating different manufacturing strategies early on within process development.  
 A Quality by Design approach (QbD) is often applied during the validation process of 
cell therapy products. QbD allows for comprehensive and methodical understanding of 
the product and the manufacturing process (Shanley 2015).  The QbD process starts when 
quality target product profile is identified (QTPP). This is a collection of the wanted 
product characteristics, such as identity and shelf life.  
The identification of the QTTP is followed by the identification of the critical quality 
attributes of the product (CQAs) such as potency and purity (Shanley 2015; Lipsitz et al. 
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2016; Davie et al. 2012). Some of these characteristics have to be defined as early as 
phase II of clinical trials (Food and Drugs Administration 2003). The potency of the 
product provides information of its in vivo activity (Lipsitz et al. 2016) and the purity of 
the product is  related to the safety of the product (Lipsitz et al. 2016). In order to identify 
these CQAs suitable assays must be developed to carryout adequate tests such as 
microbiological tests (Mycoplasma, sterility testing, adventitious agent texting), identity, 
purity, potency, viability, etc. (Food and Drugs Administration 2003). 
After the recognition of the CQAs,  the critical process parameters are identified  (Lipsitz 
et al. 2016). These are the parameters that may influence the safety and efficacy of the 
product. Subsequent to the identification of the critical process parameters a design space 
is established which shows how changes in the parameters may influence the CQAs 
(Lipsitz et al. 2016).  
The design space can be identified through the use of a design of experiment approach 
(DoE) (Campbell et al. 2015). The next stage is to create a control strategy which keeps 
the process parameters within the ranges which do not affect the quality of the product 
(Lipsitz et al. 2016). A schematic representation of QbD applied to cell therapy is shown 
in Figure 7.1. This chapter will briefly highlight some of the validation challenges facing 
cell therapy companies with emphasis in the two types of cell therapy products that were 
discussed in this thesis: allogeneic mesenchymal stem cell-based cell therapy products 
and chimeric antigen receptor cell therapy products. 
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Figure 7.1 Schematic representation of a QbD process. Adapted from Lipsitz et al. (2016). 
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7.2 Validation challenges in cell therapy  
As previously mentioned, cell therapy products are typically manufactured using single-
use technologies. Even though the use of such technologies has the benefit of a shorter 
cleaning validation processes, as the parts that come into contact with the product are 
thrown away after each batch, the use of single-use technologies have additional 
validation issues which must be carefully addressed in order to ensure that the product is 
safe to administered to patients.  
One of the key validation issues related to the use of single-use technologies is the 
potential release of leachables and extractables into the product (Flaherty & Perrone 2012; 
Levine et al. 2012; Langer & Rader 2014). As cells cannot be sterilized, it is very 
important to demonstrate that the levels of leachables and extractables in the final form 
of the product are within the pre-defined acceptable range.  
Most technologies currently available for cell therapy manufacture, require high levels of 
manual handling, which can potentially increase batch-to-batch variability. Sources for 
batch-to-batch variability are not limited to the manufacturing process and include the 
cell bank used and the cryostorage. During the validation process companies must 
demonstrate consistency across batches. Potential strategies to address this issue include 
the implementation of automated systems. Doing so however will increase the capital 
investment and development costs which may discourage smaller companies. Moreover, 
automation in combination with fully closed systems also eases the validation process for 
companies aiming to manufacture cell therapy products across multiple sites as a risk-
mitigation strategy. 
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In autologous CAR T-cell therapy, the patient is the donor and hence sources of variability 
may occur before the product enters the manufacturing facility (e.g. different centres may 
adopt different leukapheresis protocols) as well as after the product has left the 
manufacturing facility (e.g. the adoption of different thawing techniques). As the quality 
of the starting material for CAR T-cell manufacture is a crucial factor in achieving a 
successful batch, autologous CAR T-cell products may only be available in selected 
clinical sites such as to increase the success rate of these therapies (Davie 2013; Trainor 
et al. 2014; Flinn et al. 2016). Moreover, the quality of the starting material can also be 
affected by the patient itself. Patient-specific factors affecting the quality of the starting 
material include the progression of the illness as well as previous treatments undergone 
by the patient. This may difficult achieving consistent results when running the process 
performance qualification (PPQ) batches required during the validation process. 
 In allogeneic cell therapy, a single cell bank is used to manufacture multiple batches. 
Due to limitation in the expansion potential of mesenchymal stem cells, it is unlikely that 
a single cell bank will be employed throughout the lifecycle of the product. Hence, 
multiple cell banks may be required. As the quality of mesenchymal stem cells changes 
depending on multiple factors such as the cell source, age and health of the donor, it is 
crucial to screen carefully these cell banks in order to ensure that they meet the adequate 
standards for product manufacture. Moreover, it is also important to consider that each 
new cell bank must be validated which requires time and money.  
The reagents used during the manufacturing process of cell therapy products can also be 
a source for variation. For example, multiple companies use serum-containing media. 
Different batches of serum provided by the vendors may contain slightly different 
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characteristics and thus adding to the high number of factors that must be taken into 
account when validating a cell therapy process. 
A number of the factors mentioned above have been accounted for in the case studies 
described in this thesis. These include the development costs characteristic of cell therapy 
products, which were considered  in the net present value calculations in Chapter  5. 
Moreover, the batch-to-batch variability characteristic of different   processes for cell 
therapy manufacture was accounted for in Chapter 4.  This chapter also underlines the 
reductions in batch-to-batch variability achieved through the implementation of 
automation. 
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